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1. Abbreviations  
Abbreviation Acceptation 
ALS Amyotrophic lateral sclerosis 
AMBRA1 BECN1‑regulated autophagy protein 1 
ATG Autophagy-related genes 
BAFFR B-cell activating factor belonging to TNF-family receptor 
Cas9 CRISPR-associated protein 9 
CD40 Cluster of differentiation 40 
cIAP1/2 Cellular inhibitors of apoptosis 1 and 2 
CMT Charcot Marie Tooth disease 
CRISPR 
Clustered Regularly Interspaced Short Palindromic 
Repeats 
CSC Cancer stem cells 
DSMA IV Distal spinal muscular atrophy type IV 
FADD Fas-associated protein with death domain 
FIP200 Focal adhesion kinase family integrating protein 200 
GBM Glioblastoma multiforme 
GEF Guanine nucleotide exchange factor 
IKK1/2 
Inhibitor of nuclear factor kappa-B kinase subunit 
alpha/beta 
IκBα Inhibitor of nuclear factor kappa-B alpha 
LTβR Lymphotoxin beta receptor 
LUBAC Linear ubiquitin assembly complex 
MLKL Pseudokinase mixed lineage kinase like 
mTOR Mammalian target of rapamycin 
mTORC1 mTOR complex 1 
NEMO NF-kappa-B essential modulator 
NF-κB 
Nuclear factor kappa-light-chain-enhancer of activated 
B-cells 
NMJ Neuromuscular junction 
PI(P)3 Phosphatidylinositol 3-phosphate 
Plekhg5 
Pleckstrin homology domain containing, family G 
member 5 
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Rab26 Ras-related protein Rab26 
RhoA Ras homolog gene family, member A 
RIPK1 Receptor-interacting serine/threonine-protein kinase 1 
TAB2/3 TAK1-binding proteins 2 and 3 
TAK1 TGF-beta activated kinase 1 
TNFR1/2 TNF receptors 1 and 2 
TNFα Tumor necrosis factor alpha 
TRADD TNFR1 associated death domain protein 
TRAF2 TNF receptor associated factor 2 
ULK Unc-51 like autophagy activating kinase 
VEGF Vascular epidermal growth factor 
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3. Abstract 
The transcription factor NF-κB is an essential regulator in a broad range of 
cellular processes. Due to its importance, it is tightly associated with 
numerous diseases. The thesis presented deals with the roles of NF-κB in 
the context of a motoneuron disease and cancer.  
One part focused on the analysis of Plekhg5-deficient mice as a new mouse 
model for motoneuron disease. Plekhg5 is a known activator of NF-κB 
signaling and previously, mutations found within the human PLEKHG5 gene 
were associated with different motoneuron diseases. Mutant mice developed 
a pathology with late onset. With Plekhg5 being expressed in both, neurons 
and Schwann cells, research focused on both cell types. Most prominently on 
the neuronal site, a direct function of Plekhg5 as a GEF for Rab26 could be 
demonstrated. Previously, Rab26 was described as a regulator of the 
autophagy-mediated clearance of synaptic vesicles. Consequently, lack of 
Plekhg5 resulted in the accumulations of synaptic vesicles within 
neuromuscular junctions impeding proper muscle innervation. Besides this 
motoneuron-specific function, deficiency of Plekhg5 in Schwann cells 
additionally contributed to the disease observed in mutant mice, becoming 
evident as an altered myelination within peripheral nerves. Causative for 
these effects are impaired autophagy in Schwann cells and reduced 
chemokine expression resulting in reduced T-lymphocyte recruitment.  
Part two of the thesis presented focused on the generation and analysis of 
CRISPR/Cas9-mediated gene knockouts in human cells. These included the 
NF-κB activator Plekhg5 and several members of the canonical NF-κB 
signaling pathway. Genetic depletion of Plekhg5 in human glioma cells 
extended the findings of Plekhg5 as a regulator of autophagy from the 
nervous system to human cancer cells. Notably, in this different cellular 
context, Plekhg5 was shown to be involved at a different stage of autophagy.  
Deficiency of members of the NF-κB family being involved in canonical 
NF-kB signaling resulted in different results. Knockout of the NF-κB subunit 
c-Rel resulted in profound defects of the cell cycle. However most 
prominently, a double knockout of the upstream kinases IKK1 and IKK2 
vastly increased the sensitivity of human cells to TNF-induced cell death in 
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an NF-κB-independent manner. This strongly indicates that the IKK complex 
might be a promising target with regard to cancer therapy.  
 
 
Figure 1. Schematic overview of the major findings in the thesis presented. In the 
nervous system, new mechanistic insights of a motoneuron disease were obtained. In 
cancer cells, several loss-of-function approaches were performed culminating in potential 
new therapeutic approaches.  
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4. Zusammenfassung 
Der Transkriptionsfaktor NF-κB ist an der Regulation verschiedenster, 
zellulärer Prozesse beteiligt. Fehlregulierte Aktivierung von NF-κB ist 
aufgrund dessen mit einer Vielzahl verschiedener Krankheiten assoziiert. In 
der vorgelegten Dissertation wurde die Beteiligung von NF-κB im Rahmen 
einer Motorneuronerkrankung als auch im Zusammenhang mit 
Krebserkrankungen untersucht.  
Im ersten Teil dieser Arbeit erfolgte die Analyse eines Mausmodells, in 
welchem das Gen Plekhg5  entfernt worden war. Bereits in früheren Arbeiten 
konnte gezeigt werden, dass Plekhg5 NF-κB aktivieren kann. Darüber hinaus 
waren Mutationen im humanen PLEKHG5 Gen als Ursache verschiedener 
motorneuronaler Erkrankungen beschrieben worden. Plekhg5-defiziente 
Mäuse zeigten im fortgeschrittenen Alter Symptome einer motorneuronalen 
Erkrankung. Aufgrund der Tatsache, dass Plekhg5 sowohl in Motorneuronen, 
als auch in Schwann Zellen exprimiert wird, wurden anschließend Zell-
spezifische Effekte untersucht. In Motorneuronen konnte eine direkte 
Funktion von Plekhg5 als GEF für Rab26 im Rahmen des Autophagie-
vermittelten Abbaus synaptischer Vesikel gezeigt werden. Verlust von 
Plekhg5 führte zu einer Anstauung synaptischer Vesikel, welche eine 
funktionelle Innervation der Muskelzellen massiv beeinträchtigte. Abseits 
dieser motorneuronspezifischen Funktion trug der Verlust von Plekhg5 in 
Schwann Zellen ebenfalls zum beobachteten Krankheitsbild der Tiere bei. 
Hier konnten insbesondere Veränderungen der Myelinscheide in peripheren 
Nerven detektiert werden. Als ursächlich dafür konnte eine gestörte 
Autophagie in Schwann Zellen, sowie eine verminderte Ausschüttung von 
Botenstoffen für die Rekrutierung von T-Lymphozyten ausgemacht werden.  
Im zweiten Teil der hier vorgelegten Dissertation lag der Fokus auf der 
Erschaffung und Charakterisierung mehrerer genetischer Verlustmutanten in 
kultivierten menschlichen Zellen mittels des CRISPR/Cas9 Systems. Unter 
anderem wurden Mutanten für den NF-κB Aktivator Plekhg5 und mehrerer 
Mitglieder des kanonischen NF-κB Signalwegs erstellt. Mit dem Verlust von 
Plekhg5 in menschlichen Glioblastomzellen konnten die Erkenntnisse von 
Plekhg5 als Regulator der Autophagie vom Nervensystem auf menschliche 
C. Slotta – Analysis of the NF-κB signal transduction pathway in neurological disorders and cancer 
11 
 
Krebszellen erweitert werden. Interessanterweise war Plekhg5 hier an einer 
anderen Stelle innerhalb des autophagischen Prozesses beteiligt als zuvor 
im Nervensystem beschrieben.  
Die Verlustmutanten verschiedener Mitglieder der NF-κB Familie führten zu 
unterschiedlichen Effekten. Verlust der NF-κB Untereinheit c-Rel resultierte in 
einer erheblichen Störung des Zellzyklus. Die dramatischste Auswirkung 
zeigte sich hingegen in einem massiv gesteigerten Zelltod nach Zugabe von 
TNF-α in einer Doppelverlustmutante der NF-κB aktivierenden Kinasen IKK1 
und IKK2. Dieser Effekt konnte als NF-κB unabhängig identifiziert werden 
und zeigt, dass der IKK Komplex ein äußerst vielversprechendes Ziel für die 
Krebstherapie sein könnte.     
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5. Introduction 
5.1 The Nuclear Factor kappa B 
The inducible transcription factor nuclear factor kappa-light-chain enhancer of 
activated B-cells (NF-κB) plays a pivotal role in a broad range of cellular 
processes and therefore is in the center of active research. Identified more 
than thirty years ago (Sen and Baltimore, 1986), it was first described to play 
important roles within the immune system (reviewed in (Vallabhapurapu and 
Karin, 2009)). Nowadays, a large amount of studies have described NF-κB 
as a major regulator of numerous cellular processes within different cellular 
systems such as cell growth, differentiation, apoptosis, inflammation, learning 
and memory (Kaltschmidt and Kaltschmidt, 2015, Perkins, 2007).  
 
5.1.1 The NF-κB family 
In mammals, NF-κB is comprised of five subunits: RelA (p65), RelB, c-Rel, 
p50 (NF-κB1) and p52 (NF-κB2), which form either homo- or heterodimers. 
All subunits share the so-called Rel-homology domain (RHD) at their N-
terminus (Baeuerle and Baltimore, 1996). The RHD is necessary for 
dimerization of the subunits and DNA-binding. In contrast, only members of 
the Rel family (RelA, RelB and c-Rel) additionally contain a transactivation 
domain (Fig. 2). Consequently, only dimers containing at least one of the Rel 
proteins are able to activate transcription, whereas e.g. a p50:50 homodimer 
acts as transcriptional repressor (Hayden and Ghosh, 2012). The subunits 
p50 and p52 are being expressed as the precursor proteins p105 and p100. 
During signaling, they are processed by partial proteasomal degradation to 
the final and active subunits.  
In addition to the NF-κB subunits, several inhibitor proteins have been 
described. They are all defined by the presence of multiple ankyrin repeat 
domains (Fig. 2). Among these, the inhibitor of κB alpha (IκBα) is 
characterized as the key regulator in canonical NF-κB signaling (Hayden and 
Ghosh, 2014). By masking the nuclear localization sequence of NF-κB, IκBα 
restrains the transcription factor within the cytosol. Notably, IκBα also 
contains a nuclear import sequence within the second ankyrin repeat 
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allowing unbound IκBα to 
enter the nucleus. Here it is 
able to interact with DNA-
bound NF-κB resulting in its 
dissociation from the DNA 
and translocation to the 
cytosol (Sachdev et al., 
1998). Of note, in their 
precursor form p105 and 
p100, p50 and p52 can also 
act as inhibitor proteins as 
they prevent NF-κB from 
translocating into the 
nucleus (Savinova et al., 
2009).    
 
 
 
 
 
 
 
 
5.1.2 NF-κB signaling pathways 
NF-κB signaling has been described to be mediated via two distinct 
pathways. Each of them can be activated by a variety of stimuli. In the most 
common and best characterized canonical (classical) pathway, cytokines like 
TNFα or IL-1β bind to their respective receptor (e.g. TNF receptor 1) at the 
plasma membrane. A first step in this signaling cascade is the activation of 
the TGFβ-activated kinase 1 (TAK1). TAK1 will activate the IκB kinase (IKK) 
complex, a major regulatory factor in canonical NF-κB signaling. It is 
comprised of the catalytic subunits IKK1 (IKKα) and IKK2 (IKKβ) and the 
Figure 2. The NF-κB family. It can be divided into NF-
κB subunits, the inhibitory IκB proteins and the IKK 
complex. RHD, rel homology domain; TAD, 
transactivation domain; LZ, Leucin zipper domain; DD, 
death domain; ANK, Ankyrin repeat domain; SDD, 
scaffolding and dimerization domain; ULD, ubiquitin-like 
domain; Z, zinc finger domain. Taken from (Hayden and 
Ghosh, 2012). 
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regulatory subunit NF-κB essential modulator (NEMO/IKKγ) (Fig. 2). The 
activated IKK complex will phosphorylate IκBα at Ser32/36, which in turn will 
lead to its polyubiquitination mediated by SCFβ-TrCP E3 ubiquitin ligases and 
its degradation by the 26S proteasome (Ben-Neriah, 2002).  
Notably, IKK2 is generally believed to be responsible for the phosphorylation 
of IκBα since e.g. Ikk1-deficient mice do not display impairments in canonical 
signaling (Hu et al., 1999). However, CRISPR/Cas9-mediated knockouts of 
IKK1 and IKK2 in HEK293 cells resulted in comparable impairments of 
canonical NF-κB signaling (Fig. 4) questioning the universality of this dogma 
(Slotta et al. c). By degradation of IκBα, the NLS of NF-κB is unmasked so 
that NF-κB is no longer retained within the cytoplasm but translocates into 
the nucleus resulting in the expression of target genes (Perkins, 2007, 
Figure 2. Schematic overview of the canonical (left) and non-
canonical (right) NF-κB signaling pathway. Taken from (Sun, 2017). 
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Hayden and Ghosh, 2008).  
 
In the alternative, non-canonical pathway NF-κB is predominantly comprised 
of RelB and p52 (Sun, 2012). Signaling is triggered upon activation of several 
members of the TNFR superfamily, including but not restricted to B-cell 
activating factor belonging to TNF-family receptor (BAFFR) (Claudio et al., 
2002), lymphotoxin b receptor (LTβR) (Dejardin et al., 2002) and cluster of 
differentiation 40 (CD40) (Coope et al., 2002). 
Binding to their specific receptors results in the activation of IKK1 by the 
NF-κB-inducing kinase (NIK) (Fig. 3). IKK1 phosphorylates the precursor 
protein p100, which leads to processing to the NF-κB subunit p52. During 
Figure 4. Activation of canonical NF-κB signaling is strongly reduced in IKK1-, IKK2- 
and IKK1/2-deficient cells. (A,B) Nuclear translocation of NF-κB p65 after 30 min of TNF 
stimulation is significantly impaired in all mutant cells compared to wildtype cells. (C) TNF-
induced degradation of IκBα is reduced in IKK1- and IKK2-deficient cells compared to 
wildtype and not-existent in IKK1/2-double-deficient cells. (D) qPCR analysis of the NF-κB 
target genes IκBα, A20 and IL-8 display reduced NF-κB activity after 6 h of TNF-treatment in 
all mutant cells compared to wildtype cells. Taken from (Slotta et al. c). 
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processing, the NLS will be unmasked allowing NF-κB to enter the nucleus.  
 
5.1.3 NF-κB within the nervous system 
Next to the immune system, NF-κB is extensively researched within the 
nervous system. Here, it is strongly involved in neurogenesis, learning and 
memory as well as neuroprotection (reviewed in (Kaltschmidt and 
Kaltschmidt, 2009)).  
Constitutively active NF-κB has been found in cortical and hippocampal 
neurons (Kaltschmidt et al., 1994b). Moreover, inducible forms of NF-κB have 
been found in synapses suggesting it to be a regulator in response to 
synaptic transmission (Kaltschmidt et al., 1993, Meberg et al., 1996, Meffert 
et al., 2003). Indeed, upon stimulation NF-κB was found to be transported 
retrogradely from the synapse to the soma (Mikenberg et al., 2007, 
Wellmann et al., 2001, Widera et al., 2016). Forebrain neuron-specific 
inhibition of NF-κB activity resulted in loss of neuroprotection and severe 
structural and cognitive deficits in mice (Fridmacher et al., 2003, Imielski et 
al., 2012). In an inducible transgenic mouse model this could be rescued 
even in adult mice additionally indicating a role of NF-κB in adult 
neurogenesis (Imielski et al., 2012). This is in line with observations of NF-κB 
being present in neural stem cells and neuronal progenitor cells contributing 
to proliferation and differentiation (Widera et al., 2006, Koo et al., 2010).  
Due to its involvement in numerous processes, aberrant regulation of NF-κB 
is associated with several neurological disorders and neurodegenerative 
diseases, such as Alzheimer’s disease, Parkinson’s disease and 
Huntington’s disease (Kaltschmidt et al., 1999b, Hunot et al., 1997, Mogi et 
al., 2007, Ghosh et al., 2007, Marcora and Kennedy, 2010).  
 
5.1.4 Immune response in neurological disorders and its effect on 
myelination 
Many neurodegenerative diseases comprise immunological features. 
Neuroinflammation is a key feature shared by many neurodegenerative 
diseases, such as Alzheimer’s and Parkinson’s disease and amyotrophic 
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lateral sclerosis (Heneka et al., 2015, Wang et al., 2015, Philips and 
Robberecht, 2011). Often inflammation and immune response activation 
develop early during disease and precede e.g. neuronal loss (Doty et al., 
2015). In almost every disorder of the central nervous system (CNS), 
activated microglia – the CNS macrophages – can be found (Long-Smith et 
al., 2009, Prokop et al., 2013, Sargsyan et al., 2005). In addition to this 
microgliosis, reactive astrocytes and also lymphocytes can be found, e.g. in 
multiple sclerosis (MS) (Pender and Greer, 2007).  
One process that can be triggered by the neuroinflammatory environment is 
degradation of the myelin sheath (demyelination). The myelin sheath is an 
essential component for axonal integrity and function. In the CNS it is 
generated and maintained by oligodendrocytes and in the peripheral nervous 
system (PNS) by Schwann cells (Nave and Werner, 2014). Suppressing the 
immune response in demyelinating neuropathies is a promising approach for 
therapy. In mouse models for demyelinating CNS and PNS disorders, 
impairments in the immune response resulted in improved myelin 
maintenance (Ip et al., 2006, Schmid et al., 2000).  
NF-κB is a central regulator of inflammatory processes and as such in the 
center of research in the context of neurological disorders with inflammatory 
features. In reactive microglia a strong activation of NF-κB was demonstrated 
indicating NF-κB to be a key regulator in neuroinflammation (Kaltschmidt et 
al., 1994a, Bethea et al., 1998). In MS, a well-characterized demyelinating 
disease, neuroinflammation is a key feature. The blood-brain barrier 
becomes permeable, followed by strong infiltration of T-lymphocytes into the 
brain (Pender and Greer, 2007). Notably, in oligodendrocytes and activated 
microglia elevated activation of NF-κB was observed in MS patients linking 
NF-κB to demyelination (Bonetti et al., 1999). In fact, NF-κB modulating 
substances such as Fingolimod are already being used in MS therapy to 
reduce demyelination (Sanford, 2014).  
 
5.1.5 NF-κB in cancer  
Besides involvement in neurological disorders, deregulation of NF-κB 
signaling is also particularly associated with tumor formation and progression 
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(Xia et al., 2014, Li et al., 2005, Ben-Neriah and Karin, 2011). As a key 
regulator of inflammation, it cross-links cancer and inflammation (Xia et al., 
2014). A chronic inflammatory environment results in cellular stress, the 
recruitment of inflammatory factors and DNA damage, which in turn favors 
tumor formation. Therefore, “tumor-promoting inflammation” has been 
described as one of the hallmarks of cancer (Hanahan and Weinberg, 2011).  
However, besides contributing to a pro-inflammatory environment, 
deregulated NF-κB signaling promotes tumor formation and progression also 
by other means. For different types of cancer cells, it was shown that 
elevated NF-κB activity is tightly connected with proliferation of tumor cells. 
Consequently, by inhibition of NF-κB proliferation could be reduced, as was 
e.g. shown in an Ikk2-depleted mouse model for lung carcinoma (Xia et al., 
2012). Inhibiting NF-κB activation by the expression of a mutated form of 
IκBα (IκBAA1), which cannot be degraded, also resulted in reduced 
proliferation of murine tumor cells (Meylan et al., 2009) and human HeLa 
cells (Kaltschmidt et al., 1999a), a broadly used model for cervical cancers.  
Inhibition of NF-κB activity is a prominently researched approach for 
anticancer therapy. By inhibition of the IKK complex using chemicals such as 
thalidomide or BAY11-7082, the severity of lymphomas could markedly be 
reduced (Mitsiades et al., 2002, Keifer et al., 2001, Garcia et al., 2005). 
Already used for the treatment of multiple myelomas is the proteasome 
inhibitor bortezomib that prevents the degradation of IκBα (Mulligan et al., 
2007). However, global inhibition of NF-κB activity can result in severe 
adverse effects, such as systemic inflammation (Greten et al., 2007). 
Therefore, subunit-specific inhibition of NF-κB holds a great potential in 
therapy.  
 
5.1.5.1 The role of c-Rel in cancer 
Among the NF-κB subunits, particularly c-Rel is in the focus of cancer 
research. Originally, it was identified as the homologue of the avian retroviral 
oncoprotein v-REL, which induces lymphoma formation in birds (Gilmore and 
Gerondakis, 2011).  
A broad range of studies has described the involvement of c-Rel in lymphoid 
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cancers (reviewed in (Hunter et al., 2016)). In primary mediastinal B-cell 
lymphoma (PMBL), an amplification of the REL locus was observed resulting 
in increased NF-κB activity (Weniger et al., 2007). Moreover, in adult T-cell 
leukemia/lymphoma (ATLL) increased expression of c-Rel was linked with 
resistance to therapy (Ramos et al., 2007). Recently, c-Rel was shown to be 
crucial for the generation and maintenance of activated regulatory T cells 
(aTregs) (Grinberg-Bleyer et al., 2017). These cells play an important role in 
the inhibition of anti-tumor immune responses helping the tumors to evade 
recognition by the immune system. Treg-specific ablation of c-Rel, but not of 
p65, resulted in drastically reduced melanoma growth in mice and 
additionally increased the effect of immunotherapy (Grinberg-Bleyer et al., 
2017).   
Besides B- and T-cell lymphomas, an increasing number of reports describe 
the functions of c-Rel in solid tumors. Here it was reported that c-Rel does 
not necessarily promote tumors and can also act as a tumor-suppressor. In 
35 primary breast cancers, c-Rel expression was vastly increased and in a 
mouse model with forced expression of c-Rel in breast tissue, more than 
30 % of the animals developed tumors (Cogswell et al., 2000, Romieu-
Mourez et al., 2003). In HeLa cells, c-Rel-deficiency resulted in profound 
defects of the cell cycle. In particular, the prometaphase in c-Rel-deficient 
cells was markedly prolonged and a significant subset of cells even arrested 
at this mitotic stage without entering the G2 phase of the cell cycle (Fig. 5) 
(Slotta et al., 2017). These observations indicate a more tumor-promoting 
role of c-Rel. However, in a model for colitis-associated colon 
adenocarcinoma, c-Rel-deficiency resulted in a more severe phenotype 
(Burkitt et al., 2015).  
In summary, this stresses the importance of the analysis of particular NF-κB 
subunit functions resulting in potentially more specific therapeutic 
approaches with less adverse effects.   
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5.1.6 TNF signaling and its association with cell death 
The tumor necrosis factor alpha (TNFα) is a pro-inflammatory cytokine and 
one of the best characterized activators of the canonical NF-κB signaling 
pathway. TNF signaling is associated with cell death and on a broader scale 
with tissue homeostasis and inflammation (reviewed in (Kondylis et al., 
2017)). Therefore, targeting of TNF signaling provides a promising approach 
in the context of several diseases, especially of those that include 
inflammatory features (Peyrin-Biroulet, 2010). In particular, TNF signaling 
Figure 5. Significantly delayed prometaphase in c-REL-deficient HeLa cells. (A,B) Live-
cell imaging of wildtype (A) and mutant (B) cells displayed prolonged prometaphase in c-
REL-deficient cells (arrows). (C) Quantification revealed a significance delay of the 
prometaphase (39.50 ± 9.96 min) of mutant cells compared to wildtype cells (18.42 ± 1.58 
min). (D) Exemplary images of c-REL knockout cells arresting during mitosis. (E) 
Fluorescence imaging of fixed cells showed a significant subset of mutant cells within 
prometaphase compared to wildtype. Taken from (Slotta et al., 2017). 
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Figure 6. TNFR1 signaling pathway. Upon binding of TNF, complex I is 
assembled, which can result in the activation of the NF-κB signaling 
pathway but also lead to cell death mediated via complex IIa, IIb or the 
necrosome. Taken from (Kondylis et al., 2017). 
has been associated with cancer formation and progression (reviewed in 
(Wang and Lin, 2008)). In a broad range of tumorigenic tissues and tumor 
cells, expression of TNF is highly elevated (Ferrajoli et al., 2002, Szlosarek et 
al., 2006). Conversely, many tumor cells are particularly resistant to TNF-
induced cell death (Wang and Lin, 2008). Holding great anticancer potential, 
research focuses on the applicability of TNF in anticancer therapy. This 
includes the generation of mutated forms of TNF to increase its cytotoxicity, 
receptor affinity and half-life and to decrease its otherwise severe side-effects 
including systemic shock and widespread inflammation (Shibata et al., 2004, 
Lucas et al., 2001, Yan et al., 2006).  
 
Signaling by TNF is mediated by the two specific TNF receptors (TNFR) 1 
and 2, whereby signaling primarily acts via TNFR1, which in contrast to 
TNFR2 is expressed ubiquitously (Walczak, 2011). Binding of trimeric TNFα 
causes trimerization of TNFR1, which induces the formation of the so-called 
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complex I (Fig. 6). This complex consists of the receptor-interacting 
serine/threonine-protein kinase 1 (RIPK1) and TNFR1 associated death 
domain protein (TRADD), which rapidly bind to the activated TNFR1, 
followed by TRADD-mediated recruitment of TNF receptor associated factor 
2 (TRAF2) (Ermolaeva et al., 2008, Haas et al., 2009). This results in the 
binding of the E3 ubiquitin ligases cellular inhibitors of apoptosis (cIAP) 1 and 
2, which add K63-linked ubiquitin chains to RIPK1. Following this 
ubiquitination two additional complexes are recruited. The IKK complex 
directly binds to the K63-linked ubiquitination chain. Additionally, the linear 
ubiquitin assembly complex (LUBAC) is recruited, adding M1-linked ubiquitin 
chains to RIPK1 (Peltzer et al., 2016). This second ubiquitination provides a 
signal for a complex consisting of TAK1 and the TAK1-binding proteins (TAB) 
2 and 3 (Varfolomeev and Vucic, 2016). When this complex comes into close 
proximity to the IKK complex, TAK1 phosphorylates IKK2 and by this triggers 
its autophosphorylation, which is required for downstream signaling (Zhang 
et al., 2014a).  
Two checkpoints have been described to regulate cell death upon TNF 
signaling (O'Donnell and Ting, 2011). The first one is well characterized and 
dependent on the activation of canonical NF-κB signaling, which results in 
the expression of pro-survival target genes, such as cFLIP (Van Antwerp et 
al., 1996, Micheau et al., 2001, Wang et al., 1998, Panayotova-Dimitrova et 
al., 2013). By this, formation of the so-called complex IIa is inhibited 
(Micheau and Tschopp, 2003). In this complex, Fas-associated protein with 
death domain (FADD) and caspase 8 are activated dependent on TRADD 
(Fig. 6), which induces apoptosis (Ofengeim and Yuan, 2013). The second 
checkpoint in comparison is far less well understood and just gained attention 
in recent years. It regulates cell death upstream of and by this independent 
on NF-κB activation (Legarda-Addison et al., 2009, Wang et al., 2008, 
Dondelinger et al., 2013, O'Donnell et al., 2007). This checkpoint is believed 
to act in dependence on RIPK1, either by prevention of its integration in the 
apoptosis complex IIb, in which it is required for activation of FADD and 
caspase 8, or by its integration into the necrosome (Fig. 6). Formation of the 
necrosome consisting of RIPK1/3 and the RIPK3 substrate pseudokinase 
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mixed lineage kinase like (MLKL) results in necroptotic cell death, a more 
recently described programmed cell death, which is independent on caspase 
8 (He et al., 2009, Sun et al., 2012, Cho et al., 2009, Vanlangenakker et al., 
2010). Recently, the IKK complex was reported to be a major regulator in 
TNF-induced cell death. While originally believed that the IKK complex was 
only mandatory for initiating canonical NF-κB signaling, Dondelinger and 
colleagues demonstrated the complex also to act directly on RIPK1 
(Dondelinger et al., 2015). The IKK complex phosphorylates and thereby 
inhibits RIPK1 preventing its incorporation into complex IIb or the necrosome. 
By this, the IKK complex also acts as a regulator in TNF-induced cell death in 
an NF-κB-independent manner (Dondelinger et al., 2015). The study by 
Dondelinger was conducted by analyzing several knockout mouse models. 
Notably, only in mice deficient for both, Ikk1 and Ikk2, TNF-induced cell death 
was vastly elevated. Deficiency of either Ikk1 or Ikk2 was not sufficient to 
impair IKK-mediated prevention of TNF-induced cell death significantly 
(Dondelinger et al., 2015). These findings suggest the IKK complex to be a 
promising target to sensitize cells to TNF-induced cell death, which as 
described above is a highly researched approach for potential TNF 
applications in anticancer therapy. However, differences between humans 
and mice in TNF signaling have been reported in the past. Mice deficient for 
RelA, Ikk2 or NEMO die during embryonic development due to TNF-induced 
cell death of hepatocytes resulting in liver degeneration (Beg et al., 1995, Li 
et al., 1999, Tanaka et al., 1999, Rudolph et al., 2000). In contrast, Panicke 
and colleagues reported a frameshift mutation within the human IKBKB gene 
(encoding for IKK2) to be causative for severe combined immunodeficiency 
(SCID). None of the patients analyzed showed any signs of liver 
degeneration (Pannicke et al., 2013). These reported differences stress the 
necessity to analyze the role of the IKK complex in human cells in addition to 
mice.  
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To initially investigate this, IKK1 and IKK2 were genetically depleted in 
human cells using CRISPR/Cas9 (Slotta et al. c). While also IKK1 and IKK2 
single knockouts showed severe impairments in the activation of canonical 
NF-κB signaling (Fig. 4), only in cells deficient for both, IKK1 and IKK2, a 
vastly increased cell death after TNFα treatment was observed (Fig. 7). In 
line with the results obtained in mice by Dondelinger and colleagues, cell 
death was mediated in dependence of RIPK1 and independent on NF-κB 
Figure 7. Cell death is increased after TNFα treatment in IKK1/2-deficient cells. (A) 
Light microscopic analysis of cells after 24 h stimulation with TNFα. A high number of 
dead cells was observed only in cells deficient for both IKK1 and IKK2. (B) 
Immunocytochemical stainings for activated caspase-3. A strong increase in caspase-3-
positive cells in TNFa-treated double-deficient cells was detectable, which could partially 
be prevented using the RIPK1 inhibitor Necrostatin-1s (Nec-1s). Application of the MLKL 
inhibitor Necrosulfonamide only slightly lowered the amount of caspase-3-positive cells. 
Modified from (Slotta et al. c). 
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(Dondelinger et al., 2015, Slotta et al. c). This strongly indicates a similar role 
of the IKK complex as a major checkpoint in regulating TNF-induced cell 
death in human cells making it a promising target for future therapeutic 
approaches.  
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5.2 Autophagy 
Autophagy (ancient greek: autóphagos; self-devouring) is a catabolic 
process, in which damaged or non-used cellular substances are being 
degraded and subsequently recycled. By this, autophagy serves as a 
regulatory mechanism to maintain homeostasis within cells, tissues and 
organisms. Three different autophagic pathways have been described, 
macroautophagy, microautophagy and chaperone-mediated autophagy 
(CMA) (Boya et al., 2013). Here, the mechanisms of macroautophagy 
(hereafter referred to as autophagy) will be addressed. While originally 
thought to be a non-specific cellular degradation process, today numerous 
specialized forms of autophagy have been described that selectively degrade 
e.g. organelles such as mitochondria (mitophagy) or ribosomes (ribophagy) 
(Kiel, 2010), synaptic vesicles (Shen et al., 2015) or even intracellular 
pathogens (xenophagy) (Levine et al., 2011).  
As an essential cellular process, deregulation of autophagy is closely 
connected to diseases such as neurological disorders and cancer (Levy et 
al., 2017, Menzies et al., 2015).   
 
5.2.1 Basic principles of autophagy 
Today’s understanding of the importance of autophagy as well as its 
mechanisms is largely based on the discovery of the autophagy-related (Atg) 
genes in yeast (Tsukada and Ohsumi, 1993, Harding et al., 1995, Thumm et 
al., 1994). Many of these genes are conserved in humans.  
A major and well characterized regulatory factor of autophagy is the 
mammalian target of rapamycin (mTOR). Upon e.g. starving conditions, the 
mTOR complex 1 (mTORC1) – usually suppressing autophagy induction – is 
inhibited and by this initiates autophagy (Jung et al., 2010).  
The autophagic degradation process can be divided into five different stages: 
initiation, nucleation of the autophagosome (forming of the phagophore), 
expansion and elongation of the autophagosome membrane, fusion with the 
lysosome and finally the degradation of the intravesicular components (Fig. 
8) (reviewed in (Levy et al., 2017)). In the initiating phase, the ULK1 complex 
consisting of the unc-51 like autophagy activating kinases (ULK) 1 and 2, the 
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focal adhesion kinase family integrating protein 200 (FIP200), ATG13 and 
ATG101 complex is activated (Fig. 8). This in turn results in the activation of 
a complex, which comprises the class III phosphoinositide 3-kinase (PI3K) 
VPS34, which together with Beclin 1, ATG14, VPS15, UV radiation 
resistance-associated gene protein (UVRAG) and the BECN1‑regulated 
autophagy protein 1 (AMBRA1) forms phosphatidylinositol 3-phosphate 
(PI(P)3), an essential part of the autophagosome membrane. By this the 
phagophore is assembled.  
 
Elongation of the membrane, mediated by the ATG5-ATG12 complex 
conjugated to ATG16, results in the autophagosome (Geng and Klionsky, 
2008) having now engulfed the cargo that is to be degraded. ATG4B and 
ATG7 conjugate the microtubule associated protein 1 light chain 3 alpha 
(MAP1LC3A, also known as LC3I) to the lipid phosphatidylethanolamine 
(PE). The now termed LC3II protein is recruited to the membrane of the 
Figure 8. The autophagy degradation pathway and pharmacological inhibitors 
targeting at different stages of autophagy. Taken from (Levy et al., 2017). 
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autophagosome and serves as the most commonly used autophagosome 
marker (Klionsky et al., 2016). Mediated by the SNARE protein syntaxin17 
(STX17), the autophagosome now fuses with the lysosome resulting in the 
autolysosome (often also referred to as autophagolysosome). Finally, the 
engulfed cargo will be degraded.  
 
5.2.2 Autophagy in cancer – a double-edged sword 
Autophagy is strongly within the focus of cancer research. However, things 
are complicated in this context and usually autophagy is described as a 
“double-edged sword” (White and DiPaola, 2009, Hippert et al., 2006, 
Kimmelman, 2011, Kenific et al., 2010). Originally, suppression of autophagy 
was associated with the formation of tumors. The autophagy relevant gene 
BECN1 (encoding for Beclin 1) is highly suspected to be a tumor suppressor 
(Liang et al., 1999). It is monoallelically deleted in 40 % of all prostate 
cancers, 50 % of breast cancers and up to 75 % of ovarian cancers (Aita et 
al., 1999). Moreover, in heterozygous Beclin 1- deficient mice spontaneous 
malignant tumor formation was highly elevated (Yue et al., 2003, Qu et al., 
2003). However, the role of Beclin 1 as a tumor suppressor is now strongly 
being questioned. The BECN1 locus is adjacent to BRCA1 (breast cancer 1), 
a known breast and ovarian tumor suppressor (Laddha et al., 2014). 
Mutations in BRCA1 are known to cause the formation of breast and ovarian 
cancer. Monoallelic loss of BRCA1 therefore might be the driving force in 
tumor formation and not BECN1. In line with that, in mouse models with a 
monoallelic loss of Becn1 (but still carrying both copies of Brca1) 
tumorigenesis was not elevated but even reduced (Huo et al., 2013). 
Moreover, in large-scale genomic analyses no recurrent mutations within 
BECN1 or other essential autophagy genes were found (Vogelstein et al., 
2013, Lawrence et al., 2014). 
In contrast to the questionable role of autophagy in tumor formation, once a 
tumor is formed the general view is that inhibition of autophagy is beneficial 
within anticancer therapy (Amaravadi et al., 2007, Levy and Thorburn, 2011). 
In fact, many substances that inhibit autophagy at different stages are being 
used in clinical trials for anticancer therapies (for an overview see (Levy et 
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al., 2017)). Cancer cells are particularly dependent on autophagy, potentially 
due to higher metabolism caused by deregulated proliferation (Rabinowitz 
and White, 2010). Moreover, upregulated autophagy was shown in hypoxic 
tumor regions to be essential for cell survival (Degenhardt et al., 2006).  
Additionally, it was shown that especially cancer stem cells (CSCs) rely on 
autophagy (Lei et al., 2017). CSCs are a small subpopulation within a tumor, 
which have the capacity to self-renewal and differentiation (Gupta et al., 
2009). Due to this they have the ability to induce tumor formation. Being 
especially resistant to conventional anticancer therapy, CSCs are often 
responsible for tumor recurrence (Suresh et al., 2016). Inhibition of 
autophagy in combination with anticancer therapy therefore is now 
extensively being investigated to increase effectiveness of therapy and lower 
recurrence rates (Lei et al., 2017).   
 
5.2.3 Role of autophagy in neurodegenerative diseases 
Accumulation and aggregation of misfolded proteins is a feature of many 
neurodegenerative diseases, especially in those with a late onset, which e.g. 
includes Alzheimer’s disease (AD) and Parkinson’s disease (PD) (Zare-
Shahabadi et al., 2015, Lynch-Day et al., 2012). Many genes associated with 
neurodegenerative diseases – either as causative or as risk factor – also play 
a role in the autophagy pathway. Among the 27 major genes known to be 
implicated in amyotrophic lateral sclerosis (ALS), 7 genes are being 
associated with autophagy (reviewed in (Hardiman et al., 2017)). In a mouse 
model for a late onset motoneuron disease comprising features of ALS and 
Charcot-Marie-Tooth (CMT) disease, impaired formation of autophagosomes 
in motoneurons was described, strongly contributing to disease progression 
(Fig. 9) (Lüningschrör et al., 2017).  
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Figure 9. Formation of autophagosomes is impaired in motoneurons from Plekhg5-
deficient mice. (a) Motoneurons were transduced with GFP-RFP-LC3 reporter and the 
fluorescent structures were quantified in the soma (b) and within the axon (c). Modified from 
(Lüningschrör et al., 2017). 
 
While most research focusses on autophagy in neuronal cells, many 
neurological disorders have a “glia component”, meaning that also defects in 
glia cells contribute to the disease. Recent studies suggest that autophagy in 
glia cells may be equally important in the pathogenesis of the diseases, 
especially those with inflammatory features. In reactive astrocytes, 
autophagy was shown to be essential for cell survival (Motori et al., 2013). 
Moreover, autophagy was demonstrated to be protective for 
oligodendrocytes in a model of a demyelinating disease (Smith et al., 2013). 
However, more work is required to show the contributions of glial autophagy 
to the respective pathology in neurodegenerative diseases.  
With impaired autophagy being causative for the formation of 
neurodegenerative diseases, potential therapeutic approaches deal with the 
upregulation of this process (Harris and Rubinsztein, 2011).  
As described earlier, formation of the autophagy-initiating ULK1 complex is 
inhibited by mTOR. One of the first inducers of autophagy discovered is the 
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mTOR inhibitor rapamycin, which has been studied extensively in regard to 
its therapeutic potential (Ravikumar et al., 2004, Rodriguez-Muela et al., 
2012, Spilman et al., 2010, Jiang et al., 2014). Recently, research however 
concentrated on upregulating autophagy independent of mTOR, because 
mTOR also has other functions besides autophagy regulation. Though the 
mechanism is not known yet, the disaccharide trehalose can act as an 
activator of autophagy and as such was able to enhance lifespan in ALS 
mouse models (Castillo et al., 2013, Zhang et al., 2014b).   
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5.3 Plekhg5 
The Pleckstrin homology domain containing, family G member 5 (Plekhg5) is 
a guanine exchange factor (GEF), highly expressed within the nervous 
system, endothelial cells and tumor cells (Marx et al., 2005, Azzedine et al., 
2013, Liu and Horowitz, 2006, Dachsel et al., 2013). It consists of 1083 
amino acids (human transcript variant 2; NCBI refseq: NM_198681.3) and 
contains multiple functional domains for GTP/GDP exchange and membrane 
association (Fig. 10). While early publications defined Plekhg5 as a GEF 
specific for RhoA, direct interaction with a member of the Rab-family, Rab26, 
could be demonstrated recently (Lüningschrör et al., 2017). Furthermore, 
Plekhg5 is known to activate NF-κB although the exact mechanisms are not 
understood yet (Maystadt et al., 2007, Matsuda et al., 2003).   
 
5.3.1 Involvement of Plekhg5 in peripheral neuropathies 
Several mutations found within the human PLEKHG5 gene have been 
associated with different motoneuron diseases. While one point mutation 
within the pleckstrin homology (PH) domain (F647S) was associated with 
distal spinal muscular atrophy (DSMA IV) (Maystadt et al., 2007), another 
one (P630H) was found in a screening approach of patients suffering from 
ALS (Ozoguz et al., 2015). Moreover, PLEKHG5 mutations have been 
described as one cause for an intermediate form of CMT (Azzedine et al., 
2013, Kim et al., 2013). Based on measurements of the nerve conduction 
velocities (NCV), CMT diseases – the most common inherited neuropathy 
with a prevalence of 1 in 2500 (Reilly et al., 2011) – are classified into two 
major groups (Thomas and Calne, 1974, Keller and Chance, 1999, Nelis et 
al., 1999). In type I (CMT1), the NCV is lower than 38 m/s, which is caused 
by defects of the Schwann cells resulting in abnormal myelination (e.g. 
Figure 10. Schematic overview of the functional domains of Plekhg5. RBD, Rnd3 
binding domain; DH, Dbl homology domain; PH, Pleckstrin homology domain; PDZ, PDZ 
binding motif. 
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demyelination). CMT2 on the contrary is characterized by rather normal 
NCVs higher than 40 m/s, but reduced motor action potentials. Histologically, 
axonopathy – mostly a loss of large caliber axons – can be detected. While in 
CMT1 the Schwann cells and in CMT2 the neurons are affected, a third 
intermediate form has been described, showing characteristics of both forms 
(Rossi et al., 1985, Saporta et al., 2011). Since Plekhg5 was shown to be 
expressed in both, neurons and Schwann cells, it is not surprising that it is 
associated with the intermediate form of CMT (Kim et al., 2013, Azzedine et 
al., 2013, Lüningschrör et al., 2017).  
To date, two different mouse models were generated to analyze the role of 
Plekhg5 in the context of motoneuron disease. In 2013, Azzedine and co-
workers presented data based on a Plekhg5-deficient mouse generated 
earlier by Garnaas and colleagues (Azzedine et al., 2013, Garnaas et al., 
2008). In their study they demonstrated a slight decrease in the NCV 
resembling a mild intermediate CMT. However, no loss of motoneurons was 
demonstrated concluding that the phenotype of these mice did not resemble 
a lower motoneuron disease as described in humans by Maystadt and 
colleagues (Azzedine et al., 2013, Maystadt et al., 2007). Recently, a novel 
Plekhg5-deficient mouse line was characterized by Lüningschrör and co-
workers, in which significant loss of motoneurons was demonstrated, while 
the NCV was only very mildly and not significantly affected (Fig. 11c, g) 
(Lüningschrör et al., 2017). In contrast to the mouse analyzed by Azzedine 
and colleagues, these mice also developed a clear motoneuron disease 
pathology as could be demonstrated by hindlimb clasping, reduced grip 
strengths and reduced performance on the rotarod (Fig. 11b, d-f) 
(Lüningschrör et al., 2017). Two potential reasons might be the cause for the 
different observations in these mouse models. First, as described by 
Lüningschrör and co-workers, symptoms did not start before 12 months of 
age and in the study by Azzedine et al. no mice older than 12 months were 
analyzed. A potential pathology therefore might not have been detected. The 
second potential reason lies within the generation of the mouse model. The 
mice used by Azzedine were generated using the Cre-lox system, by which a 
region including the exons 9 to 13 was excised. This resulted in the 
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expression of a truncated protein lacking the RhoGEF domain but still 
containing most of the PH domain (Azzedine et al., 2013). In contrast, the 
gene-trap approach used by Lüningschrör and colleagues resulted in the 
expression of a protein lacking both functional domains (Lüningschrör et al., 
2017).  
 
 
Figure 11. Plekhg5-deficient mice develop a late onset motoneuron disease. (a) 
Reduced life-span of Plekhg5 mutant mice. (b) Hind-limp clasping in 15-month-old mutant 
mice. (c) Progressive loss of motoneurons within the spinal cord. (d, e) Decreased grip 
strengths of forelimbs (d) and hindlimbs (e). (f) Reduced performance of Plekhg5-deficient 
mice on the accelerating rotarod. (g) Slightly decreased sciatic nerve conduction velocity in 
mutant mice. Modified from (Lüningschrör et al., 2017). 
  
In the following, the roles of Plekhg5 in motoneurons and Schwann cells will 
be discussed.  
 
5.3.1.1 The role of Plekhg5 in motoneurons 
Motoneurons are the efferent neurons that innervate all cross-striated 
muscles throughout the body. While also cells residing in the motor cortex of 
the brain are classified as (upper) motoneurons, they do not directly act on 
muscle cells but are interneurons that activate the lower motoneurons 
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residing in the spinal cord, which in turn directly innervate muscles. Thus, the 
term motoneuron is often restricted to lower motoneurons. As stated above, 
several genes in humans known to be involved in autophagy are associated 
with motoneuron diseases, such as ALS (Hardiman et al., 2017). In mice 
deficient for the autophagy-related genes Atg5 or Atg7 progressive 
motoneuron loss could be observed (Hara et al., 2006, Komatsu et al., 2006). 
Besides shared autophagic pathways and functions compared to other cells, 
there is an additional need for autophagy-mediated degradation of synaptic 
vesicles in neurons. Synapses are highly dynamic structures and there is a 
persistent turnover of synaptic vesicles, which requests for controlled 
degradation (Caroni et al., 2012, Chung and Barres, 2012). Cell-autonomous 
degradation of synaptic vesicles was long thought to be mediated via the 
classical endosomal-lysosomal pathway (Raiborg and Stenmark, 2009). Still, 
not many evidences for this were reported, e.g. only sparse information is 
available, whether synaptic vesicle proteins are ubiquitinated – the initial step 
in the classical endosomal-lysosomal pathway (Katzmann et al., 2002, Na et 
al., 2012). In 2015, Binotti and colleagues reported autophagy-mediated 
degradation of synaptic vesicles, which was controlled by the GTPase Rab26 
(Binotti et al., 2015). Extending these findings, Plekhg5 could be 
demonstrated to directly act as a GEF for Rab26 in regulating this process 
(Lüningschrör et al., 2017). Hence, the autophagic impairments in Plekhg5-
depleted motoneurons presented above (Fig. 9) could be explained by 
reduced activation of Rab26. As a consequence of impaired autophagy-
mediated clearance of synaptic vesicles, large accumulations of synaptic 
vesicles were present in neuromuscular junctions (NMJs) of Plekhg5-
deficient mice (Fig. 12). By this, proper innervation of muscle cells was 
impeded resulting in the motoneuron disease phenotype described above.  
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Figure 12. The presynaptic region of neuromuscular junctions is strongly impaired in 
Plekhg5-deficient mice. Gastrocnemius (a) and intercostal (b) muscles were stained for the 
acetylcholine receptor (AChR) marking the postsynapse and for synaptophysin marking the 
presynapse. Modified from (Lüningschrör et al., 2017). 
 
5.3.1.2 The function of Plekhg5 in Schwann cells 
As stated above, Plekhg5 expression is not restricted to neurons within the 
nervous system. Particularly in Schwann cells, high expression of Plekhg5 
was demonstrated (Azzedine et al., 2013).  
Schwann cells are the myelinating glial cells in the PNS. Their main task 
under physiological conditions is the establishment and maintenance of the 
myelin sheath wrapped around the axons, which is essential for fast action 
potential propagation (Nave and Werner, 2014). However, under pathological 
conditions, Schwann cells display a great plasticity. Upon axonal lesions or in 
PNS disorders, Schwann cells are able to undergo huge differentiation 
processes. Originally, this was described as de-differentiation to a more 
immature Schwann cell type (Chen et al., 2007). However, there is now 
evidence that Schwann cells in fact differentiate to a distinct repair-cell type 
termed Bungner cell (Arthur-Farraj et al., 2012). Therefore, trans-
differentiation or reprogramming appears to be a more fitting term to describe 
these cellular changes (Jessen and Mirsky, 2016). This great plasticity of 
Schwann cells is thought to be one of the main reasons for the high 
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regenerative capacity of the PNS in contrast to the CNS since 
oligodendrocytes – the myelinating glia of the CNS – do not display this 
grade of plasticity (Vargas and Barres, 2007).  
Recently, a novel function of Schwann cells upon acute injury and potentially 
within PNS disorders has been described. Recovery of peripheral nerves 
after injury heavily relies on the clearance of axonal and myelin debris in a 
process called Wallerian degeneration (Vargas and Barres, 2007, Conforti et 
al., 2014). Gomez-Sanchez and co-workers demonstrated that initial myelin 
breakdown after sciatic nerve injury was performed directly by Schwann cells 
in an autophagy-dependent manner – a process termed myelinophagy 
(Gomez-Sanchez et al., 2015). In line with that, autophagy of myelin was also 
observed during axonal degeneration in the dental pulp (Suzuki et al., 2015). 
It was suggested that this process might not only play a role after acute injury 
but also in the context of inherited peripheral neuropathies. Extending these 
initial findings of autophagy-mediated myelin degradation, Slotta and 
colleagues reported impairments in the formation of autophagosomes in 
Schwann cells lacking Plekhg5 (Fig. 13), which resulted in demyelination 
deficits within peripheral nerves (Slotta et al. a).  
 
 
Figure 13. Biogenesis of autophagosomes is impaired in Plekhg5-depleted Schwann 
cells. (A) Primary Schwann cells were transduced with a GFP-RFP-LC3 reporter, which 
allows to selectively mark autophagosomes and autolysosomes based on the fluorescence. 
(B) Significantly decreased numbers of autophagosomes in mutant mice. Scale bar: 20 µm. 
Modified from (Slotta et al. a). 
 
Plekhg5-deficient mice displayed an increased number of axons with myelin 
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infoldings (Fig. 14) and an overall modest hypermyelination within the sciatic 
nerve (Slotta et al. a). These forms of myelin alterations were previously 
reported in demyelinating disorders preceding myelin breakdown (Quattrone 
et al., 1996, Fabrizi et al., 2000, Chung et al., 2011). However, no signs of 
demyelination were observable even in old mice (Slotta et al. a). As 
myelinophagy was described only as the initial process of myelin degradation 
(Gomez-Sanchez et al., 2015), impairments due to Plekhg5-deficiency could 
not be the single cause for the alterations observed.  
 
 
Figure 14. Altered myelination within the sciatic nerve of Plekhg5-deficient mice. (A) 
Histological analysis of semi-thin sections of mutant mice displaying severe myelin 
alterations. Most prominently infoldings of the myelin sheath were observed (blowups). (B) 
Progressive increase of fibers with abnormal myelination in Plekhg5-deficient mice. Modified 
from (Slotta et al. a).  
 
Besides this initial autophagy-mediated myelin breakdown, an increasing 
number of reports describe the immunocompetence of Schwann cells in 
pathological situations. Here Schwann cells contribute to both, the innate and 
the adaptive immune response (reviewed in (Ydens et al., 2013)). During the 
innate immune response, Schwann cells produce and secrete cytokines, 
such as TNF and IL-1β and chemokines such as monocyte chemoattractant 
protein 1 (MCP1) (Shamash et al., 2002, Tofaris et al., 2002). To a large 
extent this is regulated by NF-κB. Despite the axonal pathology in Plekhg5-
deficient mice (Lüningschrör et al., 2017), using RNAseq no increase in the 
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expression of NF-κB-regulated cytokines or chemokines was detected within 
the sciatic nerve (Slotta et al. a). As Plekhg5 is a known activator of NF-κB, 
this observation suggests an impaired activation of NF-κB in Schwann cells 
due to lack of Plekhg5 and by this the lack of inflammation within the sciatic 
nerve. Furthermore, Plekhg5-deficient mice displayed a reduced number of 
CD4- and CD8-positive T-lymphocytes within the sciatic nerve indicating also 
the adaptive immune response to be affected (Slotta et al. a).  
In summary, Plekhg5-defiency in Schwann cells culminates in an 
immunosuppression within peripheral nerves despite an axonal pathology. 
Therefore, Plekhg5 might be a promising target for the treatment of PNS 
disorders with inflammatory and/or demyelinating features. 
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5.3.2 Plekhg5 in tumor cells 
In addition to its expression in endothelial cells and within the nervous 
system, Plekhg5 was reported to be highly expressed in different tumorigenic 
tissues and cancer cell lines. In skin cancer cells Plekhg5 was shown to be 
involved in increased proliferation in response to vascular epidermal growth 
factor (VEGF) A (Yoshida et al., 2015). In U251-MG cells, a broadly used 
cellular model of GBM (Westermark et al., 1973), Dachsel and colleagues 
demonstrated Plekhg5 to regulate polarity-oriented migration (Dachsel et al., 
2013). In both studies, the role of Plekhg5 as a GEF for RhoA was described. 
However, as mentioned above, Plekhg5 was also reported to directly act as a 
GEF for a member of the Rab protein family in regulating synaptic autophagy 
in motoneurons (Lüningschrör et al., 2017). Extending the findings of Plekhg5 
as regulator of autophagy from motoneurons to cancer cells, U251-MG cells 
were genetically depleted of Plekhg5 using CRISPR/Cas9 (Slotta et al. b). 
Deficiency of Plekhg5 resulted in morphological changes from typically 
bipolar cells to a more apolar cell type, similar to observations by Dachsel 
and co-workers upon shRNA-mediated knockdown of Plekhg5 (Dachsel et 
al., 2013, Slotta et al. b). Moreover, cells lacking Plekhg5 displayed a 
significantly reduced proliferation (Slotta et al. b). 
 
 
Figure 15. Clearance of autolysosomes is compromised in PLEKHG5-deficient U251-
MG cells. (A, B) U251-MG cells were transduced with a GFP-RFP-LC3 reporter and the 
fluorescent structures were quantified. A strongly elevated number of autolysosomes was 
observed (C) Increased amount of the lysosomal marker Lamp1 in PLEKHG5-deficient cells. 
Modified from (Slotta et al. b). 
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Regarding changes in the autophagic process, Plekhg5-depleted cells 
showed a significant increase in the number of autolysosomes (Fig. 15). 
Upon application of Bafilomycin A1, levels were normalized to wildtype cells 
(Slotta et al. b). This indicated an impaired or delayed clearance of 
autolysosomes. Notably, Plekhg5-deficiency in murine motoneurons and 
Schwann cells resulted in an impaired formation of autophagosomes 
(Lüningschrör et al., 2017, Slotta et al. a), demonstrating Plekhg5 to regulate 
autophagy at different stages depending on the cellular or environmental 
context. U251-MG cells, as described earlier, are a model system broadly 
used to study GBMs. GBMs are among the most aggressive tumors and 
survival rate, even with maximum treatment, is no longer than 14 months 
(Koshy et al., 2012). Glioblastoma cells are particularly resistant to 
chemotherapy. Upon treatment with Temozolomide (TMZ), a standard 
chemotherapeutic agent, glioblastoma cells upregulate autophagic processes 
helping them to survive (Wurstle et al., 2017, Knizhnik et al., 2013). Targeting 
autophagy in GBMs next to chemotherapy therefore appears to be 
particularly promising to increase efficiency of chemotherapy. Future studies 
will have to address, whether Plekhg5 might serve as an additional target to 
impair autophagy during chemotherapy.  
In summary, Plekhg5 appears to be a promising genetic target for anticancer 
therapy, since it is involved in cancer cell proliferation and migration (i.e. 
cancer invasion) but also in regulating autophagy.  
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6. Outlook 
In part one of this thesis the different roles of Plekhg5 in motoneurons and 
Schwann cells have been analyzed. Deficiency in neurons and Schwann 
cells both contributed to the pathology observed in Plekhg5-deficient mice. 
Further extending these promising findings, cell-type-specific rescue of 
Plekhg5 could be performed. The gene-trap cassette within the Plekhg5 
locus additionally contains LoxP sites (Lüningschrör et al., 2017) allowing re-
establishment of the original genomic locus using the Cre-Lox system.   
In regard to the reduced immune response in peripheral nerves of Plekhg5-
deficient mice, it is tempting to speculate whether a Schwann cell-specific 
depletion of Plekhg5 would improve the phenotype in mouse models with a 
peripheral neuropathy that includes neuroinflammatory features, e.g. the 
classical ALS mouse model SOD1G93A. Moreover, since a significant subset 
of the downregulated genes for T-lymphocyte recruitment were target genes 
for NF-κB, Schwann cell-specific inhibition of NF-κB activity also might be a 
promising approach.   
Part two of the thesis presented focused on the analysis of several 
CRISPR/Cas9-mediated knockouts in human cells. Since all findings aimed 
to provide new mechanistic insights for future anticancer therapeutic 
approaches, they should be reproduced in primary human tumor cells in the 
next step.  
With regard to the PLEKHG5-deficient human glioma cells generated in this 
thesis, potential consequences of the altered autophagy in the context of 
chemotherapy should be investigated. Since the application of 
chemotherapeutics is known to elevate autophagy, alterations in the 
autophagic process potentially would sensitize cells to chemotherapy.  
As the simultaneous depletion of IKK1 and IKK2 greatly sensitized cells to 
TNF-induced cell death, future studies should take on this promising finding 
to analyze its applicability in the context of anticancer therapy. This in 
particular involves the delivery methods to ensure both efficient and specific 
genetic modifications, so that effectively only tumor cells are affected. 
Moreover, methods for local TNF application have to be validated.   
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Plekhg5-regulated autophagy of synaptic vesicles
reveals a pathogenic mechanism in motoneuron
disease
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Christian Kaltschmidt2 & Michael Sendtner 1
Autophagy-mediated degradation of synaptic components maintains synaptic homeostasis
but also constitutes a mechanism of neurodegeneration. It is unclear how autophagy of
synaptic vesicles and components of presynaptic active zones is regulated. Here, we show
that Pleckstrin homology containing family member 5 (Plekhg5) modulates autophagy of
synaptic vesicles in axon terminals of motoneurons via its function as a guanine exchange
factor for Rab26, a small GTPase that speciﬁcally directs synaptic vesicles to
preautophagosomal structures. Plekhg5 gene inactivation in mice results in a late-onset
motoneuron disease, characterized by degeneration of axon terminals. Plekhg5-depleted
cultured motoneurons show defective axon growth and impaired autophagy of synaptic
vesicles, which can be rescued by constitutively active Rab26. These ﬁndings deﬁne a
mechanism for regulating autophagy in neurons that speciﬁcally targets synaptic vesicles.
Disruption of this mechanism may contribute to the pathophysiology of several forms of
motoneuron disease.
DOI: 10.1038/s41467-017-00689-z OPEN
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NATURE COMMUNICATIONS |8:  678 |DOI: 10.1038/s41467-017-00689-z |www.nature.com/naturecommunications 1
In neurons, autophagosome biogenesis predominantly takesplaces in axon terminals. Newly synthesized autophagosomesmature during retrograde transport to the soma and fuse
with lysosomes1, 2. Autophagy-mediated degradation of synaptic
components is involved in neuronal network remodeling,
presynaptic neurotransmission and synaptic pruning at
polyinnervated neuromuscular junctions during development,
but could also represent a mechanism of neurodegeneration3–6.
Selective elimination of axon terminals marks disease onset in
familial amyotrophic lateral sclerosis (ALS) and loss of synaptic
vesicles precedes axon degeneration in SOD1 G93A mice7,
indicating that autophagy temporally regulates degradation of
synaptic vesicles in axon terminals. Neuron-speciﬁc disruption of
autophagy by depletion of Atg5 or Atg7 results in progressive
deﬁcits of motor function and neurodegeneration8, 9. Modulation
of the autophagy pathway modiﬁes disease onset and progression
in SOD1 G93A mice, which further points to the contribution
of autophagy to the pathology of motoneuron disease10, 11.
However, the molecular mechanisms that differentially regulate
autophagy of synaptic vesicles and components of presynaptic
active zones are not known.
Here, we show that Plekhg5 (also known as Syx, Tech or
GEF720)12–14 regulates autophagy of synaptic vesicles in moto-
neurons via its function as a guanine exchange factor (GEF) for
Rab26, a small GTPase selectively delivering synaptic vesicles into
preautophagosomes15. Plekhg5 is a pleckstrin homology domain
containing member of the GEF family. It is predominantly
expressed in the nervous system12, 14. While several studies
provided evidence for a function of Plekhg5 in endothelial
cell migration and angiogenesis in zebraﬁsh and mice13, 16, its
function in the nervous system remained elusive. Mutations in
the PLEKHG5 gene have been associated with different forms of
motoneuron diseases such as distal spinal muscular atrophy type
IV (DSMA-IV)17, intermediate Charcot-Marie-Tooth disease
(CMT)18, 19 and ALS20. The PLEKHG5-mutations identiﬁed so
far in CMT disease patients produce premature stop codons
and are predicted to result in a functional null allele18, 19. In
contrast, mutations described to be causative for a recessive lower
motoneuron disease with childhood onset lead to an exchange of
one amino acid within the pleckstrin homology domain17, 20.
To analyze the function of Plekhg5 in the nervous system and
its involvement in motoneuron disease, we generated Plekhg5-
deﬁcient mice using a gene-trap approach21. Plekhg5-deﬁcient
mice develop a late-onset motoneuron disease, characterized by
degeneration of motoneuron axon terminals. Plekhg5-depleted
cultured motoneurons show defective autophagy resulting in
accumulation of synaptic vesicles at axon terminals and impaired
axon growth. Furthermore, Plekhg5-deﬁcient cells show a
reduced activity of Rab26. In a cell-free system Plekhg5 is able to
promote GTP exchange of Rab26. Finally, constitutively active
Rab26 rescues autophagy and axon growth deﬁcits of cultured
motoneurons. Our data indicate that the function of Plekhg5 as a
GEF for Rab26 is essential for axonal integrity, and that defective
autophagy of synaptic vesicles is a pathogenic mechanism in this
speciﬁc form of motoneuron disease.
Results
Plekhg5 deﬁciency causes a late-onset motoneuron disease.
To analyze the cellular function of Plekhg5, we generated
Plekhg5-deﬁcient mice using an embryonic stem-cell line
harboring a gene-trap cassette within the Plekhg5 allele (Fig. 1),
(Supplementary Fig. 1)21. Plekhg5-deﬁcient mice developed
normally without obvious disease phenotype up to adulthood.
However, within 24 months after birth 33 out of 100 homozygous
mice died, in contrast to 10 out of 100 heterozygous and 5 out of
100 wild-type animals (Fig. 1a). Affected mice developed hind-
limb paralysis at 15 months (Fig. 1b). A reduction in body weight
became apparent in 18−24 months old Plekhg5-deﬁcient mice
(Fig. 1c). To assess the impact of Plekhg5 deﬁciency on motor
performance in more detail, grip strength (Fig. 1e, f) and rotarod
performance (Fig. 1g) were analyzed in animals of different ages.
These data indicate that the disease starts late at about 12 months
of age and progresses from hindlimbs (Fig. 1f) to forelimbs
(Fig. 1e). Correlating with reduced grip strength, we observed
a loss of motoneurons starting at 12 months as shown by
quantiﬁcation of Nissl-stained lumbar spinal cord sections
(Fig. 1d, h). This decrease was more prominent in 24-month-old
animals (Fig. 1d).
We complemented the phenotypic characterization of the
motor system with nerve conduction and electromyography
studies of the gastrocnemius and plantaris muscles (Fig. 1j–l, o).
In both muscles we observed a signiﬁcantly delayed motor
latency time (Fig. 1i). The measurements in the gastrocnemius
muscles also showed a marked reduction of motor unit
potential (MUP) amplitudes following sciatic nerve-stimulation
(Fig. 1j). Our analyses revealed elevated single motor unit
potentials (SMUP) (Fig. 1k) and a decrease in motor unit
number estimation (MUNE) (Fig. 1l) in the gastrocnemius
muscle, suggestive of sprouting of surviving motoneurons to
re-innervate muscle ﬁbers that have been denervated upon
motoneuron loss. This ﬁnding is also supported by the observed
ﬁber grouping as shown by succinate dehydrogenase (SDH)
staining (Fig. 1m). These data are similar to the observed
sprouting phenotype reported in SOD G93A mice22. As
previously described for Plekhg5 mutant mice19, we also
detected a modest decrease in nerve conduction velocities
(NCVs) (Fig. 1o).
Next, we investigated β-GEO reporter-activity of the gene-trap
cassette in mutant mice. In contrast to spinal cord,
β-galactosidase activity was not detected in skeletal muscle
(Fig. 1n). Therefore, loss of Plekhg5 apparently does not affect
the skeletal muscle directly, but rather indirectly via denervation
and motoneuron loss.
We also assessed the impact of Plekhg5 deﬁciency on sensory
and cognitive function. Sensory function was analyzed using the
von Frey and Hargreaves tests (Fig. 1p, q). Whereas Plekhg5-
deﬁcient mice did not show major changes in mechanical
withdrawal thresholds as compared to wild-type littermates
(Fig. 1p), they displayed hypersensitivity to heat (Fig. 1p),
indicating that sensory perception is not reduced in these mice.
To address whether Plekhg5 deﬁciency impairs cognitive
function, we performed behavioral tests in 12−14-month-old
mice (Supplementary Fig. 2), before motor disease symptoms
occur. Plekhg5-deﬁcient mice performed similarly in the
open ﬁeld test (Supplementary Fig. 2a, b) indicating that
anxiety-related behavior is not altered. They also did not display
differences in object recognition (Supplementary Fig. 2c, d)
and fear conditioning (Supplementary Fig. 2e, f) suggestive
for unaffected learning and memory.
Plekhg5 modulates synaptic vesicle turnover in motoneurons.
Next, we studied neuromuscular junctions (NMJs) within the
gastrocnemius muscle to analyze whether the degenerative
process in Plekhg5−/− mice involves terminal axons (Fig. 2a, c;
Supplementary Fig. 3). Wild-type animals exhibited regular
pretzel-like NMJs at an age of 12 months, as indicated by
bungarotoxin (BTX) staining for labeling of postsynaptic
acetylcholine-receptors and synaptophysin immunoreactivity
for the corresponding presynaptic compartment (Fig. 2a;
Supplementary Fig. 3). In contrast, the presynaptic nerve
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terminals of Plekhg5−/− mice appeared swollen with accumula-
tions of synaptophysin (Fig. 2a, c; Supplementary Fig. 3) and
neuroﬁlament-H (NF-H) (Supplementary Fig. 3).
Respiratory failure due to progressive impairment of the
neuromuscular system has been reported as a main cause of
death in ALS and the major trigger for premature death in SOD1
G93A mice23. We therefore investigated whether NMJs within
intercostal muscles of Plekhg5-deﬁcient mice also show signs
of degeneration. We observed a phenotype similar as in the
gastrocnemius muscle with deformed and swollen axon terminals
(Fig. 2b, d), indicating that muscles necessary for respiration
become denervated which could make a major contribution to
premature death.
At the ultrastructural level, axon terminals of Plekhg5-deﬁcient
mice were ﬁlled with membrane fragments and cytoplasmic
inclusions (Fig. 3a–e), similar as those observed in patients with
ALS24, 25. Strikingly, synaptic vesicles in Plekhg5−/− motoneuron
terminals were frequently enlarged, in contrast to synaptic
vesicles in wild-type mice, which appeared smaller and of a
more uniform size (Fig. 3f–h). Furthermore, the organization of
actin ﬁlaments in axon terminals appeared altered, with more
actin ﬁbers in close neighborhood of synaptic vesicles in active
zones (Fig. 3f, g). In line with these ﬁndings we detected elevated
protein levels of several synaptic vesicle markers in sciatic nerve
lysates of Plekhg5−/− mice (Fig. 3i, j). The ultrastructural
examination of NMJs also revealed axonal swellings in distal
axons (Fig. 4a). Axons showed a highly disorganized cytoskeleton
(Fig. 4b, c). Axonal swellings were also frequently detectable in
spinal cord and sciatic nerve cross-sections (Fig. 4d–j). In
contrast, we detected no axonal swelling in wild-type animals
(Fig. 4j). Taken together, these data indicate that Plekhg5
deﬁciency results in degradation of axon terminals, but also
affects axonal integrity in proximal parts of axons.
Next, we studied the impact of Plekhg5 deﬁciency on synapse-
morphology in the central nervous system and stained brain
sections for synaptophysin and Tuj1 (Supplementary Fig. 4). The
overall morphology and layering of the hippocampus, cerebellum
and cortex appeared normal (Supplementary Fig. 4). In contrast
to the abnormally swollen appearance of motoneuron terminals
with synaptophysin-accumulations, synapses within the brain
appeared unaffected in Plekhg5-deﬁcient mice (Supplementary
Fig. 4). These observations are in line with our data on normal
cognitive function in Plekhg5-deﬁcient mice.
Plekhg5 regulates autophagy in motoneurons. Under
physiological conditions damaged organelles are removed
from axon terminals by autophagy1, 2, 6. To assess whether
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dysregulated autophagy causes the accumulation of synaptic
vesicles at nerve terminals we examined the autophagic ﬂux in
Plekhg5-deﬁcient motoneurons (Fig. 5). Since autophagosomes
rapidly fuse with lysosomes, changes in the biogenesis of autop-
hagosomes are hardly detectable under basal conditions26, 27.
Therefore, cultured motoneurons were transduced with lenti-
viruses expressing GFP-RFP-LC3 and treated with baﬁlomycin
A1 after 7 days in culture (Fig. 5a–c). Baﬁlomycin A1 blocks the
fusion of autophagosomes and lysosomes resulting in an
enrichment of LC3-II positive autophagosomes. Since fusion of
autophagosomes and lysosomes quenches the ﬂuorescence of
GFP, RFP positive structures selectively mark autolysosomes,
whereas autophagosomes appear positive for both RFP and
GFP27. Under basal conditions we detected no difference in the
number of autophagosomes and autolysosomes in the soma of
wild-type and Plekhg5−/− cells. However, upon treatment with
baﬁlomycin A1 Plekhg5-deﬁcient cells displayed a signiﬁcantly
reduced number of autophagosomes in comparison to wild-type
motoneuron somata (Fig. 5a, b). In axons of Plekhg5−/− moto-
neurons, a reduced number of autophagosomes was detected in
both untreated cells and baﬁlomycin A1 treated cells (Fig. 5a, c).
In agreement with previous reports we only identiﬁed very few
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autolysosomes in axons of cultured motoneurons, conﬁrming
that full maturation of autophagosomes to lysosomes
mostly occurs within or close to the soma1, 26. The number of
autolysosomes was not altered indicating that acidiﬁcation of
autolysosomes, as a late step of maturation, was unaffected
(Fig. 5a–c). To examine whether Plekhg5 deﬁciency causes
impaired axonal transport of autophagosomes, motoneurons
were transduced with RFP-GFP-LC3, and the movement of
GFP-LC3+ structures was analyzed (Fig. 5d–f). Plekhg5−/−
motoneurons showed a reduced number of autophagosomes
moving retrogradely towards the soma (Fig. 5f), whereas the
relative number of retrogradely moving autophagosomes
appeared unaltered (Fig. 5e; Supplementary Movie 1, 2). Reduced
protein levels of endogenous LC3-II were also biochemically
detected in Plekhg5-deﬁcient neurosphere-derived neurons upon
treatment with baﬁlomycin A1 by western blotting
(Fig. 5g, h). This reduction of LC3-II levels was also apparent in
spinal cord extracts of 24-month-old mice (Fig. 5i, j).
Taken together, these data emphasize that the biogenesis of
autophagosomes is impaired in Plekhg5-deﬁcient motoneurons
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resulting in a reduced number of retrogradely transported
autophagosomes. The remaining autophagosomes are trans-
ported normally.
An essential process for autophagosome formation is the
production of phosphatidylinositol 3-phosphate (PI(3)P) by
phosphatidylinositol-3-kinase class III at preautophagosomal mem-
branes28. Pleckstrin homology (PH) domains form a conserved
family that mediates protein association to inositol lipids like PI(3)
P. We analyzed whether Plekhg5 binds to PI(3)P using extracts
from mouse motoneuron-like hybrid cells (NSC34) expressing Flag-
tagged Plekhg5. We could precipitate Plekhg5 with PI(3)P-coated
beads but not with control beads (Fig. 5m) suggesting that Plekhg5
is able to associate with PI(3)P at preautophagosomal membranes28.
For monitoring the fate of Plekhg5 upon induction of autophagy,
Plekhg5-YFP transfected NSC34 cells were starved for 4 h in HBSS
and the expression of Plekhg5-YFP was analyzed by western blot
(Fig. 5k). In contrast to a marked reduction of full-length Plekhg5-
YFP, the signal for smaller protease-resistant YFP-positive
fragments increased (Fig. 5k). Nutrient deprivation differently
affects cell lines and primary neurons. Therefore, we also performed
this experiment with cultured motoneurons by replacing enriched
motoneuron-media with different media each deprived of speciﬁc
nutrient components (Fig. 5l). As observed in NSC34 cells, nutrient
deprivation resulted in degradation of Plekhg5. In contrast to
overexpressed Flag-Plekhg5, endogenous Plekhg5 appeared as
multiple bands that were differently affected by nutrient deprivation
(Fig. 5l). The identity of the bands that were detected by western
blot analysis was controlled by sh-RNA-mediated knockdown of
Plekhg5 (Fig. 5l; Supplementary Fig. 5a, b). In summary, these
experiments suggest that Plekhg5 is able to bind PI(3)P, placing
Plekhg5 to the inner autophagosomal membrane. This idea is
further supported by the degradation of Plekhg5 upon autophagy
induction. Fusion of autophagosomes with lysosomes results in
digestion of proteins in the lumen of the autophagosome including
proteins localized to the inner autophagosomal membrane29.
Next, we determined whether impaired autophagy affects
survival and/or morphology of Plekhg5-depleted motoneurons
in vitro. Plekhg5-depleted motoneurons grew shorter axons,
whereas cell survival and dendritic complexity was not affected
(Fig. 6a, b; Supplementary Fig. 5). In order to ﬁnd out how altered
autophagy leads to axonal growth defects, we characterized the
morphology of axon terminals in Plekhg5−/− motoneurons.
Growth cones of cultured Plekhg5−/− motoneurons appeared
atrophic with a signiﬁcantly smaller size and with dysmorphic
densely packed accumulation and clustering of synaptophysin-
positive synaptic vesicles leading to a reduced number of F-actin
ﬁlaments (Fig. 6c, d). We next looked at the expression pattern
of Rab26 in axons of cultured motoneurons. Rab26 is a
small GTPase enriched on synaptic vesicles designated for delivery
to preautophagosomal structures15. In its GTP-bound form Rab26
is an effector of Atg16L leading to recruitment of the autophagy
machinery to synaptic vesicles. In Plekhg5-deﬁcient cells Rab26-
positive structures accumulate in regions directly at active zones,
in contrast to wild-type motoneurons where these structures are
found in more proximal areas of axonal growth cones (Fig. 6c, d).
To examine these morphological alterations in more depth, we
performed SIM microscopy (Fig. 6e). These high-resolution
images conﬁrmed the data obtained by confocal microscopy
providing additional evidence that the number of Rab26-positive
vesicles increased, and the actin cytoskeleton disorganized
(Fig. 6e). These ﬁndings support the in vivo structural analyses
demonstrating marked alterations in cytoskeletal structures
(Fig. 4b, c), which might cause the defect in axon growth.
Plekhg5 functions as a GEF for Rab26. Activation of GTPases
requires dissociation of protein-bound GDP, an intrinsically slow
process that is accelerated by speciﬁc GEFs30. To explore whether
Plekhg5 regulates the activity of Rab26, neurosphere-derived
cortical neurons were transduced with EGFP-Rab26 and labeled
with 32P for 4 h. Subsequently, EGFP-Rab26 was immunopreci-
pitated and GTP- or GDP-bound Rab26 was separated by thin
layer chromatography (TLC) (Fig. 7a), revealing a signiﬁcantly
reduced GTP/GDP ratio (Fig. 7b). Next, we asked whether
Plekhg5 is able to directly act as a GEF for Rab26 in a cell-free
system (Fig. 7c–h). Using homogenously puriﬁed recombinant
proteins we analyzed the ability of Plekhg5 to catalyze GDP
dissociation of Rab26 and observed a marked acceleration of GTP
exchange in the presence of the DH-PH (Dbl-homologous-
Pleckstrin homology) tandem domain of Plekhg5 for Rab26
(Fig. 7g, h), but not for Rab5, Rab27b, or Rab33b
(Fig. 7d–f). These data demonstrate that Plekhg5 acts as a GEF for
Rab26.
We then followed this line of experiments and tested wild-type
and a constitutively active form of Rab26, Rab26Q123L (Rab26-
QL), in cultured motoneurons (Fig. 8). As previously described,
wild-type EGFP-Rab26 accumulated in vesicles within axons15. In
Plekhg5-deﬁcien motoneurons, the size of these vesicles was
signiﬁcantly reduced (Fig. 8a, c), and the number of EGFP-Rab26
vesicles was also modestly reduced (Fig. 8a, d). With constitutive
active EGFP-Rab26, the number and size of these vesicles
normalized and no differences between wild-type and Plekhg5-
deﬁcient cells were detectable (Fig. 8a, c, d). In correlation with
these ﬁndings, EGFP-Rab26-QL also fully restored axon growth
Fig. 5 Plekhg5 regulates biogenesis of autophagosomes. a Motoneurons of Plekhg5+/+ and Plekhg5−/− mice were transduced with mRFP-GFP-LC3-
expressing lentiviruses and cultured for seven days. At day seven cells were treated with Baﬁlomycin A1 for four hours or left untreated and the number of
autophagosomes (mRFP+-GFP+-LC3) and autolysosomes (mRFP+-GFP−-LC3) was determined in the soma b and axon c (three independent experiments
with 15 cells analyzed in each experiment; mean± SEM; two-way ANOVA; Bonferroni post-test). Soma, scale bar: 5 µm. Axon, scale bar: 20 µm. Axon (blow
up), scale bar: 5 µm. d Representative kymographs of autophagosome motility. Cultured motoneurons were transduced with mRFP-GFP-LC3 and the
movement of GFP positive punctae in axons was monitored for 20min. e Proportion of retrogradely, anterogradely or stationary/bidirectionally moving
autophagosomes (mean± SEM; n= 10 cells; two-way ANOVA; Bonferroni post-test). f Number of retrogradely moving autophagosomes per minute
(mean± SEM; n= 10 cells; Studentʼs t-test; one-tailed). g Western blot analysis of LC3 expression in neurosphere-derived cortical neurons from control
and Plekhg5-deﬁcient mice. Cells were treated with 400 nM Baﬁlomycin A1 for 4 h or left untreated. LE low exposure, HE high exposure. h Quantiﬁcation of
LC3 western blots. (Mean± SEM; n= 3; mean± SEM; one-way ANOVA). i Expression of LC3 in spinal cord lysates of three mice per genotype.
j Quantiﬁcation of LC3 Western blots from spinal cord extracts. (mean± SEM; n= 4; mean± SEM; Studentʼs t-test; two-tailed). k NSC34 cells were
transfected with Plekhg5-YFP. Seventy-two hours after transfection, cells were starved for 4 h in HBSS or left untreated. The expression of Plekhg5-YFP
was analyzed by western blot. l Motoneurons were cultured for seven days in motoneuron-media. At day seven cells were cultured for 4 h with different
media each deprived of speciﬁc components. Subsequently, motoneurons were lysed and the expression of endogenous Plekhg5 was analyzed by western
blot. Asterisks label bands that do not change upon nutrient deprivation. Arrowheads point to bands that change upon nutrient deprivation. m NSC34 cells
were transfected with Flag-Plekhg5. Seventy-two hours after transfection, cells were lysed and Flag-Plekhg5 was pulled-down with PI(3)P-coated beads.
Western blot images have been cropped for presentation. Full size images are presented in Supplementary Fig. 7
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defects of Plekhg5-deﬁcient motoneurons (Fig. 8b, e). In contrast,
EGFP-Rab26-QL only moderately enhanced axon growth in wild-
type cells (Fig. 8b, e).
In order to study the effects of constitutive Rab26 on axonal
autophagy, we constructed lentiviral vectors that simultaneously
express RFP-GFP-LC3 and Flag-Rab26-WT or Flag-Rab26-QL
(Fig. 8f, g), respectively. We then quantiﬁed the number of
RFP-GFP-LC3 positive structures in proximal axons and found
that the number of autophagosomes was reduced in Plekhg5-
deﬁcient motoneurons (Fig. 8h, i). This reduction did not
occur in Plekhg5−/− motoneurons expressing constitutive active
Rab26-QL (Fig. 8h, i). In agreement with the data shown in
Fig. 5a–c, the number of autolysosomes remained unaltered.
These data conﬁrm the conclusion that Plekhg5 acts as a GEF for
Rab26 and contributes to autophagosome biogenesis.
Plekhg5 modiﬁes ER-stress in SOD1 G93A motoneurons.
Protein misfolding and endoplasmatic reticulum (ER) stress is a
common disease mechanism in different models of motoneuron
disease31–36. Deﬁciency of global autophagy in neurons results in
an impairment of proteostasis characterized by accumulation
of polyubiquitinated proteins in inclusion bodies8, 9. Plekhg5-
deﬁcient mice did not show any accumulation of
c
b
SyPhy Rab26 F-actin
Pl
ek
hg
5+
/+
Pl
ek
hg
5+
/+
Pl
ek
hg
5–
/–
Pl
ek
hg
5–
/–
5 μm
2 μm
Merge
10 μm 10 μm
Distal axonProximal axon
Plekhg5 –/–Plekhg5 +/+
Ple
kh
g5
+/+
Plekhg5 +/+ Plekhg5 –/–
Sy
Ph
y
R
ab
26
F-
ac
tin
M
er
ge
d
100 μm
G
FP
 
Ta
u
Non-transduced sh-control sh-Plekhg5 #D
Ax
on
 le
ng
th
 (μ
m
)
D
en
dr
ite
 le
ng
th
 (μ
m
)
# 
of
 d
en
dr
ite
s
**
**
Axon length
Dendrite
length
# of 
dendrites
Ax
on
 te
rm
in
al
 
 
 
si
ze
 (μ
m
2 )
Size of axon
terminals
Non-transduced
sh-control
sh-Plekhg5
200
560900
750
600
450
300
150
0
50
40
30
20
10
0
4
3
2
1
0
150
100
50
0
*
a
e
Ple
kh
g5
–
/–
Fig. 6 Depletion of Plekhg5 results in axon growth defects and degeneration of axon terminals in vitro. a Motoneurons were transduced with sh-control or
sh-Plekhg5 #D lentiviruses or left untreated. Scale bar: 100 µm. b Seven days after sh-RNA transduction, knockdown of Plekhg5 reduced axon length,
whereas dendrite length and number of dendrites were not affected. Each data point represents the mean of one individual experiment with at least 20 cells
analyzed. One-way ANOVA, Bonferroni post-test. c–e Motoneurons were cultured for seven days and stained for synaptophysin, Rab26 and F-actin and
imaged by confocal c and SIM microscopy e. c Scale bar: 10 µm. d Quantiﬁcation of axon terminal size (n= 15 cells; unpaired t-test; two-tailed).
e Motoneurons were cultured for 7 days and stained for synaptophysin, Rab26 and F-actin and imaged by SIM microscopy. Axons of Plekhg5−/−
motoneurons display synaptophysin positive swellings. Scale bar: 10 µm. Scale bar (blow up): 2 µm
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00689-z ARTICLE
NATURE COMMUNICATIONS |8:  678 |DOI: 10.1038/s41467-017-00689-z |www.nature.com/naturecommunications 9
polyubiquitinated proteins at axon terminals or in motoneuron
cell bodies as shown by immunohistochemical staining
(Supplementary Fig. 6a, b). In addition, we were not able to detect
any differences in the levels of polyubiquitinated proteins by
western blotting (Supplementary Fig. 6c). In contrast, the levels of
Chop and IRE1α were markedly elevated in Plekhg5−/− spinal
cord extracts (Fig. 9c, d). Thus, the unfolded protein response
(UPR) seems to be activated in Plekhg5-deﬁcient mice. We also
tested the expression levels of heat shock protein family members
HSP70 and HSP90 and the ER chaperone Calreticulin by western
blot analyses and found signiﬁcantly decreased expression of all
three chaperones (Fig. 9a, b). Together, these data suggest that
Plekhg5 deﬁciency results in ER-stress without affecting the
turnover of polyubiquitinated proteins.
In order to investigate the relevance of impaired
synaptic vesicle autophagy for motoneuron vulnerability in a
well-characterized model of ALS we depleted Plekhg5 in SOD1
G93A motoneurons in vitro (Fig. 9e–g). We analyzed the effect of
Plekhg5 knockdown with two independent sh-RNA lentiviral
constructs on embryonic SOD1 G93A motoneurons and
investigated ER-stress as a pathogenic mechanism. ER-stress
precedes disease onset in SOD1 transgenic mice37 and modula-
tion of the UPR has been shown to modulate disease onset and
progression in SOD1 transgenic mice38, 39. PERK phosphoryla-
tion, BIP expression and Chop activation were enhanced in a
supra-additive manner in SOD G93A motoneurons with addi-
tional Plekhg5 depletion (Fig. 9e, f). Upon knockdown of
Plekhg5, SOD1 G93A motoneurons also showed a decrease in
survival (Fig. 9g). Interestingly, this effect was observed in
embryonic motoneurons representing a developmental stage long
before disease becomes apparent in vivo. We did not observe any
signiﬁcant changes in the levels of endogenous and transgenic
SOD1 when Plekhg5 is depleted (Fig. 9e, f). Therefore, Plekhg5 is
not involved in the degradation of the mutant SOD1 protein.
These data indicate that both disease mechanisms have additive
effects, cumulating in an elevated load of ER-stress.
Discussion
In summary, our data show that Plekhg5 functions as a GEF for
Rab26, and thus regulates autophagy of synaptic vesicles in axon
terminal of motoneurons. Disruption of this process leads
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to enlarged synaptic vesicles and accumulation of synaptic
proteins resulting in dysfunction of neuromuscular junctions and
motoneuron disease.
Our data suggest that Plekhg5 associates with PIP(3) on
preautophagosomal membranes and regulates the activity of
Rab26 by exchanging GDP to GTP. The observation that Plekhg5
does not regulate Rab5, Rab27b, or Rab33b activity suggests
relative speciﬁcity, but does not exclude the possibility that
Plekhg5 could also regulate the activity of other small GTPases.
However, the observation that constitutively active Rab26 rescues
the phenotype in Plekhg5-deﬁcient motoneurons suggests that
the GEF activity for Rab26 is central for altered autophagy of
synaptic vesicles in motoneurons. In its GTP-bound form Rab26
recruits Atg16l to synaptic vesicles for initiating the delivery of
synaptic vesicles to autophagosomes. Two previously identiﬁed
interaction partners of Plekhg5, Synectin13, and the 14-3-3γ-
protein40, are involved in autophagy regulation41, 42. Both pro-
teins have been described to interact with PI(3)P-kinase, resulting
in the inhibition of autophagy biogenesis. The 14-3-3γ-protein
acts as a scaffold that inhibits the activity of PI(3)P-kinase. In the
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same manner, the 14-3-3γ-protein inhibits the GEF activity of
Plekhg5. Furthermore, protein kinase D mediated phosphoryla-
tion of Ser92 at the N-terminus of Plekhg5 prevents the
interaction between these proteins40. It is tempting to speculate
that phosphorylation of Plekhg5 is the upstream signal to release
14-3-3γ protein from the complex with Plekhg5 and probably
also from PI(3)P-kinase. This might result in initiation of
autophagy and activation of Rab26.
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Deﬁciency of global autophagy in neurons results in an
impairment of proteostasis characterized by accumulation
of polyubiquitinated proteins in inclusion bodies8, 9. Our data
suggest that Plekhg5 deﬁciency does not impair global protein
homeostasis indicating that the defect in Plekhg5−/− mice is
restricted to synaptic vesicles and does not involve misfolding
or aggregation of cytosolic proteins. Thus, Plekhg5−/− mice
represent a model of motoneuron disease without poly-
ubiquitinated protein inclusion in which defective autophagy of
synaptic vesicles stands in the center of the pathophysiology. Such
cases of motoneuron disease without polyubiquitinated inclusions
have been described43 and they seem to correlate with forms of
motoneuron disease with prolonged survival, or with unusual
familial cases of progressive muscular atrophy43.
NMJs might be particularly vulnerable to defects in synaptic
vesicle turnover due to their large presynaptic size and large
number of synaptic vesicles compared to other synapses44. This
idea is supported by the lack of behavioral deﬁcits in Plekhg5-
deﬁcient mice and by the relatively preserved morphology of
synapses in hippocampus, cerebral cortex and cerebellum.
Azzedine et al.19 had previously characterized Plekhg5-deﬁ-
cient mice until 12 months of age, and had not detected moto-
neuron loss at this stage. In our model, symptoms of motoneuron
disease did not start before 12 months (Fig. 1c, e–g). Further-
more, motoneuron loss was not detectable before 12 months of
age, and it progresseed until 24 months (Fig. 1d). Therefore, it is
possible that motoneuron loss would have become apparent in
the model described by Azzedine et al.19 in mice older than
12 months. Furthermore, different strategies for generation of the
null-allele could contribute to the severity of disease. The model
described by Azzedine et al.19 had been generated by insertion of
loxP sites ﬂanking exon 9−13. Excision of this target region
results in a truncated protein lacking the RhoGEF domain but
still containing the PH domain. In our model, the protein lacks
both domains.
Our ﬁndings add to previous reports that neuron-speciﬁc dis-
ruption of autophagy by depletion of Atg5 or Atg7 results in
progressive degeneration of motoneurons8, 9 and that missense
mutations in the autophagy receptors p62/SQSTM1 and opti-
neurin are causative for ALS45, 46. Both proteins are substrates of
Traf family member-associated NF-kappa-B activator (TANK)-
binding kinase 1 (TBK1). Upon phosphorylation, p62/SQSTM1
and optineurin are recruited to mitochondria during PTEN-
induced putative kinase protein 1 (PINK1)/Parkin-mediated
mitophagy47, a mechanism implicated in the pathogenesis of
Parkinson’s disease48. Previous reports on TBK1 mutations in
ALS49, 50 and the recently identiﬁed interaction of the putative
Rab GTPase GEF chromosome 9 open reading frame 72
(C9ORF72) with WD repeat-containing protein 41 (WDR41) and
Smith-Magenis syndrome chromosomal region candidate gene 8
protein (SMCR8)51 support the idea that impaired autophagy
could make major contributions to the pathophysiology of
motoneuron disease. Our study provides a ﬁrst mechanism to
explain how autophagy of synaptic vesicles is regulated in axon
terminals of motoneurons and adds further weight to the
hypothesis that dysregulated autophagy constitutes a major
pathogenic mechanism in motoneuron disease.
Methods
Statistics. Whiskers in box–whisker plots show minima and maxima. Boxes
extend from the ﬁrst to the third quartiles with cross lines at the median. Means are
depicted by plus signs. In dot plots, dots represent individual experiments with
cross lines at the mean ± SEM. When comparing two groups, statistics were
performed using two-tailed Student’s t-tests for unpaired samples assuming
unequal variance. When comparing multiple groups, one-way ANOVA or two-way
ANOVA (grouped analysis) was performed. P values below 0.05 were considered
signiﬁcant (*P< 0.05; **P< 0.01; ***P< 0.001). For multiple comparisons of
individual groups, the Bonferroni post-test was performed. No statistical tests were
used to predetermine sample sizes, but our sample sizes are similar to those
generally employed in the ﬁeld. Normal distribution of data was assumed, but not
formally tested. All statistical analyses were performed using GraphPad Prism 6.00.
Generation of transgenic mice. To generate Plekhg5-deﬁcient mice, embryonic
stem cells (ESCs) with a disruption of one Plekhg5 allele from gene-trap clone
E277F07 (cell line: E14TG2a.4 (ES cells 129P2 (formerly 129/Ola))) were
injected into blastocysts of B6D2F2 (C58bl6/DBA2) mice52 and transferred into
pseudo-pregnant NMRI-foster mothers. Correct insertion site of the gene-trap
cassette was veriﬁed by sequencing. Offspring were genotyped by PCR using
the following primers: a 5′primer located in the intron upstream of the GT-Cassette
(5′ TAAAAGCTGGCAGCCTGAAT 3′), a 3′ primer located in the GT-Cassette
(5′ GCTAGCACAACCCCTCACTC 3′), and a 3′primer located in the intron
downstream of the GT-Cassette (5′ ACCCCAAGGTCTGTCCTCTT 3′).
Mice were backcrossed for at least four generations onto C57Bl/6 background.
Genders within genotypes were grouped, as differences between them were not
statistically signiﬁcant. The age of mice used for individual experiments is indicated
accordingly throughout the results section.
This study was approved by the local veterinary authority (Veterinaeramt der
Stadt Wuerzburg) and Committee on the Ethics of Animal Experiments, i.e.,
Regierung von Unterfranken, Wuerzburg (License number 55.2-2531.01-8/14).
RNA extraction and RT-PCR. Dissected tissues were frozen in liquid nitrogen and
RNA was extracted using standard phenol–chloroform extraction. 1 µg of total
RNA was treated with DNase I (Fermentas) and reverse transcribed with First
Strand cDNA Synthesis Kit (Fermentas). cDNA was diluted 1:5 and 1 µl was
subsequently used as template for RT-PCR reactions.
The following primers were used to validate gene-trap cassette functionality.
According to www.ensemble.org, the murine Plekhg5 locus is can generate four
different protein-coding transcripts. Speciﬁc 5′ primers were used for each
transcript: Isoform 001 and 004: 5′ GAGCTACCCTCCCCAGACTC 3′
(ENSMUSE00000523883), Isoform 003: 5′ CTGCAGAGGAGAAGGGACTG 3′
(ENSMUSE00000594961), Isoform 002: 5′ GGTACCTAGAGGCCCGAAAC 3′
(ENSMUSE00000667027). A common 3′ primer was used for the wild-type-allele:
5′ GGTGCTGTGGAACTTGCTATC 3′ (ENSMUSE00000594961). The following
3′ primer was used to detect expression of the gene-trap-allele: 5′
GGCCTCTTCGCTATTACGC 3′.
Using 3′ primers speciﬁc for exons 6 and exon 9, we conﬁrmed that insertion of
the GT-cassette did not disturb the normal splicing pattern by altering the order of
5′exons or elimination of 5′ exons. The following 3′ primer speciﬁc to exon 6
(ENSMUSE00000594959) was used: 5′ GGCTGGCACAATTTCTGTTT 3′.
The following 3′ primer speciﬁc to exon 9 (ENSMUSE00000594955) was used:
5′ GCAGAGAACAGCTGGAAGGT 3′.
Grip strength measurements. Force measurements were performed on a thin
metal mesh connected to a force meter detecting forces within a range of 0−200 cN.
Mice were suspended and allowed to hold on the grid, and, after they had grasped
the grid using both paws, a force was applied to pull the mice from the grid. The
force required to detach the mice from the grid was recorded, and the mean value
from ﬁve attempts was taken as one data point and considered as the grip strength.
Nissl staining and quantiﬁcation of spinal motoneurons. Mice were deeply
anaesthetized and trans-cardially perfused with 4% PFA. 12.5 µm parafﬁn
serial sections of the spinal cord were produced for Nissl staining, as described
previously53. Cresyl violet intensively stains acidic structures within cells, and
renders the nucleolus and the rough endoplasmic reticulum visible. Only
motoneurons with a clearly distinguishable nucleolus, that had Nissl-stained
rough endoplasmic reticulum-like structure in the cell body were counted in
every tenth section of the lumbar spinal cord (L1–L8). Raw counts were
corrected for double counting of split nucleoli as described53.
Succinate dehydrogenase enzyme activity. Succinate dehydrogenase (SDH)
stain was used to distinguish between oxidative and glycolytic ﬁbers on 10 µm thick
cryosections of tibialis anterior leg muscles. SDH staining was performed on fresh,
untreated 10 µm cryosections that were incubated for 5 min in the dark at room
temperature in standard SDH-substrate solution (0.2 M Na-succinat, 10 mM KCN,
10 mM nitro-blue tetrazolium, 2 mM phenazin methosulfate in phosphate buffer at
pH 7.2). Reaction was stopped with 3,7% buffered formaldehyde. Stained sections
were photographed under identical conditions.
Immunohistochemical staining of neuromuscular junctions. Staining of NMJs
was carried out as previously described54. Brieﬂy, mice were deeply anaesthetized
and trans-cardially perfused with 4% paraformaldehyde (PFA). Subsequently, the
muscles were dissected and post-ﬁxed in 4% PFA for at least 2 hours. The tissue
was washed in PBS-T (0.1% Tween-20) for 20 min at room temperature (RT) and
incubated with ω-Bungarotoxin-Alexa-488 (Invitrogen) for 25 min at RT. The
tissue was then incubated overnight at 4 °C with a blocking solution (2% BSA, 0.1%
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Tween-20 and 10% donkey serum), followed by incubation with the primary
antibodies for 3 days at 4 °C. After washing with PBS at pH 7.4 (PAA Laboratories)
thrice for 15 min, the appropriate secondary antibodies were applied for 1 h at RT.
The tissue was washed again as above, and embedded in Aqua Polymount
(Polysciences). The following primary antibodies were used: anti-NF-H (1:5000;
Millipore, AB5539), anti-Synaptophysin-1 (1:500; Synaptic Systems, 101 004).
Alexa-647 and Alexa-546-conjugated secondary antibodies were from Jackson
Immuno-Research Laboratories.
Immunoﬂuorescence staining of free-ﬂoating sections. Mice were deeply
anaesthetized and trans-cardially perfused with 4% PFA. After removal of the spinal
cord, spinal cord was post-ﬁxed in 4% PFA overnight and subsequently incubated in
30% sucrose at 4 °C overnight. Thirty-ﬁve micrometers of thick free-ﬂoating
sections were cut on a Leica 9000 s sliding microtome as described previously62 and
collected in 0.1M phosphate buffer (PB) pH 7.4. After incubation of the sections for
1 h with 4% normal goat or donkey serum and 0.3% Triton X-100 for blocking of
nonspeciﬁc binding at room temperature, sections were incubated overnight at 4 °C
with primary antibodies in blocking solution. After three times 10min washing in
0.25% Triton X-100 in PB at room temperature, sections were incubated in with
ﬂuorescently labeled secondary antibodies, washed again and ﬁnally mounted with
Mowiol/DABCO. The following primary antibodies were used: anti-NeuN (1:1000;
Millipore, MAB377, clone A60), ChAT (1:1000; Millipore, MAB144P), anti-
Ubiquitin (1:500; DAKO, Z0458), anti-Synaptophysin-1 (1:500; Synaptic
Systems, 101 004). Alexa-647-, Alexa-488-, and Alexa-546-conjugated secondary
antibodies were from Jackson Immuno-Research Laboratories. For visualization of
F-actin Alexa Flour 532 conjugated Phalloidin (Invitrogen) was used.
Electron microscopy. Mice were anesthetized and trans-cardially perfused
according to local institutional guidelines in 3 steps, slightly modiﬁed according to
Forssmann et al.55 with 3% paraformaldehyde, 3% glutaraldehyde, 0.5% picric acid
in 0.1 M sodium phosphate buffer, pH 7.2 for 10 min. Dissected organs were ﬁxed
in the same solution for additional 1−2 h at 4 °C, post-ﬁxed in buffered 2% osmium
tetroxide (2.5 h, 4 °C), and embedded in Araldite.
To analyze the ultrastructure of NMJs, animals were trans-cardially perfused
under deep anesthesia for 40 s with heparin/procaine followed by 2% formaldehyde
and 4% glutaraldehyde in 0.1 M cacodylate buffer with 2 mM MgCl2 and 3 mM
CaCl2 for 10 min. Dissected organs were further ﬁxed for 2−4 h at 4 °C and
post-ﬁxed with 2% OsO4 and 0.15% potassium hexacyanoferrate(III) to enhance
visibility of the extracellular matrix.
For identiﬁcation of target regions by optical microscopy, 1.5 µm-thick sections
were stained with Richardson’s blue (1% w/v methylene blue, 1% w/v Azur II) for
3 min at 80 °C. 60−80 nm sections (stained for 40 min in uranyl acetate and 8 min
in lead citrate) were used for electron microscopy (Zeiss EM 109).
Primary motoneuron culture. Murine embryonic spinal motoneurons were iso-
lated and cultured as described56. Brieﬂy, after dissection of the ventrolateral part
of E12.5 embryos, spinal cord tissues were incubated for 15 min in 0.05% trypsin in
Hank’s balanced salt solution. Cells were triturated and incubated in Neurobasal
medium (Invitrogen), supplemented with 1× Glutamax (Invitrogen) on Nunclon
plates (Nunc) pre-coated with antibodies against the p75 NGF receptor (MLR2,
kind gift of Robert Rush, Flinders University, Adelaide, Australia) for 45 min.
Plates were washed with Neurobasal medium, and the remaining motoneurons
were recovered from the plate with depolarization solution (0.8% NaCl, 35 mM
KCl and 2 mM CaCl2) and collected in full medium (2% horse serum, 1× B27 in
Neurobasal medium with 1× Glutamax). After counting, cell number was adjusted
to 1000 in 100 µl, and 1000 cells were plated on four-well dishes (Greiner, Cellstar)
pre-coated with poly-ornithine/laminin (Invitrogen). Cells were cultured in the
presence of the neurotrophic factor BDNF. For survival assays, cells were counted
4 h after plating to ﬁnd the total number of plated cells. Cells were counted again
after 5 and after 7 days in vitro (DIV).
For lentiviral transduction, motoneurons were incubated with viral particles for
10 min at RT directly before plating.
Culture of neurospheres. The forebrain was dissected from 11.5 to 12.5-day- old
mouse embryos and transferred to 100 μl HBSS. After treatment with trypsin
(Gibco; 0.05%, 15 min), cell suspensions were generated by trituration. Trypsin was
inactivated with egg yolk sack trypsin inhibitor (Sigma; 0.05%), and cells were
plated on 75 ml ﬂasks (Greiner) in 5 ml Neurobasal medium (Invitrogen)
containing Glutamax (1:100), B27 supplement (Invitrogen), basic ﬁbroblast growth
factor (bFGF), and epidermal growth factor (EGF) (Peprotech), each at a ﬁnal
concentration of 10 ng/ml. Cells were passaged at least once before being used in
the ﬁrst experiment. For differentiation, neurospheres were dissociated using 0.05%
trypsin and plated on Poly-L-ornithine-coated dishes at a density of 20,000 cells per
cm2. One day after plating, cells were transferred to an EGF and bFGF-depleted
medium, and cultured for the indicated time intervals.
Immunocytochemistry. For immunocytochemistry, cells grown on glass coverslips
were ﬁxed with buffered PFA for 20 min at RT, washed three times with PBS for 15
min, and blocked for 30 min with blocking buffer containing 10% donkey serum
and 0.3% Triton X-100 in TBST (TBS-Tween). After three washes with TBST for
5 min at room temperature, cells were incubated with primary antibodies overnight
at 4 °C, followed by three washes in TBST at RT for 15 min, and then incubated
with the appropriate ﬂuorophore-conjugated secondary antibodies for 1 h.
Subsequently, cells were washes three times with TBST for 15 min. The coverslips
were mounted on glass slides with Aqua Polymount. Cells were imaged using an
Olympus Fluoview 1000i confocal microscope. The following primary antibodies
were used: anti-phospho-Tau (Ser199/202) (1:500; Sigma-Aldrich, T6819),
anti-Rab26 (1:500; Synaptic Systems, 269 011, clone 163E12), anti-Synaptophysin-1
(1:500; Synaptic Systems, 101 004). Alexa-647-, Alexa-488- and Alexa-546-
conjugated secondary antibodies were purchased from Jackson Immuno-Research
Laboratories. For visualization of F-actin Alexa Flour 532 conjugated Phalloidin-
(Invitrogen) was used.
Plasmid construction. FUW-RFP-GFP-LC3 was generated by digestion of the
FUWG plasmid by Xba and EcoRI, and the resulting 10 kB fragment was puriﬁed
by gel extraction. pmRFP-GFP-rLC357 was digested by NheI and EcoRI, and the
resulting insert was puriﬁed by gel extraction and cloned into the FUW backbone
by ligation. The XbaI site was destroyed during cloning.
For generation of FUW-EGFP-Rab26-WT and FUW-EGFP-Rab26-QL15,
pEGFP-Rab26-WT, and pEGFP-Rab26-WT were digested by BamHI and NheI
and the resulting fragments puriﬁed by gel extraction. Subsequently, both inserts
were ligated into the BamHI and XbaI sites of FUWG.
For generation of FUW-mRFP-GFP-LC3-CMV-Flag-Rab26, pCMV-Tag2a-
Flag-Rab26 was digested by SalI and the resulting CMV-Flag-Rab26 fragment was
puriﬁed, blunted and phosphorylated. FUW-RFP-GFP-LC3 was digested by EcoRI
and blunted. Subsequently, both fragments were ligated.
To generate Plekhg5 knockdown constructs, different short hairpin (sh)-
sequences were synthesized as sense and antisense oligos, and cloned into the
BamHI and EcoRI restriction sites of pSIH-H1-eGFP. The following sequences
were validated for their ability to knockdown Plekhg5: sh-A: 5′
TCAAGTCGGTGCTAAGGAA 3′; sh-B: 5′ ATAGCAAGATGGACGTGTA 3′;
sh-C: 5′ GGACACTATTTACAACGCA 3′; sh-D: 5′ GGACGAATCTT
CTCTCAGT 3′; sh-E: 5′ CGCAAGAACATGTCTGAAT 3′. Sh-D was used in the
experiments, if not indicated otherwise.
The DH-PH domain of Pleghg5 was generated by amplifying the coding DNA
from cDNA of human Plekhg5 (BC042606) as a template using following primers
(uppercase letters indicate gene-speciﬁc nucleotides): 5′
atctggttccgcgtggatccGATGGGCATGAGAAGCTG 3′, 5′
tcacgatgcggccgctcgagTCACTGTGCACGCAGCTG 3′. The PCR product was
cloned into the pGEX-4T vector using the Gibson assembly kit (New England
Biolabs) according to the manufacturerʼs protocol.
GST-hRab26WT and GST-mRab5WT were cloned into pGEX-2T as described.
Lentivirus production. Lentivirus was produced by co-transfecting HEK 293T cells
with the indicated expression and packaging plasmids using Lipofectamine 2000
(Invitrogen). The medium was replaced 24 h after transfection and collected 24 h
later. Subsequently, the virus was concentrated by ultracentrifugation.
Western blotting. Equal amounts of protein were separated by SDS-PAGE, and
transferred to PVDF or nitrocellulose membranes (Pall). Membranes were blocked
in TBST with 5% milk powder for 1 h at RT, probed with primary antibodies
overnight at 4 °C, and incubated with horseradish peroxidase-conjugated second-
ary antibodies for 1 h at RT. The following primary antibodies were used: anti-LC3
(1:2000; Novus Biologicals, NB100-2220), anti-Calreticulin (1:8000; Thermo Sci-
entiﬁc, PA1-902A), anti-Calnexin (1:8000; Enzo, ADI-SPA-860), anti-HSP90
(1:4000; Enzo, ADI-SPA-830-D, clone AC88), anti-HSP70 (1:2000; Cell Signaling,
4872 T), anti-BiP (1:2000; Cell Signaling, 3177P, clone C50B12), anti-CHOP
(1:1000; Cell Signaling, 2895, clone L63F7), anti-PERK (1:1000; Sigma-Aldrich,
P0074), anti-phospho-Perk (Thr980) (1:1000; Cell Signaling, 3179, clone 16F8),
anti-Tuj1 (1:4000; Neuromics, MO15013), anti-Flag (1:10,000, Sigma-Aldrich,
F7425), anti-Actin (1:8000; Millipore, MAB1501R), anti-Gapdh (1:8000; Calbio-
chem, CB1001, clone 6C5), anti-IRE1α (1:1000; Cell Signaling, 3294), anti-
Ubiquitin (1:1000, Enzo, BML-PW0930, clone P4D1), anti-Rab26 (1:1000; Cell
Signaling 269 011, clone 163E12), anti-Synaptophysin-1 (1:2000; Synaptic Systems,
101 004), anti-Synapsin-1 (1:4000; Synaptic Systems, 106 103), anti-Syntaxin 1A
(1:1000; Synaptic Systems, 110 111, clone 78.3), anti-Synaptotagmin-1 (1:1000;
Synaptic Systems, 105 011,clone 41.1), anti-Synaptobrevin-2 (1:1000; Synaptic
Systems, 104 211, clone 69.1), anti-Snap 25 (1:1000, Synaptic Systems, 111 011,
clone 71.1) Appropriate peroxidase-conjugated secondary antibodies were from
Jackson Immuno-Research Laboratories.
Culture and transfection of NSC34 cells. NSC34 cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM, Gibco) containing 10% FCS,
1× Glutamax and 1× Penicillin/Streptomycin and transfected with Turbofect
(Life Technologies). For pull-down experiments, 1 day prior to transfection
2 × 106 cells were plated on 6 cm dishes and transfected using 8 µg plasmid and
24 µl Turbofect. For starvation experiments 1 × 106 cells were plated on six-well
plates one day before transfection. The next day, cells were transfected using
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4 µg plasmid and 12 µl Turbofect. Transfections were carried out according to the
manufactures instructions. All subsequent assays were performed 72 h after
transfection.
Lipid beads pull-down assay. Lipid beads pull-down assays were performed as
described58, with minor modiﬁcations. NSC34 cells transiently expressing Plekhg5-
Flag were suspended in lipid-binding buffer (20 mM Tris-HCl, 150 mM NaCl, and
1 mM EDTA, pH 7.5). The cells were extruded 10 times through a G25 syringe
needle and sonicated on ice. After removal of insoluble debris by high-speed
centrifugation at 13,000×g for 1 h at 4 °C, a 50 µl slurry of PI(3)P-conjugated or
unconjugated beads (Echelon Bioscience) was added to the tube and rotated for 2 h
at 4 °C. After washing the rotating beads ﬁve times for 20 min at 4 °C with lipid-
wash buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 0.25% NP-40), bound proteins
were eluted by boiling in 2× Laemmli buffer.
Metabolic labeling, IP and thin layer chromatography. 106 cells from dissociated
neurospheres were plated on PORN-coated 10 cm dishes. A day after plating, the
growth medium was replaced by bFGF and EGF-depleted medium. Three days
after plating, cells were transduced with FUW-Rab26-WT and cultured for addi-
tional 96 h. Thirty minutes before 32P labeling, cells were switched to phosphate-
free medium. Subsequently, cells were labeled for 4 h in phosphate-free medium
containing 1 mCi32Pi in a volume of 6 ml phosphate-free medium. After labeling,
cells were washed once with 5 ml ice-cold PBS and placed in 500 µl lysis buffer
(50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1% Triton X-100, 0.5%
CHAPS supplemented with protease inhibitors). Plates were kept on ice for 10 min,
and then centrifuged for 3 min at maximum speed. A lysate aliquot was retained
for Western blotting to test loading similarity of the samples.
Supernatants were transferred to microfuge tubes containing 30 µl GFP
antibody conjugated to agarose (clone RQ2, MBL) and incubated for 2 h at 4 °C
while mixing. Beads were then washed ﬁve times in ice-cold lysis buffer and
nucleotides bound to the GTPase were eluted in 20 µl elution buffer (2 mM EDTA,
1 mM GTP, 0.2% SDS, 5 mM DTT) at 65 °C for 5 min. Ten microlitre eluate was
spotted on 20 × 20 cm polyethylenimine (PEI) cellulose plates (Macherey-Nagel)
and separated in a chromatography chamber saturated with 0.75M KH2PO4 (pH
3.4). Chromatography chambers were prepared one day in advance by ﬁlling the
bottom with 50 ml potassium phosphate solution. GDP and GTP were separated by
placing the dry TLC sheet upright in a sealed chamber until the solvent has
ascended to 70% of its length. After drying, TLC plates were exposed to an X-ray
ﬁlm for 3–5 days.
Protein expression and puriﬁcation. The GST-tagged DH-PH domain (amino
acids 362–748) of human Plekhg5 protein, GST-tagged human Rab26-WT and
GST-tagged mouse Rab5-WT were expressed in BL21 (DE3) E. Coli. One litre of
Terriﬁc Broth supplemented with salt and 100 mg/ml of ampicillin was inoculated
with 200 ml of an overnight (o.n.) culture for 3 h at 37 °C to an OD of 0.8.
Subsequently, expression was induced by adding 0.2 mM IPTG and bacteria were
incubated o.n. at 22 °C. Bacteria were pelleted at 4000 r.p.m. for 15 min. Pellets
were washed in 1× PBS, centrifuged again as above, and resuspended in Plekhg5
(20 mM HEPES pH 7.4, 500 mM NaCl, 1 mM DTT, 5 mM EDTA and 10% gly-
cerol), or Rab26/Rab5 (20 mM Tris pH 7.4, 500 mM NaCl, 5 mM MgCl2, 100 µM
GDP and 5 mM DTT) protein buffer. Cell suspensions were lysed with lysozym
(Roth), supplemented with inhibitor cocktail (Roche), 1 mg/l DNase (Applichem),
and 1% Triton X-100. Lysates were sonicated (Branson Soniﬁer 450) four times for
30 s. In between, lysates were and kept on ice for 30 s. Lysates were pre-cleared by
centrifugation at 13,000 r.p.m. for 45 min. Supernatants were ﬁltered through a
0.45 µm (Whatman) ﬁlter, and rotated with glutathione conjugated to sepharose
(Amersham Bioscience) for 2 h at 4 °C. After collecting the ﬂow-through, the
bound fraction was washed with 1 l of protein buffer supplemented with 1 mM
ATP and 0.1% Triton X-100 for the DH-PH domain of PleghG5, 1% Triton X-100
for Rab26, or no additive for Rab5. Subsequently, Rab5 and Rab26 samples were
digested in protein buffer supplemented with 150 mM NaCl and 5 mg/ml thrombin
o.n. at 4 °C. The Rab5 sample was loaded on a Superdex 75 16/60 column (GE
healthcare). The GST-DH/PH domain was eluted by 30 mM free and reduced
glutathione. The beads were incubated four times with 10 ml of elution buffer for
10 min. Fraction were examined by
SDS-PAGE. The protein-containing fractions were combined and dialyzed in
protein buffer containing 150 mM NaCl and 0,1% Triton X-100 o.n. Puriﬁed
proteins were snap frozen and stored at −80 °C.
For Rab27B and Rab33B the beads were washed with 500 ml wash buffer
containing 20 mM HEPES pH 7.4, 500 mM NaCl, 5 mMMgCl2 and 50 mM HEPES
pH 7.5, 200 mM NaCl, 5 mM MgCl2, respectively.
The proteins were eluted in their respective wash buffer supplemented with
400mM imidazole 4−5 times with 7ml buffer each elution fraction. Then the proteins
were dialyzed with wash buffer containing reduced salt concentration of 150mM
NaCl. Rab33B was dialyzed in wash buffer containing 30mM HEPES. All the puriﬁed
proteins were snap frozen and stored at −80 °C for downstream experiments such as
GEF assay.
Measurement of rapid kinetics. Nucleotide binding to Rab GTPases was
analyzed by stopped ﬂow instrument (SX-20 MV, Applied Photophysics) using
Mant-GppNHp (Jena Bioscience GmbH). An aliquot of 100 nM Mant-GppNHp,
either in the presence or absence of 10 µm Plekhg5, was rapidly mixed with 1 µm
Rab GTPase in 10 mM MgCl2, 20 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM DTT
and 5% glycerol. Mant-GppNHp was excited at 366 nm and ﬂuorescence emission
was monitored using a passing cut-off ﬁlter (KV395, Schott).
Electrophysiological analyses. For the electrophysiological tests six wild-type
(3 female, 3 male) and six knockout (2 female, 4 male) animals were used.
Electrophysiological experiments were carried out in accordance with the
internationally accepted principles in the care and use of experimental animals,
approved by the local Institutional Animal Care and Research Advisory Committee
and permitted by the local government (Lower Saxony, Germany; AZ 13/1070).
Mice were housed under controlled conditions in the Central Animal Facility of
Hannover Medical School for nearly one week before measurements. Animals were
anaesthetized by isoﬂurane (1.5–2% with pure oxygen (1 l/min); Baxter AG,
Unterschleißheim, Germany). Prior to the electrophysiological measurements
Carprofen (0.01 ml/100 g; 5 mg/kg; Rimadyl, Pﬁzer GmbH, Karlsruhe, Germany)
was given subcutaneously for analgesia, and dexpanthenol eye ointment
(Bepanthen Augen-und Nasensalbe, Bayer Vital GmbH, Leverkusen, Germany)
was applied to the eyes to prevent corneal dehydration. During measurements,
body temperature of the animals, monitored and recorded rectally, was maintained
between 33 and 37 °C by using a thermostat heating plate (direct current). Portable
EMG equipment (Natus Keypoint Focus, Natus Europe GmbH, Planegg, Germany)
along with the Keypoint.net (version 2.32) computer program was used. For
nerve conduction studies, the sciatic nerve of ~ 24-month-old animals was
stimulated percutaneously by single pulses of 0.1 ms and 1 Hz delivered through
a pair of needle electrodes (Spes Medica disposable monopolar needle electrode,
13 mm × 33 G, GVB geliMED KG, Bad Segeberg, Germany) placed proximally at
the sciatic notch and distally at the popliteal fossa. The distance between both
stimulation electrodes was measured. Reference electrodes were inserted
subcutaneously a few millimeters apart from the stimulation electrodes. The
maximal compound muscle action potential (CMAP) was recorded using needle
electrodes (same as for stimulation) at the gastrocnemius, anterior tibial or
plantaris muscles. The reference electrode for all three muscles was placed in the
fourth toe. The ground electrode was inserted subcutaneously rostral to the
stimulation electrodes. Amplitude (baseline-peak, mean proximal/ distal)
and latency (time from stimulus to the onset of ﬁrst negative deﬂection, mean
proximal/ distal) were measured. Nerve conduction velocity (NCV) was calculated
via the latency differences of the proximal and distal stimulation and the
stimulation distance (mean NCV per muscle gastrocnemius/ tibialis). Motor unit
number estimation (MUNE) was performed subsequently to the nerve conduction
study, based on the description in Arnold et al.59. At least ten single motor unit
potentials (SMUPs; baseline-peak amplitude) were obtained by incremental
stimulation technique (1 Hz, 0.1 ms, 0.02 mA increase). Only increases over 25 μV
in the amplitude were recorded trying to minimize the inﬂuence of alternation. The
incremental values of the SMUPs were averaged in order to determine the size of
the mean SMUP. In the end, the estimated number of motor units within the
tibialis and gastrocnemius muscle was calculated by dividing the respective mean
SMUP into the maximum CMAP amplitude.
Mechanical sensitivity. To determine mechanical paw withdrawal thresholds, we
used the von Frey test based on the up-and-down-method of Chaplan et al.60.
Experimental mice were placed on a wire mesh in individual acrylic-glas cages and
the plantar surface of the hind paws was alternately touched with a calibrated von
Frey ﬁlament applying mild pressure leading to a slight bending of the ﬁlament; the
experiment was started at 0.69 g. Upon hind paw withdrawal the next thinner von
Frey ﬁlament was used. If the hind paw was not withdrawn, the next thicker von
Frey ﬁlament was used. Each hind paw was assessed three consecutive times and
the 50% withdrawal threshold (i.e. force of the von Frey hair to which an animal
reacts in 50% of the administrations) was calculated.
Heat sensitivity. To determine paw withdrawal latencies upon heat stimulation we
applied a standard algometer (Ugo Basile, Gemonio, Italy) based on the method of
Hargreaves et al.61. Experimental mice were placed on a glass surface in individual
plexiglas cages and a radiant heat source (25 IR) was placed under one hind paw
each. Time until paw withdrawal was recorded automatically. Heat application was
limited to 16 s to avoid tissue damage. Each hind paw was tested three times
consecutively.
Behavior. Plekhg5-deﬁcient (n= 10) and control mice (n = 11), at age of
12−14 months with no symptoms of motoneuron disease were used for behavioral
analysis. Genders within genotypes were grouped, as differences between
them were not statistically signiﬁcant. Mice were housed individually under a 12 h
light/dark cycle (6:00 a.m.−6:00 p.m.) with ad libitum access to food and water. The
cages (Tecniplast, 1264 C Eurostandard Typ II, 267 × 207 × 140 mm) were kept in a
Scantainer (Scanbur Ltd. Denmark) assuring stable conditions through a constant
airﬂow and maintaining a temperature of about 21 °C and air humidity of about
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55%. Experimental procedures took place during the light phase of the cycle
between 8:00 a.m. and 5:00 p.m. Mice were transported in their home cage to a
separate room and allowed to calm down for half an hour. Then mice were taken
individually in their home cages to the experimental room for experiments. The
experimenter was unaware of the genotype to keep experiments unbiased.
For the Open Field test, mice were placed in the middle of an open ﬁeld arena
(48 × 48 cm, height 50 cm, evenly illuminated to ~ 40 lux) and ﬁlmed for 10 min
with a webcam-based system (Logitech). Movements of the mice were tracked with
VideoMot2 (TSE, Germany) and the following parameters were analyzed: time
spent in center, number of entries into center. The area was cleaned thoroughly
with water after each trial.
The Object Recognition experiments took place in the open ﬁeld arena. For the
object recognition task two kinds of objects were used: a cell culture ﬂask and a
tower of about the same size built of differently colored Lego bricks. The objects
were placed in diagonally opposing corners of the arena with 12 cm distance to
from both sides of the wall. On day 1 half of the animals were presented with two
cell culture ﬂasks, the other half with two Lego towers. Mice were placed in the
middle of the arena and allowed to explore the arena and the objects for 10 min.
On day 2 one of the objects was replaced by a novel object (either cell culture ﬂask
or Lego tower) at either position 1 or 2 in a pseudo-randomized manner to avoid
position bias. Each mouse was therefore confronted with a familiar and a novel
object and was allowed to explore freely for 10 min. Mice were automatically
tracked (see above). We scored exploratory behavior toward objects manually
whenever the mouse sniffed the object or touched the object while looking at it.
After each trial, the arena and the objects were cleaned with water.
Fear conditioning was performed in a fear conditioning apparatus (mouse
multi-conditioning system, 256060 series, TSE, Germany). Fear conditioning took
place in context A, which consisted of a square arena with two blackened sides
placed on a metal grid. Context B, a round arena, which was placed on a black
plastic ground, served as new context. To support context discrimination, mild
olfactory cues were introduced into the arenas by wiping them with tissue paper
moistened with 70% ethanol for context A and 1% acetic acid for context B. The
conditioning consisted of two phases. On day 1 (fear acquisition), mice were
exposed to context A for 180 s before a tone (CS, 80 dB, 5000 Hz) was presented for
10 s and co-terminated with an electric foot shock of 0.7 mA for 1 s (US). The CS
and the US were presented three times with an inter-stimulus-interval (ISI) of 20 s.
After the last presentation, mice stayed in context A for 150 s before being returned
to the home cage. On day 2, mice were placed in context B to test for context
discrimination. For fear retrieval, after 60 s of free exploration the CS was presented
without the US for 12 times with an ISI of 20 s. After another 60 s mice were
returned to their home cage. Mice were video tracked and movement was recorded
by a light beam system. Freezing behavior, deﬁned as immobility except for
respiration movements, was analyzed with a software-based system (TSE MCS
FCS) and a freezing threshold of 2 s. After each trial, the context was cleaned with
70% ethanol or 1% acetic acid, respectively.
To account for statistical differences between genotypes and conditions
depending on the experiment, two-way ANOVAs with post hoc Sidak’s multiple
comparison test or unpaired t-tests were performed. Analyses were performed with
GraphPad Prism 6 and are represented as± SEM. Results were considered
statistically signiﬁcant at P< 0.05.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles or
from the corresponding author on reasonable request.
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Supplementary	  Figure	  1	  
	  
 
 
Generation	  of	   Plekhg5	  deficient	  mice.	   (a)	  Scheme	  of	   the	  mutant	  Plekhg5	   locus.	  The	  gene	  
trap	   cassette	   (GT-­‐cassette)	   consisted	   of	   a	   splice	   acceptor,	   a	   β-­‐geo	   gene	   and	   a	   poly-­‐
adenylation	  signal.	  Correct	  insertion	  of	  the	  GT-­‐cassette	  within	  the	  Plekhg5	  locus	  was	  verified	  
by	  sequencing.	  According	  to	  ensemble.org,	  the	  murine	  Plekhg5	  locus	  is	  able	  to	  generate	  four	  
different	  protein-­‐coding	  transcripts	  (isoforms	  001-­‐004)	  with	  three	  distinct	  N-­‐termini.	  Isoform	  
	  	  
001	  and	  004	  only	  differ	   in	   their	  PDZ-­‐binding	  motif,	  comprising	  three	  amino	  acids	  at	   the	  C-­‐
terminus.	   The	   GT-­‐cassette	   is	   inserted	   within	   the	   fourth	   intron	   of	   the	   Plekhg5	   gene	   and	  
affects	   transcription	   of	   all	   predicted	   splice	   variants.	   Frt/F3	   flippase	   recognition	   target;	  
loxP/lox511	   Cre	   recognition	   sites;	   SA,	   splice	   acceptor;	   pA,	   bovine	   growth	   hormone	  
polyadenylation	   sequence;	   β-­‐GEO,	   β-­‐galactosidase/neomycin	   phosphotransferase	   fusion	  
gene.	  (b	  -­‐	  d)	  Splice	  events	  at	  the	  wildtype	  (b,	  c)	  and	  gene-­‐trap	  (d,	  e)	  locus,	  characterized	  by	  
RT-­‐PCR.	  To	   investigate	  which	   isoforms	  are	  expressed	  within	   the	  spinal	   cord,	  RT-­‐PCRs	  were	  
carried	   out	   with	   specific	   5´	   primers	   for	   each	   splice	   variant.	   For	   the	   wildtype-­‐allele	   one	  
common	  3´	  primer	  was	  used,	  located	  in	  the	  next	  downstream	  exon	  (ENSMUSE00000594961)	  
of	  the	  GT-­‐cassette	  (b).	  For	  detection	  of	  the	  GT-­‐cassette	  a	  specific	  3´	  primer	  was	  applied	  (d).	  
In	  wildtype-­‐animals,	  Plekhg5	   is	  dominantly	  expressed	  within	  the	  spinal	  cord	  as	  isoform	  003	  
(E2-­‐E5)	  (c).	  We	  hardly	  detected	  any	  Plekhg5	  transcripts	   in	  homozygous	  mutant	  animals	  (c).	  
Conversely,	  expression	  of	  the	  GT-­‐cassette	  was	  only	  detectable	  in	  mutant	  animals	  (e).	  Thus,	  
the	   gene-­‐trap	   locus	   predominantly	   generates	   a	   truncated	   protein	   consisting	   of	   28	   amino	  
acids	   (Exon	   2	   and	   3	   of	   isoform-­‐003)	   fused	   to	   β-­‐GEO.	   The	   28	   amino	   acids	   of	   the	   original	  
protein	  contain	  neither	  the	  RhoGEF	  nor	  PH-­‐domain.	  (f,	  g)	  Using	  5´	  primers	  specific	  for	  exon	  6	  
and	  exon	  9	  (f,	  g)	  we	  confirmed	  that	  insertion	  of	  the	  GT-­‐cassette	  did	  not	  disturb	  the	  normal	  
splicing	  pattern	  by	  altering	  the	  order	  of	  5´	  exons	  or	  elimination	  of	  5´	  exons	  (f,	  g).	  These	  data	  
demonstrate	   functionality	   of	   the	   GT-­‐cassette	   and	   confirm	   the	   absence	   of	   wildtype-­‐
transcripts	  within	  the	  spinal	  cord	  of	  mutant	  mice.	  (h)	  Using	  an	  antibody	  directed	  against	  the	  
C-­‐terminus	  of	  Plekhg5,	  we	  detected	  a	  vesicular	  staining	  within	  the	  cytosol.	  As	   indicated	  by	  
co-­‐staining	   against	  NeuN	   and	   choline	   acetyltransferase	   (ChAT),	   expression	   of	   Plekhg5	  was	  
identified	   in	   NeuN+	   neurons	   including	   ChAT+	   motoneurons.	   In	   Plekhg5-­‐/-­‐	   mice,	   Plekhg5	  
staining	  was	   completely	   abolished,	   providing	   further	   evidence	   for	   functionality	   of	   the	  GT-­‐
cassette.	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Plekhg5	  deficiency	  does	  not	  impair	  cognitive	  function.	  (a,	  b)	  Control-­‐	  and	  Plekhg5	  deficient	  
mice	  were	  placed	  in	  the	  center	  of	  the	  open	  field	  arena	  and	  their	  movement	  was	  monitored	  
for	  10	  minutes.	  (a)	  Representative	  trajectories	  of	  control-­‐	  and	  Plekhg5	  deficient	  mice	  show	  
the	  behavior	  of	  both	  groups	  in	  the	  open	  field	  test.	  (b)	  Plekhg5	  deficient	  mice	  spent	  the	  same	  
amount	  of	  time	  in	  the	  center	  as	  compared	  to	  control	  animals.	  Both	  groups	  also	  showed	  the	  
same	   number	   of	   entries	   into	   the	   center.	   (c,	   d)	   To	   assess	   the	   memory	   skills	   of	   Plekhg5	  
deficient	   mice	   the	   object	   recognition	   test	   was	   performed.	   (c)	   The	   first	   day	   two	   identical	  
objects	  were	  presented	  and	  placed	  in	  two	  diagonally	  opposing	  corners	  of	  the	  box.	  Mice	  were	  
	  	  
placed	  in	  the	  middle	  of	  the	  box	  and	  monitored	  and	  tracked	  for	  10	  minutes.	  The	  next	  day	  one	  
of	   the	  objects	  was	  replaced	  with	  a	  novel	  object.	  Whether	   the	  novel	  object	   is	  presented	  at	  
position	  1	  or	  2	  was	  randomized	  to	  avoid	  position	  bias.	  Again,	  mice	  were	  placed	  in	  the	  middle	  
of	   the	  box	   and	  monitored	   and	   tracked	   for	   10	  minutes.	   (d)	   At	   day	   1,	   control-­‐	   and	  Plekhg5	  
deficient	  mice	   spent	   half	   of	   the	   time	   at	   both	   objects.	   The	   second	   day	   both	   groups	   spent	  
significantly	  more	  time	  at	  the	  novel	  object	  suggesting	  that	  both	  groups	  are	  able	  to	  recall	  the	  
familiar	   object	   and	   recognize	   the	   new	   object.	   (e,	   f)	  We	   investigated	   fear	   acquisition	   and	  
context	  discrimination	  of	  Plekhg5	  deficient	  mice	   in	  a	  paradigm	  of	   fear	   conditioning.	   (e)	  At	  
day	  1,	  mice	  were	  trained	  to	  associate	  a	   tone	  with	  a	   foot	  shock	   in	  context	  A.	  After	  a	  180	  s	  
habituation	  phase,	  mice	  received	  a	  10	  s	  tone	  of	  which	  the	  last	  second	  is	  accompanied	  by	  an	  
electric	  foot	  shock	  delivered	  via	  the	  metal	  grid	  in	  the	  cage.	  The	  stimuli	  are	  presented	  3	  times	  
with	  an	   inter	  stimulus	   interval	   (ISI)	  of	  20	  s.	  At	  day	  2,	  mice	  have	  to	  recall	   the	  acquisition	   in	  
context	  B.	  After	  a	  60	  s	  habituation	  phase,	  mice	  receive	  a	  10s	  tone	  that	  is	  not	  accompanied	  
by	   an	   electric	   foot	   shock.	   The	   sound	   is	   presented	   12	   times	   with	   an	   ISI	   of	   20s.	   (f)	  
Quantification	  of	  freezing	  time.	  During	  acquisition	  (context	  A)	  both	  groups	  show	  a	  significant	  
increase	   in	   freezing	   time	  after	   receiving	  an	  electric	   foot	   shock.	  At	  day	  2	  both,	   control	   and	  
Plekhg5	  deficient	  mice	  are	  able	   to	   recall	   the	  acquisition	   in	   context	  B.	  Both	  groups	   show	  a	  
significantly	  increase	  in	  freezing	  time	  after	  receiving	  the	  tone	  without	  electric	  foot	  shock.	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Degradation	  of	  neuromuscular	  junctions	  in	  Plekhg5	  deficient	  mice.	  Representative	  images	  
of	   neuromuscular	   junctions	   within	   the	   gastrocnemius	   muscle	   of	   adult	   mice	   stained	   for	  
acetylcholine	  receptors	  (BTX	  labeling),	  NFM	  and	  synaptophysin.	  Scale	  bar:	  10	  µm.	  
	   	  
	  	  
Supplementary	  Figure	  4	  
 
 
Histological	   analysis	   of	  major	   brain	   areas.	  Brain	   sections	  of	   control	  and	  Plekhg5	  deficient	  
mice	  were	  stained	  for	  synaptophysin,	  Tuj1	  and	  DAPI.	  The	  morphology	  and	  layering	  of	  major	  
brain	  areas	  as	  well	  as	  the	  synapse	  morphology	  appeared	  normal	  in	  Plekhg5	  deficient	  mice	  as	  
compared	  to	  controls	  animals.	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  Figure	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Depletion	  of	  Plekhg5	  does	  not	  impair	  survival	  of	  cultured	  motoneurons.	  (a,	  b)	  Different	  sh-­‐
RNA	   constructs	   were	   validated	   for	   their	   ability	   to	   knockdown	   Plekhg5.	   Co-­‐transfection	   of	  
HEK293T	  cells	  with	  mRFP-­‐Plekhg5	  and	  different	  sh-­‐RNAs	  targeting	  Plekhg5.	  After	  48h,	  cells	  
were	  lysed	  and	  submitted	  to	  SDS-­‐PAGE	  and	  Western	  blotting.	  Images	  have	  been	  cropped	  for	  
presentation.	  Full	  size	  images	  are	  presented	  in	  Supplementary	  Fig.	  7.	  (c)	  After	  five	  and	  seven	  
days,	   knockdown	   of	   Plekhg5	   with	   construct	   #	   D	   did	   not	   significantly	   affect	   motoneuron	  
survival	   when	   cultured	   with	   or	   without	   BDNF	   (each	   data	   point	   represents	   one	   individual	  
experiment;	  Mean	  ±	  SEM;	  Two-­‐way	  ANOVA;	  Bonferroni	  post-­‐test).	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Global	  protein	  homeostasis	  is	  not	  impaired	  by	  Plekhg5	  deficiency.	  (a)	  Ubiquitin	  staining	  of	  
spinal	   cord	   cross-­‐sections	   from	   control-­‐,	   Plekhg5	   deficient-­‐	   and	   SOD1	  G93A	  mice.	   Plekhg5	  
deficient	  mice	  showed	  no	  enrichment	  for	  polyubiquitinated	  protein	  inclusions,	  in	  contrast	  to	  
SOD1	   G93A	   mice.	   Arrowheads	   point	   to	   Synaptophysin	   accumulations.	   Arrows	   point	   to	  
accumulations	   positive	   for	   Synaptophysin	   and	   Ubiquitin.	   (b)	   Ubiquitin	   staining	   of	   NMJs.	  
Ubiquitinated	  protein	  inclusions	  were	  not	  detectable	  at	  NMJs	  of	  Plekhg5	  deficient	  mice.	  (c)	  
Western	  bot	  analysis	  of	  spinal	  cord	  extracts	  probed	  for	  Ubiquitin.	  Plekhg5	  deficient	  mice	  did	  
not	   reveal	   any	  enrichment	   for	   polyubiquitinated	  proteins.	   (d)	  Western	  blot	   quantification.	  
(Four	  animals	  per	  genotype	  were	  analyzed;	  Mean	  ±	  SEM;	  unpaired	  t-­‐test;	  two-­‐tailed)	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Full	   size	   images	   of	   Western	   blots.	   Arrows	   indicate	   reprobing	   of	   Western	   blots.	   Lines	  
separate	  individual	  Western	  blots.	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Abstract 
Inflammation and an active immune response are hallmarks of several 
neurodegenerative diseases. An activated immune response is considered as the 
cause for myelin breakdown in demyelinating disorders. In the peripheral nervous 
system, myelin can be degraded in an autophagy-dependent manner directly by 
Schwann cells or by recruitment of immune cells. Here, we show that the NF-κB 
activator Pleckstrin homology containing family member 5 (Plekhg5) regulates both, 
Schwann cell autophagy and recruitment of T-lymphocytes in peripheral nerves 
during motoneuron disease. Plekhg5-deficient mice show myelin infoldings and 
hypermyelination in peripheral nerves during motoneuron disease. Even at late 
stages Plekhg5-deficient mice do not show any signs for demyelination and 
inflammation. Using RNAseq we unraveled a transcriptional signature for an impaired 
immune response in sciatic nerves, which manifested in a reduced number of CD4+ 
and CD8+ T-cells. These findings identify Plekhg5 as a promising target to impede 
myelin breakdown in demyelinating PNS disorders.  
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Introduction 
The myelin sheath is an essential cellular component for axonal integrity and 
function. While oligodendrocytes generate myelin in the central nervous system 
(CNS), in the peripheral nervous system (PNS) it is formed by Schwann cells (Nave 
& Werner, 2014). Nerve conduction velocity is highly dependent on an intact myelin 
sheath. However, in pathological situations, e.g. upon infections or in the context of 
neurodegenerative diseases, such as hereditary motor and sensory neuropathies 
(HSMN), myelin breakdown (demyelination) can occur leading to impairments in 
axonal integrity and function but also to axonal loss. At the same time several 
demyelinating neuropathies are associated with excessive myelin production that 
appears histologically as myelin outfoldings or focal thickening of the myelin sheath 
(‘tomacula’) (Chung et al, 2011; Fabrizi et al, 2000; Quattrone et al, 1996). Excessive 
myelin production in these disorders precedes demyelination and axon loss (Adlkofer 
et al, 1995).  
Abnormalities of the myelin architecture, especially in the context of 
neurodegenerative diseases, are often linked to inflammation and an immune 
response. By impairing the immune response, myelin maintenance was improved in 
mouse models for a demyelinating CNS disorder (Ip et al, 2006) and for Charcot 
Marie Tooth (CMT) disease (Schmid et al, 2000). While myelin breakdown in the 
CNS is mediated predominantly by macrophages (Brosius Lutz & Barres, 2014), 
within the PNS an additional mechanism for initial myelin degradation has been 
described. After acute injury Schwann cells degrade their own myelin sheath via a 
specific form of autophagy (myelinophagy) in response to axonal stress (Gomez-
Sanchez et al, 2015). 
A key regulator of inflammation and immune response is the transcription factor NF-
κB (Kaltschmidt & Kaltschmidt, 2009; Tak & Firestein, 2001). Besides its involvement 
in acute injury such as viral infections of the CNS, NF-κB is also tightly linked to 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s disease or the 
demyelinating disease multiple sclerosis (MS) (reviewed in (Mattson & Meffert, 
2006)). Increased amount of nuclear NF-κB has been found within oligodendrocytes 
and microglia next to lesion sites of MS patients (Bonetti et al, 1999). Consequently, 
substances such as fingolimod that directly or indirectly modulate NF-κB activity are 
already being used in MS therapy (Sanford, 2014).  
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The guanine exchange factor (GEF) Plekhg5 (also known as Syx or Tech) is a known 
activator of NF-κB (Matsuda et al, 2003; Maystadt et al, 2007), which is highly 
expressed within the nervous system (De Toledo et al, 2001; Marx et al, 2005). 
Mutations within the human PLEKHG5 gene are associated with different 
motoneuron diseases such as an intermediate form of CMT, distal spinal muscular 
atrophy type (DSMA) IV and amyotrophic lateral sclerosis (ALS) (Azzedine et al, 
2013; Kim et al, 2013; Maystadt et al, 2007; Ozoguz et al, 2015). Mice lacking 
Plekhg5 developed a late-onset motoneuron disease caused by an impaired 
autophagy-mediated clearance of synaptic vesicles at the neuromuscular junctions 
(Luningschror et al, 2017).  
Within the nervous system, expression of Plekhg5 is not limited to neuronal cells. 
Especially in Schwann cells a high expression of Plekhg5 was demonstrated 
(Azzedine et al, 2013). In line with moderately decreased nerve conduction velocities 
(NCVs) observed in Plekhg5-deficient mice (Azzedine et al, 2013; Luningschror et al, 
2017), a direct or indirect role of Plekhg5 in myelin maintenance can be 
hypothesized. In contrast, based on RNA-sequencing data, expression in myelinating 
oligodendrocytes – the CNS counterpart – appears to be very low suggesting this 
potential function of Plekhg5 to be PNS-specific (Zhang et al, 2014).  
In this study, we analyzed the role of Plekhg5 in Schwann cells and its role in 
myelination. We detected myelin abnormalities, mostly characterized by infoldings of 
the myelin sheath and by a modest hypermyelination. Strikingly, using RNA-
sequencing we found prominent downregulation of genes in the context of immune 
response. In line with that, we observed a reduced number of T-lymphocytes within 
the sciatic nerve indicating an impaired immune response despite axonal pathology. 
A significant subset of the downregulated genes were validated target genes of the 
transcription factor NF-κB. We hypothesize a reduced NF-kB activation due to 
Plekhg5-deficiency to be the cause of impaired immune response within peripheral 
nerves. Targeting Plekhg5 and/or NF-κB in Schwann cells therefore appears to be 
promising regarding therapeutic approaches in demyelinating PNS disorders.    
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Results/discussion 
Plekhg5-deficiency results in profound alterations of the myelin sheath in 
peripheral nerves 
To investigate a putative role of Plekhg5 in Schwann cells, we histologically analyzed 
the sciatic nerve of Plekhg5-deficient mice. Most prominently, we observed profound 
alterations of the myelin sheath in the sciatic (Fig. 1) and the phrenic nerve (Fig. S1). 
Particularly infoldings of the myelin sheath could be detected (Fig. 1A, F-I). The 
number of fibers with an altered myelination progressed with age and significantly 
differed in comparison to control mice at 12 months and older (Fig. 1B). Additionally, 
we detected a significantly reduced axonal diameter in Plekhg5-deficient animals 
(Fig. 1C) and a hypermyelination in 24 months old animals as indicated by g-ratio 
analysis (Fig. 1D, E). Notably, fibers with myelin alterations were excluded in this 
analysis. Focal in- and outfoldings of the myelin sheath have been described to 
precede demyelination in several demyelinating neuropathies (Chung et al, 2011; 
Fabrizi et al, 2000; Quattrone et al, 1996). Moreover, myelin alterations have been 
described in different mouse models for demyelinating PNS disorders (Cai et al, 
2006; Lee et al, 2013; Robinson et al, 2008). However, we detected no signs of 
demyelination, even in 24 months old mice, suggesting an impaired myelin 
breakdown in Plekhg5-deficient mice.  
Next, we wondered whether Schwann cell dysfunction caused the myelin alterations 
and the lack of subsequent myelin degradation. Using qPCR we analyzed the 
expression of several Schwann cell markers within the sciatic nerve (Fig. 1J). With 
significantly altered expression of several markers for both, mature and immature 
Schwann cells we hypothesized a Schwann cell dysfunction in Plekhg5-deficient 
mice. In line with this, we observed an increase in the number of Schwann cells 
within the sciatic nerve of Plekhg5-deficient mice compared to control mice. Notably, 
this increase was already significant in 3 months old animals (Fig. 1K) and persisted 
in older animals (Fig. S2).  
 
Impaired formation of autophagosomes in Plekhg5-deficient Schwann cells 
Since we did not detect any signs for demyelination within peripheral nerves, we 
aimed to promote demyelination by an ex vivo approach investigating general 
impairments in myelin breakdown. As previously described, we cultivated segments 
of the sciatic nerve from Plekhg5-deficient mice to simulate sciatic nerve injury 
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resulting in demyelination of the axons predominantly by Schwann cells due to the 
absence of invading macrophages (Fernandez-Valle et al, 1995). After 5 days in 
culture, we counted the remaining intact myelin sheaths and observed a significantly 
increased number in segments derived from mutant mice compared to wildtype (Fig. 
2A, B). Recently, Schwann cell-specific autophagy (myelinophagy) was described for 
initial myelin breakdown following injury (Gomez-Sanchez et al, 2015). In teased fiber 
preparations of cultivated nerve segments, we detected fragments positive for the 
myelin protein zero (P0) in control mice but not in mutant mice (Fig. 2C).  
We recently described Plekhg5 to be involved in regulating the autophagy-mediated 
clearance of synaptic vesicles in motoneurons (Luningschror et al, 2017). To analyze, 
whether Plekhg5-deficiency additionally results in autophagy impairments within 
Schwann cells, we cultivated primary Schwann cells of mutant mice transduced with 
a lentiviral GFP-RFP-LC3 reporter. Using this reporter, autophagosomes and 
autolysosomes can be distinguished based on their fluorescent signals, as the GFP 
signal is rapidly lost after fusion of autophagosomes and lysosomes due to the pH 
drop. Structures positive for RFP alone are therefore classified as autolysosomes, 
whereas structures positive for both, GFP and RFP, are considered as 
autophagosomes. Under basal conditions, a modestly reduced number of 
autophagosomes was observed in Plekhg5-deficient Schwann cells although not 
reaching statistical significance (Fig. 2D, E). Upon treatment with Bafilomycin A1, 
which blocks the fusion of autophagosomes and lysosomes, the increase in the 
number of autophagosomes in Plekhg5-depleted cells was significantly lowered 
compared to wildtype cells indicating an impaired autophagosome biogenesis. This 
observation is comparable to previous results in cultured motoneurons of Plekhg5-
deficient mice (Luningschror et al, 2017).   
  
Reduced recruitment of T-lymphocytes within the sciatic nerve 
Schwann cell autophagy-mediated myelin degradation was described as the initial 
response to injury (Gomez-Sanchez et al, 2015). However, after this initial phase, 
myelin is being degraded via phagocytosis mediated by macrophages (Brosius Lutz 
& Barres, 2014). Furthermore, in mouse models for demyelinating PNS disorders, 
increased levels of both T-lymphocytes and macrophages have been found 
contributing to myelin breakdown (Ip et al, 2006; Wang Ip et al, 2006). We therefore 
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wondered whether a defective immune response also contributes to the impaired 
myelin breakdown.  
For an unbiased approach, we performed RNAseq with RNA derived from the sciatic 
nerve of 12 months old animals. Strikingly, a high number of the 95 significantly 
(q<0.05) downregulated genes (Fig. 3A) were associated with the gene ontology 
(GO) term “immune response” (Fig. 3B). A significant subset of the downregulated 
genes in Plekhg5-deficient mice represented validated target genes of the 
transcription factor NF-κB (Fig. 3C). Among these, the chemokines Ccl22, Ccl5 and 
Cxcl9 are known mediators of T-cell recruitment and activation (Charo & Ransohoff, 
2006; Gobert et al, 2009; Miyagishi et al, 1997). Furthermore, we detected a reduced 
expression of the chemokine receptor Ccr7, which is expressed in T-cells and binds 
the chemokines Ccl21 and Ccl19. Ccr7 regulates T-cell migration and recruitment 
from peripheral tissues (Noor & Wilson, 2012). A reduced expression of Cx3cl1, 
which is also a potent chemoattractant of T-cells (Imai et al, 1997), further points to 
an impaired T-cell infiltration into the sciatic nerve of Plekhg5-deficient mice. 
Schwann cells reportedly have the capability to act as facultative antigen presenting 
cells, expressing MHC complex II molecules (Bergsteinsdottir et al, 1992; Meyer zu 
Horste et al, 2010). In addition, several myelin proteins were described as 
autoantigens in neuropathologies (Braun et al, 1982; de Rosbo & Ben-Nun, 1998; 
Kaushansky et al, 2010). Antigens presented by Schwann cells are recognized by T-
lymphocytes to initiate macrophage-mediated clearance. To confirm a reduced 
number of T-lymphocytes in sciatic nerves of Plekhg5-deficient mice, we performed 
immunostainings of sciatic nerve cross-sections for CD4 and CD8 and detected 
reduced numbers of both, CD4- and CD8-positive T-lymphocytes in sciatic nerves of 
Plekhg5-deficient mice (Fig. 3E, F).  
In addition to the macrophage-secreted chemokines Ccl22 and Cxcl9, the RNAseq 
data also revealed a reduced expression of Siglec-1, a macrophage-restricted 
adhesion molecule. Depletion of Siglec-1 in P0-mutant mice results in an attenuated 
demyelination and a reduced number of CD8+ T-lymphocytes (Kobsar et al, 2006). 
To address whether the reduced expression of Ccl22, Cxcl9 and Siglec-1 was 
caused by a reduced number of macrophages we stained sciatic nerve cross-section 
for F4-80 and CD68. Notably, we detected no elevated levels of F4-80- positive 
macrophages (Fig. 3G) or CD68-positive activated macrophages (Fig. 3H) indicating 
that the impaired expression of the aforementioned genes is rather caused by 
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macrophage dysfunction. Recently, expression of Plekhg5 in macrophages was 
reported (Iwatake et al, 2017). Moreover, elevated activation of NF-κB in microglial 
cells – the resident CNS macrophages – was reported to be causative for 
motoneuron death within the spinal cord in amyotrophic lateral sclerosis (ALS) 
(Frakes et al, 2014). While NF-κB in macrophages within peripheral nerves was not 
evaluated, high numbers of macrophages are reportedly being observed in the sciatic 
nerve of SOD1 G93A mice, a model for ALS (Chiu et al, 2009). It is therefore 
tempting to speculate, that Plekhg5-deficiency additionally leads to macrophages 
dysfunction within the sciatic nerve and thereby results in an impaired immune 
response during motoneuron disease.   
Taken together our data suggest that Plekhg5-deficiency results in defective 
Schwann cell autophagy and in an impaired recruitment of T-lymphocytes to 
Schwann cells leading to myelin infoldings and hypermyelination. Recent reports on 
TBK1 mutations in ALS (Freischmidt et al, 2015) and the identification of a putative 
role for C9ORF72 in immune response regulation (Burberry et al, 2016) further 
support the idea that the immune system makes major contributions to the 
pathophysiology of motoneuron disease. Furthermore, OPTN has recently been 
described to suppress receptor-interacting kinase 1 (RIPK1) signaling for 
maintenance of axonal integrity. Notably, loss of OPTN from oligodendrocytes and 
myeloid cells, but not from astrocytes or motoneurons resulted in RIPK1-mediated 
axon degeneration by promoting inflammation and necroptosis (Ito et al, 2016). Our 
data add further weight to the notion that the interaction between the immune system 
and the nervous system needs to be tightly regulated and that a dysregulation of this 
interplay contributes to the axon pathology in demyelinating PNS disorders and 
motoneuron disease. We therefore hypothesize that targeting Plekhg5 and/or NF-κB 
in Schwann cells represents a potential therapeutic approach in demyelinating PNS 
disorders and motoneuron disease.  
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Materials and methods 
Statistical analysis 
Statistical evaluation was done using GraphPad Prism 5 (GraphPad Software, La 
Jolla, USA). Data is presented as the mean ± SEM if not stated otherwise. The 
statistical test used for each experiment is listed within the respective figure legend.  
 
Animals 
Plekhg5-deficient mice were described previously (Luningschror et al, 2017). Animals 
were kept under specific pathogen free conditions as defined by the Federation 
European Laboratory Animal Science Association (FELASA) in the central animal 
facility of the University of Bielefeld.  
 
Light and electron microscopy 
Mice were anaesthetized and transcardially perfused according to local institutional 
guide lines in 3 steps essentially as described by Forssmann and colleagues 
(Forssmann et al, 1977) with 3 % paraformaldehyde, 3 % glutaraldehyde, 0.5 % 
picric acid in 0.1 M sodium phosphate buffer, pH 7.4 for 10 minutes. After dissection, 
organs were fixed in the same solution for additional 2 hours at 4°C followed by 2 h 
postfixation in buffered 2% osmium tetroxide at 4°C. Afterwards they were embedded 
in Araldite. For light microscopy, semi-thin sections were stained with Richardson's 
blue (1% w/v methylene blue, 1% w/v Azur II) for 3 min, 80°C. For electron 
microscopy using Zeiss EM 109, ultra-thin (60-80 nm) sections (stained for 40 min in 
uranyl acetate and 7 min in lead citrate) were prepared. 
 
Determination of g-ratio and counting of Schwann cell nuclei 
Semi-thin sections stained with Richardson's blue as stated above were used for 
analyzing the g-ratio of myelinated axons within the sciatic nerve. High Resolution 
images were taken and afterwards stitched together with Photoshop CS software 
(Adobe Systems) resulting in a high resolution image of the whole sciatic nerve 
cross-section. Using the g-ratio plugin for ImageJ software (Goebbels et al, 2012), 
100 randomly chosen axons per cross-section were measured. Fibers with myelin 
abnormalities were excluded. In addition, nuclei within these images were counted, 
distinguishing between Schwann cell and other nuclei according to Patzig et al.. A 
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nucleus in direct contact to an axon was considered to be a Schwann cell nucleus 
(Patzig et al, 2016).  
 
RNA extraction and qPCR 
For extraction of total RNA TRIReagent (Sigmal-Aldrich) was used according to the 
manufacturer’s protocol. 500 ng of RNA were used for cDNA synthesis. cDNA was 
diluted 1:50 and 2 µL/reaction were used. qPCR was carried out with SYBR Green 
Master Mix (Thermo Fisher Scientic). The following primers were used: Ppia (fwd 5‘-
GTCTCCTTCGAGCTGTTTGC-3‘, rev 5‘-GTCTCCTTCGAGCTGTTTGC-3‘), EeF2 
(fwd 5‘-GGAACATGTCAGTCATCGCC-3‘; rev 5‘-GGAACATGTCAGTCATCGCC-3‘), 
RPLP0 (fwd 5’-TGGGCAAGAACACCATGATG-3’; rev 5’ 
AGTTTCTCCAGAGCTGGGTTGT-3’), Plp1 (fwd 5‘-
CTCCAAAAACTACCAGGACTATGAG-3‘; rev 5‘-AGGGCCCCATAAAGGAAGA-3‘), 
Mag (fwd 5‘-TGATAAGTATGAGTCCAGAGAGGTC-3‘; rev 5‘-
TGATAAGTATGAGTCCAGAGAGGTC-3‘), Sox10 (fwd 5‘-
TGATAAGTATGAGTCCAGAGAGGTC-3‘; rev  5’-TTCGTTCAGCAACCTCCAGA-3’), 
Egr2 (fwd 5’-GCCAAGGCCGTAGACAAAAT-3‘; rev 5’-
AATGTTGATCATGCCATCTCCC-3‘), Pmp-22 (fwd 5’-
AATGTTGATCATGCCATCTCCC-3‘; rev  5’-CGGTGCCTGTTTCAGTTCAA-3’) P0 
(fwd 5‘-TTCTTTGGTGCTCTCTCCAGC-3‘; rev 5‘-TTCTTTGGTGCTCTCTCCAGC-
3‘), c-Jun (fwd 5’-CCTTCTACGACGATGCCCTC-3’; rev 5’-
CCTTCTACGACGATGCCCTC-3’), p75 (fwd 5’-GGGCACATACTCAGATGAAGC-3’; 
rev 5’-CGTAGACCTTGTGATCCATCG-3’). 
 
RNAseq 
Total RNA was isolated from sciatic nerves using TRIReagent (Sigmal-Aldrich) 
according to the manufacturer’s guidelines and cDNA library generation was 
performed using the SENSE mRNA-Seq Library Prep Kit V2 (Lexogen, Vienna, 
Austria) according to the manufacturer’s protocol. Libraries were pooled and 
sequenced on the Illumina NextSeq 500 with the High Output Kit v2 (75 cycles). 
Adapters and low quality reads were trimmed with TrimGalore, v0.4.0 
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) powered by 
Cutadapt, v1.8 (https://cutadapt.readthedocs.io/en/stable) (Martin, 2011). 
Additionally, the first nine nucleotides were removed as described in the Lexogen 
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user manual. Reads were then mapped using STAR v2.5.0a 
(https://github.com/alexdobin/STAR) and differentially expressed transcripts were 
determined using the Cufflinks package v2.2.1 (http://cufflinks.cbcb.umd.edu/) as 
described before (Briese et al, 2016). Venn diagrams were generated using BioVenn 
(Hulsen et al, 2008). For gene ontology (GO) analysis we used the Database for 
Annotation, Visualization and Integrated Discovery (DAVID, 
http://david.abcc.ncifcrf.gov/home.jsp) (Huang da et al, 2009). As background dataset 
for the GO term analysis we used all expressed genes which we defined as those 
transcripts with an average FPKM≥0.1 in either the Plekhg5-deficient or wildtype 
sciatic nerve datasets. NF-κB targets were extracted from https://www.bu.edu/nf-
kb/gene-resources/target-genes/. The sequencing files have been deposited in 
NCBI's Gene Expression Omnibus (Edgar et al, 2002) and are accessible through 
GEO Series accession number GSEXXX. 
 
Immunohistochemical stainings  
Mice were sacrificed by cervical dislocation, the sciatic nerve was dissected, 
embedded in Tissue-Tec O.C.T. compound (Sakura Finetek) and frozen in 2-
methylbutane at -30°C. 10 µm thick sections were cut using CM1900 microtome 
(Leica Microsystems). Frozen sections were shortly thawed and depending on 
primary antibody, they were fixed using -20° C cold acetone for 10 minutes, with 4% 
paraformaldehyde for 10 min or left unfixed. Following repetitive washing using 
phosphate buffered saline (PBS), sections were incubated in PBS containing 5% 
BSA to block non-specific bindings. Primary antibodies were applied for overnight at 
4° C, followed by washing in PBS and application of secondary fluorochrome-
conjugated antibodies. For nuclear counterstaining DAPI (1 µg/ml; AppliChem) was 
used. After washing, sections were finally cover slipped with Mowiol/DABCO.  
For stainings of cultivated nerve segments, segments were fixed in 4 % PFA for 1h, 
followed by repetitive washing. Teased fiber preparations were done using fine 
forceps. Fibers were placed on collagen-coated coverslips and after permeabilization 
using 0.3 % Triton X-100, staining was performed as stated above.  
Primary antibodies used according to the manufacturer’s protocol were: CD4 
(YTS191.1), CD8 (YTS169.4) F4-80 (Cl:A3-1), CD68 (FA-11) (all from Serotec), 
MPZ/P0 (ab39375; Abcam) 
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Primary Schwann cell culture 
Murine neonatal Schwann cells were cultured essentially as described (Honkanen et 
al, 2007). Neonatal animals were sacrificed by decapitation at postnatal day five and 
six. The sciatic nerves were dissected and maintained in ice-cold PBS until all nerves 
were prepared. Remaining connective tissue was removed and the nerves were 
transferred to a new dish containing fresh ice-cold PBS, where they were shredded 
with forceps. Following enzymatic digestion using trypsin (final concentration 0.125%) 
and collagenase A (final concentration 0.05%) for 30 min at 37°C, nerve fragments 
were centrifuged for 5 min at 190 x g. After three washing steps with 7 mL DMEM 
containing 10% horse serum and centrifugation for 5 min at 190 x g, the pellet was 
resuspended in basic growth medium (DMEM containing 10% horse serum, 4 mM L-
Glutamine, 100 u/mL Penicillin/Streptomycin, 2ng/mL human heregulin-β1 and 0.5 
µM forskolin), plated on a poly-D-lysine coated 60 mm tissue culture dish and 
incubated at 37° C and 5% CO2. After two days in culture, basic growth medium was 
replaced and the cells were allowed to grow for two additional days. To get rid of 
upcoming fibroblasts, complement-mediated cytolysis was done at day four in 
culture. Medium was removed and the cells were rinsed with HBSS in 20 mM 
HEPES, followed by rinsing with HMEM (DMEM containing 10% horse serum, 4 mM 
L-glutamine, 100 u/mL penicillin/streptomycin and 20 mM HEPES). Anti-mouse CD90 
antibody was diluted in HMEM to a final concentration of 4 µg/mL and added to the 
cells. After 15 min at 37°C complement sera was added and incubation continued for 
additional two hours. Cells were rinsed twice with HBSS containing 20 mM HEPES 
and finally Schwann cell growth medium (basic growth medium containing 10 ng/mL 
FGF-2 and 20 µg/mL bovine pituitary extract) was added. Medium was changed 
every two days and cells were subcultured when reaching 80% confluency. All cells 
were passaged at least once before being used for experiments. 
 
Cultivation of sciatic nerve segments 
Sciatic nerve segments were cultivated as described (Gomez-Sanchez et al, 2015). 
Briefly, adult mice were sacrificed by cervical dislocation and the sciatic nerves were 
prepared and placed on ice in HBSS. Connective tissue was removed and the 
desheathed nerves were cut into 5 mm long segments. Segments were transferred to 
culture medium (DMEM containing 5 % FCS) and cultivated for 5 days at 37° C and 
5% CO2. 
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Lentivirus production 
For lentivirus production, HEK 293FT cells were transfected with the plasmids 
indicated and packaging plasmids VSV-G and delta8.91 using standard calcium 
phosphate precipitation. 8 hours after transfection, medium was exchanged and 48 to 
72 h after transfection supernatants were collected and concentrated by 
ultracentrifugation. For transduction, lentiviral particles were diluted in the respective 
growth medium and polybrene was added to a final concentration of 8 µg/mL. 
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Figure 1 – Histopathological analysis of the sciatic nerve 
A Semi-thin sections of the sciatic nerve of wildtype (Plekhg5+/+) and mutant 
mice (Plekhg5-/-) at different ages. Scale bars: 20 µm and 5 µm (blow-up).  
B Relative amount of axons with myelin alterations. Five animals per genotype 
and age (n=5, unpaired, two-tailed t-test).  
C Mean axonal diameter of wildtype and mutant mice at different ages. Three 
animals per genotype and age (n=3, unpaired, two-tailed t-test) 
D, E G-ratio analysis of 3 (D) and 24 (E) months old mice. Three animals per age 
and genotype, 100 axons per animal were analyzed.  
F, G, H Electromicrographs of Plekhg5-deficient mice depicting myelin 
infoldings at different stages. Scale bars: 2 µm (F, H) and 1 µm (G) 
I Teased fiber preparations of wildtype and mutant mice. Arrows point to nodes 
of Ranvier, arrowheads to myelin accumulations. Scale bar: 10 µm 
J qPCR analysis of several Schwann cell markers within the sciatic nerve of 
wildtype and mutant mice (n = 5/6 (wildtype/mutant), unpaired, two-tailed t-test).  
K Number of nuclei within the sciatic nerve of 3 months old mice distinguishing 
between Schwann cell nuclei and others. Three animals per genotype (n=3, two-way 
ANOVA with Bonferroni posttest).  
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Figure 2 – Impairments in Schwann cell autophagy upon Plekhg5-deficiency 
A Representative images of semi-thin sections of sciatic nerve fragments from 
wildtype and mutant mice cultivated for 5 days.  
B Amount of intact myelin sheaths, normalized to the area of the section 
analyzed. At least 5 sections per animal were analyzed; 3 animals per genotype 
(n=3, unpaired, two-tailed t-test).  
C Immunohistochemical stainings of teased fiber preparations derived from 
cultivated sciatic nerve fragments against the myelin protein zero (P0). Arrows point 
to degraded myelin. Scale bar: 10 µm 
D  Immunofluorescent analysis of primary Schwann cells transduced with mRFP-
GFP-LC3 reporter. Prior to fixation, cells were treated with 400 nM Bafilomycin A1 for 
4 hours or left untreated.  
E Quantitative analysis of fluorescent structures within transduced Schwann 
cells. GFP+-RFP+-structures were defined as autophagosomes, GFP--RFP+-
structures as autolysosomes. At least 5 cells per experiment were analyzed; 3 
independent experiments (n = 3, two-way ANOVA with Bonferroni posttest).  
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Figure 3 – Lack of Plekhg5 results in a reduced immune response within the 
sciatic nerve  
A Volcano plot showing the significance of transcript change [-log10(p-value)] vs. 
the magnitude of change [log2(fold change)]. Downregulated transcripts with q<0.05 
are marked in red, upregulated transcripts with q<0.05 are marked in blue. Data 
points for transcripts with log2FC<-10 or >10 (all of which were not significantly 
altered) were omitted for visualization purposes. 
B Gene-ontology (GO) term analysis of significantly downregulated genes 
C,D Venn diagrams depicting the number of NF-κB targets within (C) all 
downregulated genes and (D) within the GO term “immune response”.  
E-H Immunohistochemical stainings of sciatic nerve sections against the T-
lymphocyte markers CD4 (C) and CD8 (D) and the macrophage markers F4-80 (E) 
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and CD-68 (H). For each marker at least 8 sections per animal were analyzed. Three 
animals per genotype (n=3, unpaired, two-tailed t-test). Scale bars: 100 µm 
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Supplementary figures 
 
Figure S1 – Histopathological analysis of the phrenic nerve 
A Semi-thin sections of the phrenic nerve of wildtype and mutant mice at 
different ages. 
B Relative amount of axons with myelin alterations. Five animals per genotype 
and age (n=5, unpaired, two-tailed t-test). 
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Figure S2 – Elevated numbers of Schwann cells in Plekhg5-deficient mice 
A Semi-thin section of a sciatic nerve. Arrowheads point to Schwann cell nuclei, 
arrows to other nuclei. Scale bar: 10 µm 
B Number of nuclei within the sciatic nerve of 12 and 24 months old mice 
distinguishing between Schwann cell nuclei and others. Three animals per genotype 
and age (n=3, two-way ANOVA with Bonferroni posttest).  
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Figure S3 – Upregulated genes within the sciatic nerve of Plekhg5-/- mice 
A Gene-ontology (GO) term analysis of significantly upregulated genes. 
B Venn diagram showing the number of NF-κB target genes among the 
upregulated genes. 
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Abstract 
The autophagy-mediated degradation of cellular components recently is the focus of 
cancer research. Cancer cells rely on autophagy for survival. Moreover, elevated 
autophagy is associated with increased resistance of tumor cells during therapy.      
Here, we applied CRISPR/Cas9-mediated genome editing to perform a knockout of 
PLEKHG5 in U251-MG cells as a model for glioblastoma multiforme. Homozygous 
deletions within the PLEKHG5 gene resulted in the lack of Plekhg5 protein, validated 
using genomic PCR and immunocytochemistry. Profound changes of cellular 
morphology and significantly impaired proliferation was observed after depletion of 
Plekhg5. Changes in the procession of autophagy within PLEKHG5-deficient cells, as 
demonstrated by highly elevated levels of autolysosomes indicating an impaired 
clearance. Targeting autophagy remains a promising approach within anticancer 
therapy, in particular for chemo-resistant tumors such as glioblastoma. Thus, the 
findings presented in this study have direct clinical implications and point towards 
new therapy options for glioblastoma.  
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Introduction 
Autophagy is a cellular process, in which damaged or non-used biomolecules such 
as lipids, proteins or even organelles are being degraded and recycled (reviewed in 
(Boya et al, 2013)). It serves both as an alternative energy source for the cell during 
metabolic stress and in preventing the accumulation of e.g. aggregated proteins. In 
the context of disease, particularly in cancer, opposing effects of autophagy have 
been reported. While the contribution of autophagy on tumor formation remains a 
matter of scientific debate (Thorburn, 2014), inhibition of autophagic processes might 
generally be beneficial within anticancer therapy (Amaravadi et al, 2007; Levy et al, 
2017). Presumably due to a higher metabolic rate, tumor cells rely on autophagy as 
an important recycling mechanism for cell survival (Rabinowitz & White, 2010). 
Importantly, elevated autophagy was described as essential for cell survival in 
hypoxic tumor regions (Degenhardt et al, 2006).    
Malignant glioblastomas (GBM) are the most common and lethal primary brain 
tumors (Stupp et al, 2009). Although immuno- and chemotherapies are one therapy 
option, surgical resection remains the most applied treatment for glioblastoma. 
However, even with maximum treatment, survival time is no longer than 14 months 
(Koshy et al, 2012). Major obstacles preventing successful therapy are the 
heterogeneity of the tumor cells (hence the name “multiforme”) and the variety of 
underling causative mutationsm. Moreover, Glioblastoma cells are particularly 
resistant against chemotherapeutics, which in turn leads to tumor recurrence and 
decreased survival. Upregulation of autophagy upon chemotherapeutic treatment 
increases glioblastoma cell survival, suggestively contributing to therapy resistance 
and recurrence (Knizhnik et al, 2013; Wurstle et al, 2017). The cell line U251-MG 
derived from a grade III-IV malignant glioma and was isolated in 1973 (Ponten & 
Macintyre, 1968; Westermark et al, 1973). Since then U251-MG cells were used 
extensively as a model to study cellular mechanisms of glioblastoma cells. 
The Pleckstrin homology containing family member 5 (Plekhg5) is a guanine 
exchange factor (GEF). Plekhg5 is highly expressed in endothelial cells, within the 
nervous system as well as in cancer cells (Dachsel et al, 2013; Liu & Horowitz, 2006; 
Marx et al, 2005). In skin cancer cells, Plekhg5 was reported to function in VEGF-
induced proliferation (Yoshida et al, 2015).  In U251-MG cells, it was demonstrated to 
regulate polarity-orientated cell migration (Dachsel et al, 2013). Recently, a novel role 
of Plekhg5 in the regulation of autophagy-mediated clearance of synaptic vesicles 
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was described (Luningschror et al, 2017). We hypothesized Plekhg5-mediated 
regulation of autophagy not to be restricted to motoneurons and aimed to analyze its 
putative function within cancer cells.    
In this study, we generated a CRISPR/Cas9-mediated knockout of the PLEKHG5 
gene in U251-MG cells. Clonally grown Plekhg5-depleted cells showed significantly 
reduced proliferation and profound loss of cellular polarity. Moreover, lack of Plekhg5 
resulted in a significantly increased number of autolysosomes. As the formation of 
autophagosomes was not altered, an impaired termination of autophagy was 
suggested. Targeting autophagy is a promising approach to sensitize tumor cells to 
chemotherapeutic agents. Importantly, autophagy is particularly relevant for the 
survival and recurrence of glioblastoma. Thus, the observations made in this study 
have direct implications for the development of new treatment strategies. 
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Results 
Successful generation of PLEKHG5-deficient cells using CRISPR/Cas9 
To target autophagy-mediated recycling processes in glioblastoma cells, we first 
generated U251-MG cells deficient for PLEKHG5 by applying CRISPR/Cas9. In first 
instance, a genomic deletion spanning the boundary of intron 2 and exon 3 to 
efficiently knockout the gene was designed (Fig. 1A). The genomic deletion in 
clonally grown cells was detected using genomic PCR with primers flanking the 
desired deletion (Fig. 1B). Using immunocytochemistry, a clear reduction in the 
intensity of the fluorescent signal was detected in mutant cells when compared to 
wildtype cells (Fig. 1C). Thus, we confirmed that the genomic deletion resulted in a 
lack of PLEKHG5 protein in U251-MG. 
 
 
Figure 1. Generation of CRISPR/Cas9-mediated PLEKHG5 knockout in U251-MG cells. (A) 
Target design for the genomic deletion. sgRNAs used are depicted in red. (B) Clonally grown cells 
display the desired genomic deletion as shown by genomic PCR using primers flanking the deletion. 
(C) Immunocytochemistry revealed a nearly complete loss of Plekhg5 protein in mutant cells 
compared to wildtype cells.  
 
Knockout of PLEKHG5 results in a loss of cellular polarity and a markedly 
reduced proliferation 
We wanted to further analyze potential effects of PLEKHG5-deficiency on cellular 
polarity and proliferation. Cells lacking Plekhg5 displayed prominent morphological 
changes (Fig. 2A, B). In general, cell polarization was markedly reduced, as was 
observed by light microscopy (Fig. 2A). Phalloidin staining clearly revealed an altered 
organization of the actin cytoskeleton (Fig. 2B). In contrast to a mostly bipolar 
structure of wildtype cells, mutant cells rather appeared apolar. As a consequence of 
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the loss of polarity, a markedly reduced migratory behavior was observed. In contrast 
to wildtype cells, which usually grow homogenously distributed, mutant cells grew in 
local spots without spreading out. However, despite their clonal origin, mutant cells 
rapidly adapted a heterogenic phenotype. This was particularly apparent in terms of 
cell polarity ranging from complete apolar (Fig. 2B) to multipolar cells (Fig. S1). Of 
note, migratory behavior of the mutant cells did not change over time. 
Mutant cells additionally displayed reduced proliferation. The population doubling 
time of 29.3 ± 2.1 hours was significantly elevated compared to 22.9 ± 0.9 hours 
observed in wildtype cells to (Fig. 2C). In line with this, using Orangu™ Cell 
Proliferation Assay Kit dehydrogenase activity measured in PLEKHG5-deficient cells 
was significantly reduced (Fig. 2D).  
 
 
Figure 2. PLEKHG5-deficiency in U251-MG resulted in adaptation of an apolar phenotype and 
decreased proliferation. (A) Lightmicroscopic images of wildtype and mutant cells display differences 
in cellular morphology. (B) Immunofluorescent stainings of f-actin using phalloidin reveals  de-
organization of the actin cytoskeleton in PLEKHG5-deficient cells. (C) Significantly reduced population 
doubling tome of PLEKHG5-deficient cells (n=3; unpaired, two-tailed t-test). (D) Reduced absorbance 
due to reduced dehydrogenase activity was shown in knockout-cells compared to wildtype cells (n=6; 
unpaired, two-tailed t-test). 
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PLEKHG5-/- cells display an impaired clearance of autolysosomes 
Previously, we demonstrated direct involvement of Plekhg5 in the formation of 
autophagosomes within motoneurons (Luningschror et al, 2017). We therefore 
wanted to test potential effects on the autophagic process within the newly generated 
mutant cells. We biochemically assessed the levels of LC3-II as a marker for 
autophagosomes. Mutant and wildtype cells were treated for 4 h with 200 nM 
Bafilomycin A1 to block fusion of autophagosomes and autolysosomes, resulting in 
an enrichment of LC3-II-positive autophagosomes. No differences in the LC3-II levels 
were detectable in mutant cells under basal conditions as well as upon treatment with 
Bafilomycin A1, as compared to wildype cells (Fig. 3A).  
Figure 3 Lack of Plekhg5 leads to accumulation of acidic organelles. (A) Formation of 
autophagosomes assessed by LC3-II levels is not altered under basal conditions and upon 
treatment with Bafilomycin A1 (Baf) in PLEKHG5-deficient cells (B, C) Western blot analysis 
reveals a significantly elevated Lamp1 protein amount in mutant cells (n=4, paired, two-tailed t-
test). (D, E) Staining of acidic organelles using Lysotracker Deep Red revealed increased 
numbers of acidic organelles in PLEKHG5-deficient cells (five cells per experiment and genotype 
were analyzed, n=3, unpaired, two-tailed t-test). 
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However, we observed a significantly increased number of acidic organelles in 
PLEKHG5-deficient cells after applying LysoTracker Deep Red (Fig. 3D, E). In line 
with that, significantly elevated protein levels of the lysosomal marker Lamp1 were 
detected using Western blot (Fig 3B, C).  
Next we addressed, whether the acidic and Lamp1-positive structures marked 
autolysosomes. Thus, a RFP-GFP-LC3 reporter was stably introduced into wildtype 
and mutant cells. Fusion of autophagosomes and lysosome quenches the GFP 
fluorescence due to the pH drop (Mizushima et al, 2010). Therefore, structures 
positive for both RFP and GFP mark autophagosomes, whereas structures positive 
only for RFP mark autolysosomes. In line with the endogenous levels of LC3-II (Fig. 
3A), no differences in the number of autophagosomes were detected (Fig. 4A, B). 
However, the number of autolysosomes was highly significantly increased in mutant 
cells (Fig. 4A, B). Upon treatment with Bafilomycin A1, the number of autolysosomes 
decreased back to wildtype levels. This indicates an impaired clearance of 
autolysosomes and by this a delayed termination of autophagy.  
 
 
Figure 4 Clearance of autolysosomes is impaired in PLEKHG5-deficient cells. (A) Wildtype and 
mutant cells were transduced with lentiviral GFP-RFP-LC3 reporter. Cells were treated with 400 nM 
Bafilomycin A1 for 4 hours or left untreated. (B) The number of autophagosomes (GFP
+
-RFP
+
-LC3) 
and autolysosomes (GFP
-
-RFP
+
-LC3) was determined (five cells per experiment and genotype, n=3, 
two-way ANOVA with Bonferroni post-test).   
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Discussion 
The present study showed the successful CRISPR/Cas9-mediated knockout of the 
GEF Plekhg5 in U251-MG cells, a broadly applied model for glioblastoma. 
PLEKHG5-deficiency in U251 cells resulted in profound changes in the cellular 
morphology, as well as in significantly reduced proliferation. Moreover, an increased 
number of autolysosomes were detected in PLEKHG5-/- cells. Thus, it was suggested 
that Plekhg5 has a particular function in the termination of autophagy in glioblastoma 
cells. 
The role of Plekhg5 was particularly investigated in cells of the nervous system and 
in endothelial cells (Liu & Horowitz, 2006; Luningschror et al, 2017; Marx et al, 2005). 
However, several reports described Plekhg5 to be expressed in a variety of cancer 
cells. To understand the involvement of Plekhg5 in glioblastoma, we first developed a 
PLEKHG5-specific knockout cell line using CRISPR/Cas9 genome editing. We were 
able to confirm a successful knockout on both mRNA and protein level (Fig 1). In 
order to understand the cellular mechanisms Plekhg5 is involved in, particularly in 
cancer cells, we further characterized the cell line generated. Plekhg5 was originally 
described to be a GEF specific for RhoA.  Here, it was reported that Plekhg5 has a 
specific function on the actin cytoskeleton, which is known to be regulated by RhoA 
(Sit & Manser, 2011). In U251-MG cells, Plekhg5 influenced the migratory behavior of 
these cells by activating RhoA and its downstream kinase Dia1 (Dachsel et al, 2013). 
Recently, similar results were obtained in macrophages and osteoclasts 
demonstrating impairments in polarity and migration upon shRNA-mediated 
knockdown of Plekhg5 (Iwatake et al, 2017). In line with this, we demonstrated 
profound changes in the arrangement of the actin cytoskeleton upon knockout of 
PLEKHG5, which also resulted in a reduced migratory behavior.  
In the human skin cancer cell line DJM-1, activation of the VEGF-A receptor 
neuropilin (NRP1) was demonstrated to lead to the recruitment of Plekhg5 to the 
receptor and subsequent activation of RhoA (Yoshida et al, 2015). Active RhoA was 
reported to induce the degradation of the cyclin-dependent kinase (CDK) inhibitor 
p27. This degradation initiates the transition of the G1 phase to the S-phase of the 
cell cycle (Hu et al, 1999; Mammoto et al, 2004). The reduced proliferation of 
PLEKHG5-deficient U251-MG cells presented here is presumably caused by reduced 
RhoA activation and  improper degradation of p27.   
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The role of autophagy in tumor formation remains a matter of scientific debate (for an 
overview see (Thorburn, 2014)). However, reports describe beneficial effects of 
targeting autophagy in cancer therapy (reviewed in (Levy et al, 2017)). Particularly, 
this appears to be a promising approach for glioblastoma. Glioblastoma cells are very 
resistant to conventional anticancer therapy. Partly, this is caused by an upregulation 
of autophagy during therapy (Paglin et al, 2001; Sui et al, 2013). Treatment with 
temozolomide (TMZ), a chemotherapeutic agent regularly used for GBM (Messaoudi 
et al, 2015; Stupp et al, 2005; Wait et al, 2015), results in profoundly elevated levels 
of autophagy and thereby increases cell survival (Knizhnik et al, 2013; Wurstle et al, 
2017).  
We recently described that Plekhg5regulates autophagy-mediated clearance of 
synaptic vesicles in motoneurons (Luningschror et al, 2017). In contrast to previous 
studies which focused on RhoA, Plekhg5 was reported to directly act as a GEF on 
Rab26. Importantly, Rab26 was previously reported to mediate degradation of 
synaptic vesicles via autophagy (Binotti et al, 2015). Notably, in motoneurons derived 
from Plekhg5-deficient mice, an impaired formation of autophagosomes was 
demonstrated (Luningschror et al, 2017). In contrast, an impaired clearance of 
autolysosomes upon PLEKHG5 knockout in human glioma cells was reported in the 
present study. Plekhg5 was shown to associate to phosphatidylinositol 3-phosphate 
(PI(3)P) (Luningschror et al, 2017), which is an essential component of the 
autophagosome membrane (Carlsson & Simonsen, 2015). This indicates that 
Plekhg5 resides within the membranes of autophagosomes, however it remains 
unclear, how this influences the degradation of the formed autolysosomes after 
fusion with the lysosome. In 2015, impaired clearance of autolysosomes was 
reported in HeLa cells upon shRNA-mediated knockdown of Rab24 (Yla-Anttila et 
al, 2015). However, Rab24 was described as an unusual Rab protein occurring in 
a predominantly GTP-bound state due to a low intrinsic GTPase activity (Erdman 
et al, 2000). Its function therefore might not rely on a GEF. We analyzed the 
colocalization of Rab24 to LC3-positive structures in wildtype and Plekhg5-
deficient cells and observed no differences (data not shown). Therefore, an 
involvement of Rab24 in the observed phenotypewas excluded. In comparison to 
the initiation and maturation of the autophagic process, termination of autophagy 
is poorly understood. Potentially, different termination mechanisms exist, 
depending on the initial stimulus for autophagy induction. Nutrient-depletion 
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results in the induction of autophagy via initial inhibition of the mammalian target 
of rapamycin complex 1 (mTORC1). Notably, mTORC1 later resides in the 
lysosomal membrane and is reactivated, when nutrients are replenished (Efeyan 
et al, 2013; Yu et al, 2010). Moreover, mTORC1 is also involved in the extrusion 
of proto-lysosomal tubules from autolysosomes, which subsequently matured into 
lysosomes (Yu et al, 2010). In general, evidence was provided leading to the 
suggestion that preventing autophagy termination increases the sensitivity to cell 
death stimuli (Antonioli et al, 2014; Liu et al, 2016).  
In summary, our findings demonstrate the involvement of Plekhg5 in multiple cellular 
processes, which are directly linked to cancer progression and recurrence. As such, 
Plekhg5 appears to be a promising target with regard to anticancer therapy.  
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Materials and methods 
Statistics 
Statistical tests used in this study were performed using GraphPad Prism 5 
(GraphPad Software, La Jolla, USA). The specific test used is displayed within the 
respective figure legend. ns, not significant, *p<0.05, **p<0.01, ***p<0.001.  
 
Target design and cloning 
Design of single guide RNAs (sgRNAs) was done using the online prediction tool 
from the University of Heidelberg (Stemmer et al, 2015). We took advantage of the 
Cas9n (D10A) nickase mutant (Ran et al, 2013a) to minimize putative off-side effects 
and chose nicking pairs accordingly. To effectively generate a gene knockout, two 
nicking pairs were chosen to create a genomic deletion spanning an intron-exon 
boundary. Each sgRNA was cloned into pSpCas9n(BB)-2A-Puro (PX462) V2.0 
(Addgene plasmid #62987) as already described (Ran et al, 2013b). Oligos used for 
sgRNA design were: oligo 1 (fwd 5‘-CACCgACAGCACCATGCATTATGA-3‘; rev 5’-
AAACTCATAATGCATGGTGCTGTC-3‘), oligo 2 (fwd 5’-
CACCgGCTGTCACAGGCCTCGCAG-3‘; rev 5’-
AAACCTGCGAGGCCTGTGACAGCC-3‘), oligo 3 (fwd 5’-
CACCgGGGAGAGGGGGGACTGCTG-3’; rev 5‘-
AAACCAGCAGTCCCCCCTCTCCCC-3‘), oligo 4 (fwd 5’-
CACCgCATCAAGTTTCCCCTCTGC-3‘; rev 5’-
AAACGCAGAGGGGAAACTTGATGC-3‘).  
 
Cell culture and transfection 
U251-MG and HEK293 FT cells were cultivated in in Dulbecco's Modified Eagle's 
Medium (DMEM) (Sigma Aldrich, Taufkirchen, Germany) supplemented with 10% 
(v/v) heat-inactivated fetal calf serum (FCS) (VWR, Darmstadt, Germany), 2 mM L-
glutamine (Sigma Aldrich) and 100 U/ml Penicillin/Streptomycin (P/S) (Sigma Aldrich) 
at 37°C and 5% CO2 at saturated humidity.  
U251-MG cells were transfected using TurboFect transfection reagent (Thermo 
Fisher Scientific) according to the manufacturer’s guidelines.  
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Genomic PCR 
For DNA isolation, cells were lysed in cell lysis buffer (0.1 µg/mL Gelatine, 50 mM 
KCl, 1.5 mM MgCl2, 0.45% NP40, 10 mM TRIS pH 8.3, 0.45 % TWEEN 20, 200 
µg/mL proteinase K) for 1 h at 55°C followed by 5 min at 95°C. Lysate was directly 
used as template for genomic PCR. Primers used for genomic PCR were: Plekhg5 
(fwd 5’-TTGTCCTTATGACGCCCTAGC-3’; rev 5’-
CACTGCACTCCCTGTCTCAAAGAA-3’).  
 
Western bloting 
Cells were lysed in RIPA buffer (1 mM EGTA, 150 mM NaCl, 1 mM Na2EDTA, 1 mM 
Na3VO4, 1% (w/v) NP-40, 1 µg/mL leupeptin, 1 % (w/v) sodium deoxycholate, 2.5 
mM sodium pyrophosphate, 20 mM Tris-HCl (pH 7,5), 1 mM β-glycerophosphate). 
Equal amounts of protein were separated by SDS-PAGE and transferred to a PVDF 
membrane using a semi-dry blotter. Non-specific binding was blocked with PBS 
containing 0.05% Tween 20 and 5% milk powder for 1 h at 37°C, followed by probing 
with primary antibodies LC3B (#2775; Cell Signaling) and Lamp1 (deposited to the 
DSHB by August, J.T. / Hildreth, J.E.K. (DSHB Hybridoma Product H4A3) overnight 
at 4°C. Horseradish peroxidase-conjugated secondary antibodies were applied for 1h 
at room temperature and blots were developed using enhanced chemiluminescence. 
As loading control, protein amounts of GAPDH (#32233; Santa-Cruz Biotechnology) 
were detemined.  
 
Immunocytochemistry 
For immunocytochemical stainings, cells were cultivated on tissue-culture treated 
coverslips. Cells were fixed for 10 min at RT using 4 % paraformaldehyde (PFA). 
Prior to applying primary antibodies (1 h at RT), non-specific binding was blocked 
with PBS containing 5 % goat serum for 30 min. Secondary fluorochrome-conjugated 
antibodies were added for 1 h at RT under exclusion of light. DAPI (1 µg/mL) was 
used for nuclear counterstaining and samples were mounted using Mowiol/DABCO. 
Imaging was accomplished by confocal laser scanning microscopy (LSM 780, Carl 
Zeiss, Oberkochen, Germany) and image processing with Fiji (Schindelin et al, 2012) 
and Corel Draw X5 (Corel Corporation, Ottawa, Canada). 
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Proliferation assay 
For conventional proliferation assay, 5 x 104 cells were seeded in 6-well multiwell 
plates and cultivated for 2 days. Cells were counted again and population-doubling-
time was calculated.  
The Orangu™ Cell Proliferation Assay Kit (Cell Guidance Systems) was used 
according to the manufacturer’s protocol. Briefly, 2000 cells were seeded and 
cultivated for 2 days before applying Orangu™ solution. After 2 hours, the 
absorbance at 450 nm was measured.  
 
Lentivirus production 
For the production of lentiviral particles, HEK293 FT cells were transfected with 
FUW-RFP-GFP-LC3 (Luningschror et al, 2017) and the packaging plasmids VSV-G 
and Δ8.91 using standard calcium phosphate precipitation. 72 h after transfection, 
the supernatant was collected and subsequently concentrated by ultracentrifugation.  
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Abstract
Cervical cancer is the fourth common cancer in women resulting worldwide in 266,000
deaths per year. Belonging to the carcinomas, new insights into cervical cancer biology may
also have great implications for finding new treatment strategies for other kinds of epithelial
cancers. Although the transcription factor NF-κB is known as a key player in tumor forma-
tion, the relevance of its particular subunits is still underestimated. Here, we applied
CRISPR/Cas9n-mediated genome editing to successfully knockout the NF-κB subunit c-
REL in HeLa Kyoto cells as a model system for cervical cancers. We successfully generated
a homozygous deletion in the c-REL gene, which we validated using sequencing, qPCR,
immunocytochemistry, western blot analysis, EMSA and analysis of off-target effects. On
the functional level, we observed the deletion of c-REL to result in a significantly decreased
cell proliferation in comparison to wildtype (wt) without affecting apoptosis. The impaired
proliferative behavior of c-REL-/- cells was accompanied by a strongly decreased amount of
the H2B protein as well as a significant delay in the prometaphase of mitosis compared to c-
REL+/+ HeLa Kyoto cells. c-REL-/- cells further showed significantly decreased expression
levels of c-REL target genes in comparison to wt. In accordance to our proliferation data, we
observed the c-REL knockout to result in a significantly increased resistance against the
chemotherapeutic agents 5-Fluoro-2’-deoxyuridine (5-FUDR) and cisplatin. In summary,
our findings emphasize the importance of c-REL signaling in a cellular model of cervical can-
cer with direct clinical implications for the development of new treatment strategies.
Introduction
Cervical cancer is an epithelial cancer, also called carcinoma, and the fourth common cancer
in women worldwide with an estimated 5-year survival rate of 70% following diagnosis [1, 2].
Based on the degenerated cell type in the uterus, cervical cancer can be classified into
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squamous cell cancer and adenocarcinoma [1]. The most common reason for cervical cancer
is an infection by the human papilloma virus (HPV), namely by HPV 16 and HPV 18 causing
malignant transformations or carcinogenesis in 85% of the diagnosed cases [3, 4]. Treatment
strategies of cervical cancer highly depend on the stage of progression and range from radio-
therapy and surgery [5] to chemotherapy with cisplatin or 5-fluorouracil (5-FU) [6, 7].
Discovered in 1986 [8, 9], the transcription factor nuclear factor kappa-light-chain-
enhancer of activated B-cells (NF-κB) has been shown to play a key role in various cellular pro-
cesses as cell growth, differentiation, apoptosis, inflammation, learning and memory as well as
immunity [10, 11]. Given the importance of NF-κB in these processes, deregulation of its sig-
naling is directly associated to the formation of tumors and cancer progression [12–14], partic-
ularly regarding breast cancer [15] and cervical carcinomas [1]. In 2003, Nair and coworkers
showed a constitutive activation of the NF-κB subunit p65 during human cervical cancer pro-
gression. Here, NF-κB p65 was demonstrated to be particularly activated in high-grade squa-
mous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix [16].
Next to NF-κB p65, the subunit c-REL was shown to possess a key role in tumor formation.
Initial studies demonstrated severe B-cell lymphomas in chickens infected with avian reticu-
loendotheliosis comprising V-REL [17]. Expression of wildtype human c-REL in primary
chicken spleen cell cultures was likewise shown to result in malignant transformation events
[18], although respective mutations increasing the oncogenicity of the c-REL protein in the
avian system were not observable in human cancers (reviewed in [19]). However, amplifica-
tion of c-REL was observed in a broad range of human B-cell lymphomas [20, 21]. In terms of
human cervical cancer, Shehata and coworkers demonstrated a 6-fold slowed cell growth in
cultivated cervical cancer cells by expression of the c-REL homolog Xrel3 from Xenopus laevi
[22]. Accordingly, downregulation of c-REL by small interfering RNA was shown to result in
reduced proliferation of human keratinocytes [23], directly correlating c-REL signaling to
impaired cell cycle progression in a non-cancerous environment. Expression of the c-REL
homolog Xrel3 in human cervical cancer cells was further shown to lead to anti- or pro-apo-
ptotic effects during cisplatin-treatment in a concentration-dependent manner. These findings
emphasize the importance of c-REL-signaling in resistance of cervical carcinoma to chemo-
therapeutic agents [24].
The present study further extends these promising findings by showing a profound overex-
pression of c-REL in cancers located in human ovary, cervix and endometrium using database
mining. To investigate the role of c-REL in human cervical cancers in more detail, we applied
CRISPR/Cas9n-mediated genome editing in a multiplex way to delete c-REL in HeLa Kyoto
cells. Initially discovered as a part of adaptive immune system of bacteria and archaea [25], the
clustered regularly interspaced short palindromic repeats (CRISPR) system has been devel-
oped to a state-of-the-art technique for editing the human genome [26, 27]. Applications of
the CRISPR/Cas9-system particularly include cancer modeling [28] or knockout studies using
human cancer cell lines [27, 29]. In the present study, we applied a Cas9 nickase mutant
(Cas9n) inducing single-strand breaks to minimize the possibility of off-target cleavage in turn
increasing the specificity of genome editing [30].
Using the CRISPR/Cas9n approach, we successfully deleted the c-REL gene on chromo-
somes 2 of HeLa Kyoto cells (c-REL-/-). In comparison to wildtype, c-REL-/- HeLa Kyoto cells
showed a significantly decreased proliferation accompanied by strongly reduced amounts of
histone H2B, a delay in the prometaphase of mitosis and decreased expression levels of c-REL
target genes. We further observed a significantly increased resistance against the chemothera-
peutic agents 5-Fluoro-2’-deoxyuridine (5-FUDR) and cisplatin in HeLa Kyoto cells with c-
REL deletion compared to wildtype (wt). Our findings emphasize the importance of c-REL
c-REL deletion results in cell cycle defects
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signaling in a cellular model of cervical cancer with direct clinical implications concerning the
resistance of cervical carcinoma to chemotherapeutic agents.
Materials and methods
Target design and cloning
The design of the sgRNAs was done using the CRISPR/Cas9n Target Online Predictor from
University of Heidelberg (crispr.cos.uni-heidelberg.de). The gene sequence was taken from
Ensembl Genome Browser (ensembl.org). Two nicking pairs were designed resulting in two
double strand breaks creating a deletion. Nicking pairs were chosen according to the criteria
described by Ran and coworkers [30]. All oligos designed were cloned into one vector essen-
tially as described [31].
Cell culture and transfection
HeLa Kyoto cells [32] were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma
Aldrich, Taufkirchen, Germany) containing high glucose (25 mM), and sodium pyruvate (1
mM). This medium was supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS)
(VWR, Darmstadt, Germany), 2 mM L-glutamine (Sigma Aldrich), 100 U/ml Penicillin/Strep-
tomycin (P/S) (Sigma Aldrich), and 0.5 mg/ml geneticin (G418) (Sigma Aldrich). Cells were
cultivated at 37˚C with 5% CO2 at saturated humidity.
Transfection of HeLa Kyoto cells (3 x 105 cells / transfection) was performed by electropo-
ration using Amaxa Cell Line Nucleofector Kit R (Lonza, Basel, Schweiz) according to the
manufacturer’s protocol. 48 hours after transfection knockout generation was checked by
genomic PCR and cells were used for limiting dilution to obtain clonal c-REL knockout cells.
Genomic PCR and Native PAGE
For cell lysis, cells were harvested at 300 g for 5 min and resuspended in cell lysis buffer
(0.1 μg/mL gelatine, 50 mM KCl, 1.5 mM MgCl2, 0.45% NP40, 10 mM TRIS pH 8.3, 0.45%
TWEEN 20). Proteinase K (20 mg/ml, Serva Electrophoresis, Heidelberg, Germany) was
added followed by incubation of the cell lysate for at least 1 h at 55˚C and 5 min at 95˚C. 2 μL
were used for PCR (c-REL primers: Fw 5´-TGCATTTTCATTTTCAGTGAATGGT-3´,Rev
5´-ACCTGTGGAGATGACTGTGAAG-3´). Resulting bands on agarose gels were extracted
using NucleoSpin Gel and PCR Clean up Kit (Macherey Nagel) according to manufacturer’s
guidelines and subsequently analyzed by sequencing.
For Native PAGE, DNA of the PCR product was denaturized and re-annealed (5 min at
95˚C, -2˚C/s from 95˚C to 85˚C and 0.1˚C/s from 85˚C to 25˚C). PCR product was separated
on a 10% native Polyacrylamide-gel for 2 h at 150 V. Gene Ruler DNA Ladder Mix (Thermo
Fisher Scientific, Waltham, MA, USA) served as marker, gel was immersed in 0.05% ethidium
bromide (Carl Roth GmbH, Karlsruhe, Germany) for 5 min prior to visualization.
Quantitative real-time PCR
RNA isolation was done with NucleoSpin1RNA Kit (Macherey-Nagel) according to
manufacturer’s guidelines. 500 ng RNA were used for cDNA synthesis. Quantitative real-
time PCR (qPCR) was performed using SYBR Green Master Mix (Thermo Fisher Scientific).
cDNA was diluted 1:50 and 2 μL/reaction were used as template. Primer sequences were
5´-CTCCTGACTGACTGACTGCG-3´ (Fw c-REL target deletion), 5´-TACGGGTTATACGC
ACCGGA-3´ (Rev c-REL target deletion), 5´-CCTGGAGCAGGCTATCAGTC-3´ (Fw RELA),
5´-CACTGTCACCTGGAAGCAGA-3´ (Rev RELA), 5´-ACATCAAGGAGAACGGCTTCG-3´
c-REL deletion results in cell cycle defects
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(Fw RELB), 5´-GACACTAGTCGGCCCAGG-3´ (Rev RELB), 5´-GCACCCTGACCTTGCCTA
TT-3´ (Fw NFKB1), 5´-GCTCTTTTTCCCGATCTCCCA-3´ (Rev NFKB1), 5´-CAACCCAG
GTCTGGATGGTA-3´ (Fw NFKB2), 5´-CTGCTTAGGCTGTTCCACGA -3´ (Rev NFKB2),
5´-TGACAGTGAGCCCTGAAAGC-3´ (Fw IKBKE), 5´-CCGGATTTCCCACACTCTGA-3´
(Rev IKBKE), 5´-CGGAGACCCGGCTGGTATAA-3´ (Fw TBK1), 5´-ATCCACTGGACGAAG
GAAGC-3´ (Rev TBK1), 5´-CTGAAAACGAACGGTGACGG-3´ (Fw A20), 5´-TCCAGTTG
CCAGCGGAATTT-3´ (Rev A20), 5´-CAGGATAACGGAGGCTGGGATG-3´ (Fw BCL2), 5´-
TTCACTTGTGGCCCAGATAGG-3´ (Rev BCL2), 5´-GCTTGGATGGCCACTTACCT-3´ (Fw
BCL-XL), 5´-ACAAAAGTATCCCAGCCGCC-3´ (Rev BCL-XL), 5´-GCAAGTGGACATCAA
CGGGT-3´ (Fw TGFB1), 5´- TCCGTGGAGCTGAAGCAATA-3´(Rev TGFB1), 5´-GTAGT
GGAAAACCAGCAGCC-3´ (Fw MYC), 5´-AGAAATACGGCTGCACCGAG-3´ (Rev MYC),
5´-ATGGCAACGACTCCTTCTCG-3´ (Fw ICAM-1), 5´-GCCGGAAAGCTGTAGATGGT-3´
(Rev ICAM-1). Ct values were normalized to reference genes GAPDH (Fw 5´-CATGAGAAG
TATGACAACAGCCT-3´,Rev 5´-AGTCCTTCCACGATACCAAAGT-3´),RPLP0 (Fw 5´-
TGGGCAAGAACACCATGATG-3´ , Rev 5´-AGTTTCTCCAGAGCTGGGTTGT-3´) and eEF2
(Fw 5´-AGGTCGGTTCTACGCCTTTG-3´,5´-TTCCCACAAGGCACATCCTC-3´).
Western blotting
For analysis of RELA and A20, c-REL-/- and c-REL+/+ cells were treated with human recombi-
nant TNFα (10ng/ml, Calbiochem, Merck, Darmstadt, Germany) for 24h prior to protein iso-
lation. Protein extracts were made using cell lysis buffer (0.01 M TRIS, 3 mM EDTA, 1% SDS)
and equal amounts of protein were separated by SDS-PAGE and transferred to a PVDF mem-
brane. Membranes were blocked using PBS containing 0.05% Tween 20 and 5% milk powder
and probed with primary antibodies (rabbit anti-c-REL (#4727), Cell Signaling Technology,
Danvers, MA, USA); rabbit anti-p65 (#8242), Cell Signaling; mouse anti-A20 (sc-166692),
Santa Cruz Biotechnology, Heidelberg, Germany) overnight at 4˚C. Horseradish peroxidase-
conjugated secondary antibodies were applied for 1h at room temperature and blots were sub-
sequently developed using enhanced chemiluminescence.
Electrophoretic mobility shift assay
Electrophoretic Mobility Shift Assay was performed using DIG Gel Shift Kit, 2nd generation
(Deutschland Holding GmbH, Grenzach-Wyhlen, Germany) according to manufacturer’s
guidelines. For c-REL probe sequence (5´-TCGAGGGCTCGGGCTTTCCATCTCTCGA-3´),
c-REL binding site CGGGCTTTCC was assessed using the JASPAR Tool (jaspar.genereg.net).
Protein isolation procedure and unspecific competitor sequence were applied as described by
Tokunaga and coworkers [33]. PAGE was performed as described above.
Immunocytochemistry and fluorescence imaging of H2B-mcherry
For immunostaining and imaging of H2B-mCherry cells were seeded and cultivated on cover-
slips. Fixation was done by adding 4% paraformaldehyde (PFA) for 10 min. After repetitive
washing using phosphate-buffered saline (PBS), cells were either directly mounted with
Mowiol/DABCO or carried over to immunostaining. For immunocytochemistry, cells were
blocked and permeabilized using 0.02% PBST (PBS with Triton X-100) containing 5% goat
serum for 30 min at RT. Primary antibody (rabbit anti-c-REL (#4727), Cell Signaling; mouse
anti-CD54/ICAM MAB1379, Chemicon, Merck) was applied for 1 h at RT. After washing, cells
were incubated with secondary antibody (goat anti-rabbit Alexa Fluor 647, Thermo Fisher Sci-
entific) for 1 h at RT under exclusion of light. Finally, coverslips were mounted with Mowiol/
DABCO. Imaging was done by confocal laser scanning microscopy (LSM 780, Carl Zeiss,
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Oberkochen, Germany) and image processing was done using Fiji) and Adobe Photoshop CS6
(Adobe Systems, San Jose´, USA) or Corel Draw (Corel Corporation, Ottawa, Canada).
Proliferation & survival assay
Proliferation was analyzed with Orangu Cell Proliferation Assay Kit (Cell Guidance Systems,
Cambridge, UK) used following the manufacturer’s protocol. Cells were counted with Cell-
ometer Auto T4 Cell Viability Counter (Nexcelom, Lawrence, USA). For a calibrating curve
1000, 2500, 5000, 7500, 10000 and 15000 wildtype cells were seeded and incubated for 24 h at
37˚C. For correct cell number determination after one day, one well of each condition was
recounted.
For survival assay 5000 cells in 100 μl were seeded one day before treatment. Cells were
incubated with chemotherapeutic agents cisplatin (CDDP) (P4394, Sigma Aldrich) and
5-Fluoro-2´-deoxyuridine (5-FUDR) (Sigma Aldrich) for 21 h and subsequently Orangu Cell
Proliferation Assay Kit was applied.
Flow cytometric analysis of the cell cycle, apoptosis and histone H2B-
mCherry
DNA content measurement for analyzing cell cycle parameters was performed according to
Kaltschmidt and colleagues [34] by harvesting 1 x 106 cells at 300 g for 5 min followed by fixa-
tion with 70% (v/v) ethanol. After centrifugation at 300 x g for 10 minutes, staining solution
(PBS containing 1 mg/ml glucose (Carl Roth GmbH), 4´,6-diamidino-2-phenylindole (DAPI;
0.5 mg/ml; Sigma-Aldrich), and 100 Kunitz units RNaseA (Thermo Fisher Scientific) was
applied for 60 min under exclusion of light.
For apoptosis measurement, 1 x 106 cells were labeled with Annexin V-PE (Miltenyi Biotec,
Bergisch Gladbach, Germany) according to the manufacturer’s instructions. For analysis of
H2B-mCherry, 1 x 106 c-REL+/+ and c-REL-/- cells were harvested and directly applied for flow
cytometric analysis without additional staining procedures.
DAPI or Annexin V-PE-labeled cells as well as unstained cells (H2B-mCherry) were ana-
lyzed using a Gallios™ 10/3 flow cytometer (Beckman Coulter, Brea, CA, USA). Data analysis
was performed using FlowJo Software (TreeStar, Olten, Switzerland), doublet discrimination
for cell cycle analysis was assured by appropriate gating strategies.
Live cell imaging
We imaged H2B-mCherry alpha-tubulin-eGFP expressing HeLa Kyoto c-REL+/+ and c-REL
-/- cells in growth conditions at 37 degrees for more than 20 hours with a DeltaVision Elite
imaging system (GE Healthcare). At 20x magnification (Olympus UPlanSApo 20x 0.75), we
recorded on a CoolSNAP HQ2 (Photometrics, USA) CCD camera 15 different lateral positions
with 3 axial position with 1μm spacing for each c-REL+/+ and c-REL-/- cells respectively every
10 minutes for each fluorescent emission channels (LED excitation source 461-489nm, 553-
597nm and emission filtered at 501-549nm, 603-647nm respectively). A DIC image was
recorded for reference at each timepoint. The fluorescent images were deconvolved with the
appropriate OTF in SoftWoRx (version 6.1.3, GE Healthcare), analysed with Fiji and figures
were prepared with Omero.
Promoter analysis
Sequence of promoter regions (1500 bp downstream and 100 bp upstream to respective ATG,
5000 bp downstream for c-Myc promoter) of interest were taken from Eukaryotic Promoter
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Database (epd.vital-ti.ch) for Homo sapiens. Binding sites for gene of interest in chosen pro-
moter sequence were looked up using JASPAR Tool (jaspar.genereg.net). A relative score
threshold of 85% was used. RELA and c-REL binding sites were compared in promoter regions
of selected target genes.
Statistics
All statistical tests were performed with PrismGraph Pad 5 (GraphPad Software, La Jolla,
USA). Statistical significance of qPCR results and fluorescence intensity quantification was
analyzed using unpaired t-test. Welch correction was performed, if variances were significantly
different. Data of proliferation and survival assays were shown to be not normally distributed
(Shapiro-Wilk test) and analyzed using Kruskal-Wallis test with Dunn post-hoc test.
Results
c-REL is overexpressed in human cervical cancers
To assess the clinical implications of a c-REL knockout, we assessed levels of c-REL overexpres-
sion in human cancers by database mining using COSMIC [35]. We found c-REL to be pro-
foundly overexpressed in human cancers, particularly within those located in human ovary,
cervix and endometrium in comparison to oesophagus (Fig 1A, cancer.sanger.ac.uk; 02-14-
2017 16:00; 02-21-2017 15:10). Due to their human cervix origin, we decided to apply HeLa
Kyoto cells for the CRISPR/Cas9n-mediated c-REL knockout.
Successful knockout of c-REL in HeLa Kyoto cells using CRISPR/Cas9n
To generate a c-REL knockout in HeLa Kyoto cells, we designed a target deletion around 450
bp between intron 1 and exon 2 of chromosome 2 using the CRISPR/Cas9 Target Online Pre-
dictor tool (Fig 1B, [36], crispr.cos.uni-heidelberg.de). All designed oligonucleotides were
cloned into an all-in-one vector according to Golden Gate Assembly method (mCRISPR, [31])
allowing easier generation of knockouts. Genomic PCR depicted a profound deletion of the
Fig 1. Assessment of c-REL overexpression in human cancers and target design of CRISPR/Cas9n-mediated c-REL knockout. A: Database
mining revealed more profound overexpression of c-REL in cancers from human ovary, cervix and endometrium compared to oesophagus ([35], sancer.
sanger.ac.uk; 02-14-2017 16:00; 02-21-2017 15:10). B: Target design showing the proposed c-REL knockout with an expected deletion around 450 bp
targeting the intron 1-exon 2-boundary of the c-REL gene. The design was done with the CRISPR/Cas9n Target Online Predictor from the University of
Heidelberg [36], crispr.cos.uni-heidelberg.de) and the gene sequence was taken from Ensembl Genome Browser (ensembl.org).
https://doi.org/10.1371/journal.pone.0182373.g001
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c-REL gene in clonally grown HeLa Kyoto cells after transfection with the constructed
CRISPR/Cas9 vector in comparison to untransfected HeLa Kyoto wt cells (Fig 2A). Sequenc-
ing analysis confirmed the knockout of around 433 bp in exon 2 of c-REL within the trans-
fected HeLa Kyoto clone.
CRISPR/Cas9n-mediated c-REL knockout can be validated on mRNA
and protein level
After initial analysis of the c-REL knockout on DNA level, we assessed the expression level of
c-REL in the HeLa Kyoto knockout clone by qPCR with primers in the targeted deletion. In
contrast to HeLa Kyoto wt cells showing a robust expression of c-REL on mRNA level, no
expression was detectable in the c-REL knockout clone (Fig 2C). Notably, we analysed the top
three predicted exonic off-targets and detected no significant signs of off-target effects in the c-
REL kockout clone (S1 Fig).
Fig 2. Successful validation of the c-REL knockout in HeLa Kyoto cells on DNA, mRNA and protein level. A: Genomic PCR depicting a profound
deletion of the c-REL gene in the c-REL knockout clone (band at 300 bp) compared to the wt clone (band at 700 bp). B: Sequencing analysis confirmed the
knockout in exon 2 of c-REL. C: qPCR with specific primers in targeted deletion of exon 2 showed no expression of c-REL on mRNA level in the c-REL
knockout clone in comparison to wt. D: Western blot analysis validated the knockout of c-REL on protein level. E: Electrophoretic mobility shift assays
(EMSA) showed DNA-binding of c-REL in HeLa Kyoto wt cells (arrow), which was not observable in the c-REL KO clone. F: Immunocytochemistry
depicted a nearly complete loss of c-REL-protein in c-REL knockout clone compared to HeLa Kyoto wt cells.
https://doi.org/10.1371/journal.pone.0182373.g002
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In contrast to HeLa Kyoto wt cells, no c-REL protein was detectable in knockout cells by
western blot analysis even after TNFα-dependent stimulation, confirming the knockout of c-
REL on protein level (Fig 2D). Assessing a potential loss in functionality of the c-REL protein,
we investigated DNA binding activity of c-REL using electrophoretic mobility shift assay
(EMSA). c-REL-/- cells showed no DNA-binding activity of c-REL (Fig 2E), whereas a clear
shift was observable using HeLa Kyoto wt cells (Fig 2E, arrow). Immunocytochemistry further
validated the c-REL knockout in the transfected HeLa Kyoto clone by showing a nearly com-
plete loss of c-REL protein in comparison to HeLa Kyoto wt cells (Fig 2F).
CRISPR/Cas9n-mediated deletion of c-REL results in a decreased
proliferation of HeLa Kyoto cells without affecting apoptosis
We next analyzed potential effects of the c-REL knockout on proliferation and apoptosis of
HeLa Kyoto cells. Using Orangu Cell Proliferation Assay Kit (Cell Guidance Systems), prolif-
eration of c-REL knockout and wt cells was assessed after 2 days. HeLa Kyoto c-REL-/- cells
showed a strongly increased population doubling time of 26.54 h compared to wt HeLa Kyoto
cells displaying a population doubling time of 15.68 h (Fig 3A). This robustly decreased prolif-
erative behavior of c-REL knockout cells was accompanied by a 0.81 fold decrease in the
amount of mitotic cells compared to wildtype, as shown by cell cycle analysis using flow cyto-
metric DNA content measurements (Fig 3B). However, we observed only slightly increased
levels of Annexin V-positive apoptotic cells in c-REL-/- cells compared to wt cells (Fig 3C),
indicating the effect of the c-REL knockout on proliferation of HeLa Kyoto cells to be apopto-
sis-independent.
c-REL-/- HeLa Kyoto cells reveal strongly reduced levels of histone H2B
accompanied by a significantly delayed prometaphase or complete
arrest of the cell cycle
Assessing the reduced proliferative behavior of c-REL-/- HeLa Kyoto cells in more detail, we
analyzed the protein level of histone H2B, which is fused to mCherry in HeLa Kyoto cells [32].
Flow cytometric analysis of H2B-mCherry showed a strongly decreased amount of the H2B
protein in 41.48% of c-REL-/- HeLa Kyoto cells. On the contrary, we observed a reduced H2B
protein level in only 8.67% of HeLa Kyoto wt cells (Fig 3D). Taking advantage of the H2B-
mCherry and alpha-tubulin-EGFP fusion in HeLa Kyoto cells, we further visualized the differ-
ent stages of mitosis in fixed cell samples and living cells. Fluorescence imaging of fixed cells
revealed a significantly increased amount of c-REL-/- HeLa Kyoto cells within the prometa-
phase compared to wt cells (Fig 4E). We investigated this effect of the c-REL deletion in more
detail by live cell imaging. Here, c-REL-/- cells showed a length of the prometaphase of
39.50 ± 9.96 min, which was significantly delayed in comparison to wt cells revealing a dura-
tion of the prometaphase of 18.42 ± 1.58 min (Fig 4A–4C, S1 Movie). In addition, we observed
only 5.4% of wt cells but 25.7% of c-REL-/- cells (n = 40) to arrest during mitosis without entry
of the G2 phase of the cell cycle (Fig 4D, S2 Fig).
c-REL knockout leads to significantly decreased expression levels of
NF-κB family members and cell cycle-associated c-REL target genes
Analyzing effects of the c-REL knockout in HeLa Kyoto cells on other NF-κB family members,
we assessed respective gene expression levels by qPCR. c-REL knockout cells revealed signifi-
cantly decreased mRNA levels of RELA,NFKB1 (p50),NFKB2 (p52), IκB-Kinase ε (IKBKE)
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and TANK-binding kinase 1 (TBK1) compared to wildtype cells (Fig 5A). On the contrary,
expression levels of RELB were not significantly affected in the c-REL knockout clone (Fig 5A).
In accordance to the observed decrease in proliferation and in c-REL knockout cells, we fur-
ther observed significantly decreased mRNA levels in cell cycle-related c-REL target genes. In
particular, expression levels of A20 (TNFAIP3), B-cell lymphoma 2 (BCL2), B-cell lymphoma-
extra large (BCLXL, BCL2L1) and transforming growth factor beta 1 (TGFB1) were found to
be significantly decreased in comparison to HeLa Kyoto wildtype cells (Fig 5B). In addition,
expression levels of the c-REL target genes MYC and Intercellular Adhesion Molecule 1
(ICAM-1) were likewise significantly decreased compared to wildtype HeLa Kyoto cells (Fig
5C).
Promoter analysis was further performed using the JASPAR Tool (jaspar.genereg.net) to
validate the analyzed genes to be direct c-REL target genes. Binding sites for c-REL and RELA
were analyzed in each promoter region and their presence confirmed IKBKE, TBK1,A20,
BCL2, BCL-XL, TGFB1,MYC and ICAM-1 to be direct c-REL target genes (S3 Fig).
Fig 3. CRISPR/Cas9-mediated deletion of c-REL results in a decreased proliferation of HeLa Kyoto cell accompanied by strongly reduced
amounts of histone H2B. A: Cell number assessed by Orangu Cell Proliferation Assay Kit (Cell Guidance Systems) set against cultivation time
showed a strongly increased population doubling time of c-REL knockout cells compared to wt HeLa Kyoto cells. PDT: Population doubling time. B:
Flow cytometric DNA content measurements of DAPI-stained c-REL knockout cells showed a decrease in the amount of mitotic cells in c-REL
knockout cells compared to wildtype. C: Flow cytometric analysis of Annexin V-stained c-REL-/- and wt HeLa Kyoto cells revealed only slightly
increased amounts of apoptotic cells upon c-REL deletion in comparison to wt. D: Flow cytometric analysis of histone H2B-mCherry showed a
strongly decreased amount of the H2B protein in 41.48% of c-REL-/- HeLa Kyoto cells, which was observable in only 8.67% of HeLa Kyoto wt cells.
https://doi.org/10.1371/journal.pone.0182373.g003
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Fig 4. Knockout of c-REL leads to a significantly delayed prometaphase or even complete arrest of the cell cycle. A-B: Live cell imaging of c-
REL-/- and c-REL+/+ cells showed delayed duration of the prometaphase in c-REL-/- (arrows) in comparison to wildtype. Mitosis was visualized by H2B-
mCherry and alpha-tubulin-EGFP. C: Quantification of life cell imaging validated the significant delay of c-REL-/- in length of the prometaphase
(39.50 ± 9.96 min) in comparison to wt (18.42 ± 1.58 min) (n = 20). D: Exemplary images of c-REL-/- cells arresting during mitosis without entry of the G2
phase of the cell cycle. E: Fluorescence imaging of H2B-mCherry in fixed cells displayed a significantly increased amount of c-REL-/- HeLa Kyoto cells
within the prometaphase compared to wt cells. (>1000 cells quantified per genotype, n = 3). Scale bar: 25 μm.
https://doi.org/10.1371/journal.pone.0182373.g004
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To validate the decreased expression levels of c-REL target genes in c-REL-/- HeLa Kyoto
cells on protein level, we performed western blot analysis and immunocytochemistry. Western
blot analysis revealed reduced amounts of RELA and A20 protein in c-REL-/- cells in compari-
son to wt (Fig 5D). We further observed a nearly complete loss of ICAM protein in c-REL-/-
cells by immunocytochemistry, while HeLa Kyoto wt cells showed an unchanged amount of
ICAM protein (Fig 5E).
Fig 5. c-REL knockout leads to significantly decreased expression levels of NF-κB family member and cell
cycle-associated genes. A: qPCR analysis showing significantly decreased mRNA levels of NF-κB family
members RELA, NFKB1 (p50), NFKB2 (p52), IKBKE and TBK1 in c-REL knockout cells compared to wildtype
cells. B-C: Expression levels of cell cycle-related c-REL target genes A20, BCL2, BCL-XL and TGFB1 and c-REL
target genes MYC and ICAM-1 were significantly decreased in c-REL knockout cells in comparison to HeLa Kyoto
wildtype cells. D: Western blot analysis validated the reduced expression levels of RELA and A20 in c-REL-/- cells
in comparison to wt on protein level. WB were performed after TNFα-dependent stimulation of c-REL-/- and c-
REL+/+ cells. E: Immunocytochemistry revealed a strongly decreased protein amount of ICAM in c-REL-/- cells in
comparison to wt.
https://doi.org/10.1371/journal.pone.0182373.g005
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HeLa Kyoto cells with c-REL deletion show a significantly increased
resistance against chemotherapeutic agents
With regards to the assessed overexpression of c-REL in human cancers (Fig 1A), potential
clinical implications of the c-REL knockout were assessed by determining cell survival upon
exposure to the chemotherapeutic agents 5-Fluoro-2’-deoxyuridine (5-FUDR) and cisplatin.
Here, treatment with increasing concentration of 0.45–100 μM 5-FUDR for 21 h led to cell
death of both c-REL-/- and wildtype cells (Fig 6A).
However, 5-FUDR-treated c-REL knockout clone showed significantly increased cell num-
bers in comparison to wildtype cells, indicating a profoundly increased resistance against
5-FUDR (Fig 6A). We likewise observed this effect after treatment of HeLa Kyoto wildtype
and knockout cells with cisplatin. While cisplatin-treatment of 0.45–4.5 μM led to cell death of
wildtype cells, assessed cell numbers of the c-REL knockout clone were significantly increased
Fig 6. Significantly increased resistance against chemotherapeutic agents in HeLa Kyoto cells with c-REL deletion. A:
Although both HeLa Kyoto wildtype and c-REL knockout cells showed cell death after treatment with 5-Fluoro-2’-deoxyuridine, the c-
REL knockout clone showed significantly elevated cell numbers in comparison to wildtype cells. Cells were exposed to
chemotherapeutic agents for 21 h, cell numbers were assessed using Orangu Cell Proliferation Assay Kit (Cell Guidance Systems) after
2 h of incubation. Cell number of untreated cells were set to 1 and used for comparison. B: Although cisplatin-treatment of 1–4 μM led to
cell death of wildtype cells, survival of the c-REL knockout clone was significantly increased even in comparison to untreated control.
Increasing concentrations of cisplatin (10–100 μM) affected survival of c-REL knockout cells, but cell numbers were still significantly
elevated compared to wildtype. Cells were exposed to chemotherapeutic agents for 21 h, cell numbers were assessed using Orangu
Cell Proliferation Assay Kit (Cell Guidance Systems) after 2 h of incubation. Cell number of untreated cells were set to 1 and used for
comparison (n = 8).
https://doi.org/10.1371/journal.pone.0182373.g006
c-REL deletion results in cell cycle defects
PLOS ONE | https://doi.org/10.1371/journal.pone.0182373 August 2, 2017 12 / 19
even in comparison to untreated control (Fig 6B). Although exposure to increasing concentra-
tions of cisplatin (10–100 μM) also resulted in cell death of c-REL knockout cells, cell number
were still found to be significantly increased compared to wildtype, validating a robust resis-
tance against cisplatin (Fig 6B).
Discussion
The present study shows a successful CRISPR/Cas9n-mediated knockout of the NF-κB subunit
c-REL in HeLa Kyoto cells. HeLa cells are one of the most frequently used model systems for
epithelial and in particular cervical cancers [37–39]. Here, we observed a significantly
decreased proliferation of c-REL-/- cells accompanied by a significant decline in expression lev-
els of NF-κB target genes in comparison to wt cells. HeLa Kyoto cells with c-REL deletion fur-
ther revealed a significantly increased resistance against the chemotherapeutic agents
5-Fluoro-2’-deoxyuridine (5-FUDR) and cisplatin. These are commonly used as the trade-
marked chemotherapeutics Platinol1 and FUDR1 in the clinic.
With NF-κB being involved in many cellular processes [10, 11], a broad range of genes were
described to be direct targets of NF-κB, including cytokines, chemokines, cell adhesion mole-
cules, cell surface receptors, regulators of apoptosis and growth factors [40]. Interestingly, par-
ticular subunits of NF-κB were only rarely directly linked to specific target genes. In the present
study, c-REL-/- HeLa Kyoto cells showed significantly decreased expression levels of NF-κB fam-
ily members RELA,NFKB1,NFKB2 as well as IKBKE and TBK1. We also observed several c-
REL binding sites in the promoter region of the TBK1 and IKBKE gene, suggesting TBK1 and
IKBKE as direct c-REL target genes. In addition to their role in phosphorylating NF-κB p65
[41], TBK1 and IKBKE were in turn described to directly phosphorylate the C-terminal domain
of the c-REL protein resulting in its nuclear accumulation [42]. Extending these promising find-
ings, we suggest a positive feedback loop by c-REL-mediated expression of TBK1 and IKBKE in
turn leading to a pronounced activation of c-REL. Being also closely linked to the pathogenesis
of breast cancer by promoting activation of NF-κB [43], targeting IKBKEmay be an interesting
future perspective for developing new treatment strategies against cervical cancer. Next to
TBK1 and IKBKE, c-REL knockout was observed to be sufficient to downregulate the expression
of MYC in growing HeLa cells by more than 50% with the relative MYC expression being highly
elevated in comparison to other target genes. Accordingly, Grumont and coworkers showed an
impaired expression of MYC in stage III thymocytes with a RELA/c-REL double knockout [44].
We also demonstrated the presence of three c-REL binding sites in the downstream region of
the MYC promoter, further validating MYC as a direct target gene of c-REL.
In comparison to wildtype, c-REL-/- HeLa Kyoto cells further revealed a significantly
decreased expression of BCL-2, BCL-XL and A20, which are commonly known as anti-apopto-
tic genes [45, 46]. In accordance to our promoter analysis depicting c-REL-binding sites,
BCL-XL and BCL2were described to be direct c-REL target genes [47, 48]. Expression of
TGFB1, already known as direct target of c-REL [49] and a common inducer of cell prolifera-
tion [50], was also significantly reduced in c-REL-/- HeLa Kyoto cells. On functional level, we
observed the c-REL knockout to result in a significantly reduced proliferation, which we sug-
gest to be at least in part mediated by the depicted decline in pro-proliferative target gene
expression. In consistence with these findings, knockdown of the c-REL target gene IKBKE in
HeLa cells was also shown to result in a suppression of proliferation [51]. In human keratino-
cytes, small interfering RNA-mediated knockdown of c-REL was reported to directly affect cell
cycle progression by cell cycle delay of the G2/M phase [23]. The present study further
extended these findings by showing the CRISPR-Cas9n-mediated knockout of c-REL to result
in a robustly delayed prometaphase of mitosis accompanied by strongly reduced levels of
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histone H2B protein. In addition, we observed a novel linkage between the decreased amount
of histone H2B protein and the prolonged prometaphase in c-REL-/- cells. In mice, silencing of
c-Rel by siRNA was shown to lead to a reduction of mitosis in a B cell tumor cell line [52]. Gru-
mont and coworkers likewise demonstrated a cell cycle arrest in B-cells of c-Rel-/- mice [53].
Our present findings for the first time transfer these promising data to the human cancerous
systems and provide deeper insights into the biology of cervical cancers in relation to c-REL-
signaling. In this regard, we were also able to observe significantly reduced expression levels of
ICAM1 in c-REL-/- HeLa Kyoto cells. Downregulation of this adhesion molecule was described
to result in a suppression of human breast cancer cell invasion with the level of expression
being directly correlated to their metastatic potential [54]. Accordingly, inhibition of MYC
protein family members have been shown to induce regression of lung cancer in mice [55],
suggesting the downregulation of MYC observed here likewise to be linked to the reduced pro-
liferation of c-REL-/- cells.
The NF-κB subunit c-REL is also directly linked to cancer development and progression. In
1999, Krappmann and colleagues described a constitutive NF-κB-activity with NF-κB-com-
plexes containing RELA and c-REL in malignant cells derived from Hodgkin’s disease [56].
Whereas c-REL was currently discussed as being mutated in hematopoietic and lymphoid
tumors [57], a high throughput database analysis performed in the present study including
3397 hematopoietic and lymphoid tumors detected mutations in only a few samples [35, 58].
In 2004, Futreal and coworkers described a ‘census’ of human cancers indicating mutations in
>1% of genes of the human genome to contribute to cancer, although genes showing solely
altered expression levels were not included in this initial ‘census’ [59]. Here, we applied data-
base mining using the COSMIC database [35] and observed profound overexpression of c-REL
in various human tumors (Table 1), which is in accordance to the observed amplification of c-
REL in human B-cell lymphomas [20, 21]. Likewise in line with previous studies, c-REL can be
Table 1. Overexpression of REL in human cancers.
tissue type % of REL overexpression no. tested
Ovary 7.52 266
Lung 7.26 1019
Urinary tract 7.11 408
Endometrium 6.81 602
Pancreas 6.7 179
Haematopoietic and lymphoid 6.33 221
Soft tissue 6.08 263
Cervix 5.86 307
Upper aerodigestive tract 5.75 522
Kidney 5.5 600
Thyroid 5.46 513
Large intestine 4.92 610
Stomach 4.91 285
Liver 4.83 373
CNS 4.73 697
Prostate 4.62 498
Breast 3.71 1104
Skin 3.59 473
Oesophagus 3.2 125
Adrenal gland 2.53 79
https://doi.org/10.1371/journal.pone.0182373.t001
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considered as one of the most oncogenic members of the NF-κB family, in fowl reticuloen-
dotheliosis virus also contains mutated oncogenic v-Rel [18, 19, 52, 60].
In the present study, knockout of c-REL in a cellular model of cervical carcinoma resulted
in a significantly increased resistance against the chemotherapeutic agents 5-FUDR and cis-
platin. Due to direct interaction of cisplatin and 5-fluorouracil with the DNA, highly prolifer-
ating cells are exposed to DNA damage resulting in cell-cycle arrest and cell death [61, 62].
Thus, we suggest the reduced proliferation of HeLa c-REL-/- cells to account for the observed
increase in resistance against cisplatin and 5-FUDR. Although activation of NF-κB was also
described to lead to a decreased sensitivity of cancer cells against chemotherapeutic treatment
[63, 64], our present findings propose a subunit specificity of NF-κB in terms of chemoresis-
tance. While a knockout of c-REL promoted survival of HeLa cells to chemotherapy, expres-
sion of the c-REL homolog Xenopus Xrel3 in cervical cancer cells treated with 5 μM cisplatin
was shown to result in increased apoptosis [24].
In summary, our findings emphasize the importance of c-REL-signaling in a cellular model
of cervical cancer particularly in terms of proliferation and resistance to chemotherapeutic
agents. Considering the proposed NF-κB-subunit specificity of chemoresistance, we provide
deeper insights into cervical cancer biology with direct clinical implications for the develop-
ment of new treatment strategies.
Supporting information
S1 Fig. PAGE-analysis of top three predicted exonic off-targets revealed no signs of off-tar-
get effects in the c-REL knockout clone.
(TIF)
S2 Fig. Live cell imaging showing c-REL-/- cells, which arrested during mitosis without
entry of the G2 phase of the cell cycle. Scale bar: 25 μm.
(TIF)
S3 Fig. Promoter analysis using the JASPAR Tool (jaspar.genereg.net) validated IKBKE,
TBK1,A20, BCL2, BCL-XL, TGFB1,MYC and ICAM-1 to be direct c-REL target genes. c-
REL binding site is shown in magenta, RELA binding site is depicted in cyan and common
binding sites are shown in purple.
(TIF)
S1 Movie. Live cell imaging of c-REL-/- and c-REL+/+ cells showed delayed duration of the
prometaphase in c-REL-/- in comparison to wildtype. Mitosis was visualized by H2B-
mCherry and alpha-tubulin-EGFP.
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Abstract 19 
TNF signaling is directly linked to cancer development and progression. A broad range of 20 
tumor cells is able to evade cell death induced by TNF impairing the potential anti-cancer 21 
value of TNF in therapy. Although sensitizing cells to TNF-induced death therefore has great 22 
clinical implications, detailed mechanistic insights into TNF-mediated human cell death still 23 
remain unknown. Here, we analyzed human cells by applying CRISPR/Cas9n to generate cells 24 
deficient of IKK1, IKK2, IKK1/2 and RELA. Despite stimulation with TNF resulted in impaired 25 
NF-κB activation in all genotypes compared to wildtype cells, increased cell death was 26 
observable only in IKK1/2-double-deficient cells. Cell death could be detected by Caspase-3 27 
activation and binding of Annexin V. TNF-induced programmed cell death in IKK1/2-/- cells 28 
was further shown to be mediated via RIPK1 in a predominantly apoptotic manner. Our 29 
findings demonstrate the IKK complex to protect from TNF-induced cell death in human cells 30 
independently to NF-κB RelA suggesting IKK1/2 to be highly promising targets for cancer 31 
therapy.  32 
 2 
 
Introduction 33 
The tumor necrosis factor (TNF) is a well-characterized pro-inflammatory cytokine known to 34 
activate the canonical NF-κB signaling pathway. A particular important regulatory factor in 35 
NF-κB signaling is the IκB kinase (IKK) complex. It consists of the catalytic subunits IKKα 36 
(IKK1) and IKKβ (IKK2) and the regulatory subunit NF-kappa-B essential modulator (NEMO; 37 
IKKγ). The IKK complex is required for the activation of the transcription factor NF-κB, which 38 
ultimately results in the expression of NF-κB target genes involved in cell growth, survival, 39 
but also inflammation and cell death (1). Deregulation of NF-κB signaling is strongly 40 
associated with diseases, in particular with tumor formation (2, 3).  41 
In the canonical NF-κB signaling pathway binding of TNF to the TNF receptor 1 (TNFR1) 42 
results in the formation of the so-called complex I consisting of the TNFR1 associated death 43 
domain protein (TRADD), TNF receptor associated factor 2 (TRAF2), cellular inhibitors of 44 
apoptosis 1 and 2 (cIAP1/2), linear ubiquitin assembly complex (LUBAC) and Receptor-45 
interacting serine/threonine-protein kinase 1 (RIPK1) (4). Ubiquitination of RIPK1 leads to 46 
the recruitment of the IKK complex by binding of NEMO to M1-linked ubiquitin chains on the 47 
one hand and of the TAK1/TAB2/3 complex via K63-linked chains on the other hand (5, 6). 48 
Being phosphorylated by TAK1, IKK2 in turn phosphorylates IBα at Ser32/36. 49 
Phosphorylated IκBα will be polyubiquitinated by SCFβ-TrCP E3 ubiquitin ligases leading to its 50 
proteasomal degradation (7). This results in the unmasking of the nuclear localization 51 
sequence of NF-κB, in canonical signaling mostly comprised of a p65/p50 dimer, whereby 52 
p65 is the transactivating subunit (8). Due to the unmasked NLS, NF-κB is no longer retained 53 
in the cytoplasm and can enter the nucleus leading to the expression of target genes (9). 54 
Tight regulation of the specificity of this process is achieved by a broad range of post-55 
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translational modifications (PMTs) potentially resulting in conformational changes of NF-κB 56 
and by this specifying the subset of target genes being expressed (10, 11).  57 
Although TNFR1 belongs to the death receptor family (12), under physiological conditions 58 
TNF signaling will not induce cell death in a broad range of cell types, since TNF-mediated 59 
activation of NF-κB will result in the expression of anti-apoptotic genes such as c-FLIP, cIAP-60 
1,cIAP-2 and Bcl-2 (13-16). However, genetic or pharmacological inhibition of NF-κB is known 61 
to increase sensitivity to TNF-induced apoptosis (17). Here, cell death is mediated via the so-62 
called complex IIa comprised of TRADD, Fas-associated protein with death domain (FADD) 63 
and caspase-8, which only assembles upon NF-κB inhibition (18, 19). However, programmed 64 
cell death induced by TNF signaling can also be mediated via an NF-κB – independent 65 
manner (20). In this context, cell death occurs via the complex IIb (20). In contrast to 66 
complex IIa, FADD and caspase-8 are recruited by RIPK1 in complex IIb. Upon inhibition of 67 
caspase-8, NF-κB – independent cell death via TNFR1 can also be necroptotic. Necroptosis is 68 
a more recently described way of programmed cell death, which is independent on caspase-69 
8 activation and induced by RIPK3 and the pseudokinase mixed lineage kinase like (MLKL) 70 
(21-23).  71 
Most studies regarding TNF-induced cell death were performed using mouse models, in 72 
which members of the NF-κB signaling pathway were genetically depleted. Many of these 73 
genetic knockouts are resulting in lethality during embryonic development, e.g. in RelA- and 74 
Ikk2-deficient mice (24-26). In both cases, embryonic lethality is caused by TNFα-induced 75 
death of hepatocytes and subsequent liver degeneration, which can be rescued by additional 76 
depletion of TNFR1 (25, 27). In contrast to this, a frameshift mutation within the human 77 
IKBKB gene, which was found in patients suffering from severe combined immunodeficiency 78 
(SCID), had no effect on embryonic survival or liver constitution (28). These findings suggest 79 
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the presence of potential differences in the regulation of TNFα-induced cell death between 80 
mouse and human. Since TNF signaling is highly elevated in a broad range of cancer cells, 81 
which are resistant to cell death induced by TNF (29), sensitizing these cells to TNF-induced 82 
cell death appears to be a promising approach for cancer therapy. Despite this clinical 83 
relevance, the detailed molecular mechanisms of TNF-induced cell death in human cells still 84 
remain unknown.  85 
Facing this challenge, we made use of the CRISPR/Cas9 system to generate genomic 86 
knockouts of several members of the NF-κB signaling pathway in human cells. Originally 87 
discovered as part of the bacterial adaptive immune system (30, 31), the clustered regularly 88 
interspaced short palindromic repeats (CRISPR) system has become a state-of-the-art tool 89 
broadly applied for efficient genome editing (32, 33). In this study, a nickase mutant of the S. 90 
pyogenes Cas9 (D10A; Cas9n) has been used minimizing potential off-target effects and by 91 
this increasing the specificity of genome editing (34). We successfully generated cells 92 
deficient for IKK1, IKK2, IKK1/2 and RelA and demonstrate that TNFα-induced cell death in 93 
human cells is mediated predominantly via RIPK1 and independently of NF-κB. Targeting the 94 
IKK complex in tumor cells genetically or pharmacologically therefore appears promising to 95 
increase sensitivity to TNF-induced cell death with direct implications for potential 96 
therapeutic approaches.  97 
 5 
 
Results 98 
Knockout of IKK1 and IKK2 leads to strongly impaired NF-B activation  99 
To assess clinical implications of IKK1 and IKK2 knockouts, we first analyzed levels of 100 
overexpression in human cancer with database mining using COSMIC (35). Here, particularly 101 
IKBKB (IKK2) was found to be profoundly overexpressed in a variety of tissues including 102 
breast, endometrium, large intestine and skin (Fig. S1).  103 
We now aimed to analyze the role of IKK1 and IKK2 in the context of TNF signaling and 104 
activation of NF-κB. For this, we utilized the CRISPR/Cas9n system to generate IKK1- and 105 
IKK2-deficient cells as well as an IKK1/IKK2 double knockout by inducing two double-strand 106 
breaks spanning an intron-exon border (Fig. 1A). Deletions within the IKBK1 and IKBK2 gene 107 
of clonally grown cells were validated by genomic PCR using primers flanking the deletion 108 
(Fig. 1B) and by RT-PCR using primer pairs with one primer set within the deletion (Fig. 1C). 109 
Absence of IKK1 and IKK2 protein was finally shown on western blot (Fig. 1D). Notably, we 110 
did not observe a strong reduction in the amount of the NF-κB subunit p65 in the knockout 111 
clones, which was described earlier for IKK2-deficient human fibroblast (28). Only in IKK1-112 
deficient cells, a slight reduction was detected (Fig. S2).  113 
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 115 
Figure 1. Generation of IKK1, IKK2 and IKK1/2-deficient cells. (A) Target design showing the 116 
desired genomic deletion in the IKBKA and IKBKB gene. Marked in blue are the designed 117 
sgRNAs and marked in green are the flanking primers used for genomic PCR. (B) Genomic 118 
PCR of clonally grown cells demonstrating the desired deletion in the respective genotype. 119 
(C) RT-PCR using primers designed within the deletion showing no amplification in the 120 
respective genotype. (D) Western blot analysis revealing lack of IKK2 protein in IKK2-121 
deficient cells, lack of IKK1 protein in IKK1-deficient cells and lack of both in double-deficient 122 
cells.  123 
 124 
Next, we examined NF-κB activation in all genotypes after stimulation with TNFα. Nuclear 125 
translocation of p65 was significantly impaired compared to wildtype cells (Fig. 2A, B). This 126 
effect was strongest in the double-deficient cells. In line with this, qPCR analysis of the NF-κB 127 
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target genes IBα, A20 and IL-8 after TNFα stimulation revealed a significantly reduced 128 
expression in all genotypes compared to wildtype cells (Fig. 2D). In IKK1/2-double-deficient 129 
cells, no increase in expression upon stimulation was detected at all (Fig. 2D). Moreover, we 130 
detected no signs of IκBα degradation upon TNFα treatment in these cells (Fig. 2C). 131 
However, degradation of IBα was reduced in IKK1 and IKK2 single knockouts, although to a 132 
lesser extent than in wildtype cells.  133 
 134 
 135 
 136 
Figure 2. Strongly impaired NF-κB activation in knockout cells. (A) Immunocytochemical 137 
stainings of cells stimulated for 20 min with 10 ng/mL TNFα. Only in wildtype cells a clear 138 
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nuclear translocation of p65 after stimulation is observable. (B) Quantification of the nuclear 139 
intensity of cells stained against p65 (One-way ANOVA, Bonferroni post-test, n=3). (C) 140 
Western blot analysis demonstrating degradation of IκBα upon stimulation with 10 ng/mL 141 
TNFα for 20 min. While in IKK1- and IKK2-deficient cells a partial degradation is shown 142 
compared to wildtype cells, no degradation is visible in the double-deficient cells. (D) qPCR 143 
analysis of the NF-κB target genes IκBα, A20 and IL-8 revealed reduced expression in the 144 
knockout cells after 6 h of TNFα (10 ng/mL) treatment compared to wildtype cells (One-way 145 
ANOVA, Bonferroni post-test, n=3).  146 
 147 
IKK1 and IKK2 double-deficiency results in TNFα-induced cell death 148 
We aimed to analyze TNFα-induced cell death in our newly generated knockout cells. After 149 
long-term exposure (24 h) to TNFα, a high number of dead cells was observable only in the 150 
double-deficient cells, while there was hardly any difference detectable between the single 151 
knockouts and wildtype cells (Fig. 3A). Immunocytochemical staining of TNFα-treated cells 152 
also revealed 32.1% of the IKK1/IKK2-/- cells to be positive for activated Caspase-3. In 153 
comparison, only 3.0% Caspase-3-positive cells were found in wildtype cells (Fig. 3B). 154 
Without TNFα stimulation, in both genotypes less than 0.3% cells were positive (Fig. 3B). We 155 
additionally detected the increased cell death in the IKK1/2 double-deficient cells using DNA 156 
content measurements (Fig. S3). In the IKK1 and IKK2 single knockout cells, no difference in 157 
the amount of apoptotic cells upon TNFα stimulation was observable compared to wildtype 158 
cells. However, in IKK1/2-double-deficient cells, this amount was increased from 4.2% 159 
(wildtype) to 34.7% (Fig. S3). Furthermore, increased cell death of the IKK1/2-/- cells within 160 
24 h of TNFα stimulation could be demonstrated using an Annexin V-based apoptosis assay 161 
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(Fig. 3C, D). Annexin V-based luminescent signal was strongly elevated in the double-162 
deficient cells (Fig. 3D) in relation to wildtype (Fig. 3C).  163 
 164 
 165 
Figure 3. IKK1/2-deficiency results in profound TNFα-induced cell death. (A) Vastly 166 
increased cell death in IKK1/2-double deficient cells upon 24 h exposure to TNFα (20 ng/mL). 167 
(B) Immunocytochemical stainings of wildtype and IKK1/2-/- cells revealed a huge increase in 168 
caspase-3-positive cells in the double knockout after 24 h of TNFα stimulation (20 ng/mL) 169 
(n=3; for each genotype and condition more than 2500 cells were analyzed). (C,D) RealTime 170 
Glo Annexin V apoptosis assay of wildtype (C) and IKK1/2-deficient cells (D). Compared to 171 
wildtype cells, a strong increase in apoptotic cells was observed.  172 
 173 
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In the presence of Nescrostatin-1s (Nec-1s), a potent inhibitor of RIPK1, cell death was 174 
markedly reduced in IKK1/2-deficient cells (Fig. 4A). Stainings against activated caspase-3 175 
revealed 12.8% caspase-3-positive cells (Fig. 4B), a strong reduction when compared to the 176 
32.8% positive cells, which were stimulated only with TNFα (Fig. 3B). Application of 177 
Necrosulfonamide, an inhibitor of MLKL resulted only in slightly reduced amounts of dead 178 
cells, when stimulated with TNFα (Fig. 4A, bottom panel). After 24 h, 26.7% of the double-179 
deficient cells were positive for the cleaved caspase-3 (Fig. 4B). However, using the Annexin 180 
V-based apoptosis assay, cell death was reduced to similar extents with both inhibitors used 181 
(Fig. 4C, D). No protective effects of Nec-1s or Necrosulfonamide were observed on wildtype 182 
cells (Fig. 4A, B; Fig. 3B).  183 
 184 
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Figure 4. TNFα-induced cell death is mediated via RIPK1. (A) Stimulation of IKK1/2-deficient 185 
cells with 20 ng/mL TNFα and the RIPK1 inhibitor Nec-1s (10 µM; middle panel) or the 186 
inhibitor of the MLKL necroptosis complex necrosulfonamide (1 µM; bottom panel) resulted 187 
in a profound protection from TNFα-induced cell death for Nec1s and a small for 188 
necrosulfonamide. (B) Upon TNFα treatment immunocytochemistry revealed 12.8% caspase-189 
3-positive cells in the presence of Nec-1s and 26.7% in the presence of necrosulfonamide 190 
(n=3; for each genotype and condition more than 2500 cells were analyzed). (C,D) RealTime 191 
Glo Annexin V apoptosis assay of TNFα-stimulated wildtype and IKK1/2-deficient cells in the 192 
presence of Nec-1s (C) or the MLKL inhibitor Necrosulfonamide (D).  193 
 194 
TNFα does not induce programmed cell death upon RelA deficiency 195 
Since cells deficient for either IKK1 or IKK2 also showed strongly impaired NF-B activation, 196 
we speculated an NF-κB-independent mechanism might lead the cell death observed. To 197 
further analyze this, we generated cells deficient for the NF-κB-subunit RelA (p65) (Fig. 5). 198 
Using the same approach, we generated a genomic deletion spanning the intron-exon 199 
boundary of exon 2 (Fig. 5A), which is present in all transcript variants listed at ENSEMBL.org. 200 
We validated the designed deletion using genomic PCR and qPCR (Fig. 5B, C) and lack of p65 201 
protein by immunocytochemistry (Fig. 5D). Analysis of NF-κB activation in these cells was 202 
assessed by qPCR of the NF-κB target genes IκBα and A20 showing reduced expression in the 203 
RelA-/- cells after stimulation with TNFα compared to wildtype cells (Fig. 5E). This impairment 204 
was validated by usage of an NF-κB-driven luciferase reporter demonstrating reduced 205 
activation of NF-κB in the knockout cells (Fig. 5F).  206 
 207 
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 208 
Figure 5. Generation of RELA-deficient cells. (A) Target design for the CRISPR/Cas9-209 
mediated knockout of RELA. Depicted in blue are the sgRNAs and depicted in red are the 210 
flanking primers used for genomic PCR. (B) Genomic PCR of clonally grown cells revealed 211 
genomic deletion within the RELA gene. (C) qPCR analysis using a primer set, where one 212 
primer is designed within the deletion showed a highly significant downregulation of RelA 213 
mRNA (t-test, two-tailed, n=3). (D) Immunocytochemical stainings depicted almost complete 214 
loss of RelA protein in RelA-deficient cells. (E) Expression of the NF-κB target genes IκBα and 215 
A20 is markedly reduced in RelA-/- cells after 6 h of TNFα stimulation (10 ng/mL) compared 216 
to wildtype cells (One-way ANOVA, Bonferroni post-test, n=3). (F) An NF-κB driven luciferase 217 
 13 
 
reporter assay revealed a significantly reduced NF-κB activation after 24 h TNFα stimulation 218 
in RelA-deficient cells (One-way ANOVA, Bonferroni post-test, n=3).  219 
 220 
Upon long-term exposure to TNFα we detected no increased amount of dead RelA-deficient 221 
cells compared to wildtype cells (Fig. 6A). In an immunocytochemical analysis, the amount of 222 
cells positive for the activated form of caspase-3 only very mildly increased (Fig. 6B), being 223 
even below the values for TNFα-stimulated wildtype cells (Fig. 3B). Signals for Annexin V 224 
were hardly elevated in the GloMax Annexin V Apoptosis Assay in RelA-/- cells within 24 h of 225 
TNFα treatment (Fig. 6C).  226 
 227 
Figure 6. No increase in TNFα-induced cell death upon RelA deficiency. (A) After 24 h of 228 
TNFα stimulation (20 ng/mL) no differences in the amount of dead cells between RelA-229 
deficient and wildtype cells was observable. (B) Immunocytochemistry revealed only a small 230 
increase in Caspase-3-positive cells after TNFα treatment (n=3; for each condition more than 231 
5000 cells were analyzed). (C) RealTime Glo Annexin V apoptosis assay of TNFα-treated RelA-232 
/- cells showed no difference in the amount of apoptotic cells compared to untreated cells.   233 
  234 
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Discussion 235 
In the present study, we successfully generated genomic knockouts for IKK1, IKK2, IKK1/2 236 
and RelA in HEK293 cells to initially analyze the role of IKK1 and IKK2 in the context of TNF-237 
induced cell death. HEK293 cells are a broadly used cellular model for TNF-signaling (18). 238 
Upon stimulation with TNFα, a vast increase in cell death was observed only in cells deficient 239 
for both IKK1 and IKK2. We further partially rescued cell death in these cells using the RIPK1-240 
specific inhibitor Necrostatin-1s indicating RIPK1 activity to be the predominant cause of the 241 
cell death observed.  242 
Activation of the death receptor TNFR1 does not necessarily lead to death but often results 243 
in cell survival or even increased proliferation (36, 37). Downstream of TNFR1 two major 244 
pathways – an NF-κB – dependent and an –independent one – have been described to 245 
regulate and control cell death (38). The first one is well characterized and demonstrates the 246 
activation of NF-κB by TNF-signaling resulting in the expression of anti-apoptotic NF-κB 247 
target genes such as cIAP-1, cIAP-2 or c-FLIP (13, 14, 17). In contrast, signaling via TNFR1 248 
independently of NF-κB activation is far less well understood and just gained attention in the 249 
last years (38, 39). In the present study, we carefully investigated NF-κB activation in 250 
response to TNFα in all genotypes we created. While differences between the different 251 
knockouts were observable, all cells showed significantly reduced activation when compared 252 
to wildtype cells. In contrast, experiments conducted in Ikk1-deficient mice showed no major 253 
impairments in canonical NF-κB signaling, although strong developmental aberrations and 254 
death shortly after birth were observable (40). Consequently, IKK2 is concluded to be the 255 
catalytic subunit needed for canonical NF-kB signaling by directly phosphorylating IκBα. 256 
However, in IKK1-deficient cells we observed severely affected NF-κB activation after TNFα 257 
stimulation. In fact, most experiments demonstrated impairments within the same range as 258 
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in IKK2-deficient cells indicating that IKK2 cannot compensate loss of IKK1 in the cells we 259 
used. Interestingly, although activation of NF-κB via TNF is associated with cell growth, 260 
especially in the context of tumor formation and progression, we detected no signs of 261 
reduced proliferation in any of the genotypes created (data not shown). Recently, we 262 
generated HeLa cells deficient for the NF-κB subunit c-Rel, which showed a significantly 263 
lowered proliferation rate (41). However, although NF-κB activation was significantly 264 
impaired in these cells, no increase in cell death was observed after treatment with TNFα 265 
already suggesting the presence of an NF-κB-independent mechanism to prevent from TNF-266 
induced cell death in human cells. In 2015, Dondelinger and colleagues described a novel 267 
function of both Ikk1 and Ikk2 in mice by demonstrating RIPK1 to be a bona fide target of the 268 
Ikk complex (42). By directly phosphorylating RIPK1, Ikk1/2 inactivate RIPK1 and prevent 269 
from TNF-induced cell death independently of NF-κB. In this NF-κB independent pathway, 270 
RIPK1 will be required to recruit FADD into the so-called complex IIb resulting in apoptosis. 271 
Upon caspase-8 inhibition RIPK1 can also be incorporated into the necrosome, which will 272 
lead to the activation of RIPK3 and its substrate MLKL leading to necroptotic cell death (20). 273 
Interestingly, deficiency of either Ikk1 or Ikk2 was not sufficient to induce cell death upon 274 
TNFα. However, in fibroblasts derived from Ikk1/2-double deficient mice, cell death was 275 
vastly increased when cells were exposed to TNFα (42). Extending these findings, we 276 
observed no strong increase in cell death when either, IKK1 or IKK2 was genetically depleted. 277 
Only in cells deficient for both, IKK1 and IKK2, significant increase in cell death was 278 
detectable. We hypothesized that cell death predominantly occurred in an NF-κB – 279 
independent way mediated via RIPK1. Confirming this, application of the RIPK1-specific 280 
inhibitor Nec-1s partially rescued from TNF-induced cell death in the IKK1/2-double deficient 281 
cells. Dondelinger and colleagues – as it is done in most studies dealing with the causes of 282 
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cell death induced by TNFα – applied mouse models to gain their findings. However, 283 
differences between humans and mice have been reported in the past in terms of TNF and 284 
NF-κB signaling. Mice deficient for either, RelA, Ikk2 or NEMO were reported to die during 285 
embryonic development, in each case due to TNF-induced death of hepatocytes resulting in 286 
liver degeneration (24-26, 43). In 2013, Panicke and co-workers described a frameshift 287 
mutation in the human IKBKB gene to be the cause of severe combined immunodeficiency 288 
(28). Patients carrying this loss-of-function mutation did not show any signs of liver 289 
degeneration indicating potential differences in TNF signaling between humans and mice. 290 
This elucidates the necessity to analyze TNF-mediated cell death in human cells, especially 291 
when considering that TNF signaling is closely connected to human diseases, in particular 292 
with cancer. Several reports describe TNF being involved in all parts of carcinogenesis, 293 
namely transformation of healthy cells, survival, proliferation, invasion, angiogenesis and 294 
metastasis of tumor cells (reviewed in (29)). In a broad range of tumorigenic tissues or tumor 295 
cells, TNF expression is strongly increased (44, 45). Consequently, many types of tumor cells 296 
are particularly resistant to TNF-induced cell death (29). A better understanding of the 297 
mechanisms, on how tumor cells evade death therefore is a promising approach to increase 298 
the anti-cancer value of TNF. Supporting our findings of NF-κB-independent cell death in 299 
human cells, Legarda-Addison and co-workers demonstrated in Jurkat cells increased 300 
sensitivity to TNF-induced cell death upon NEMO deficiency, which was independent of NF-301 
κB (46). As was observed from Dondelinger, NEMO deficiency in mice also sensitized cells 302 
regarding TNF-induced cell death, in a similar manner as Ikk1/2 combined (42).  303 
In summary, our findings demonstrate that in human cells IKK1 and IKK2 have an NF-κB – 304 
independent function in preventing from TNF-induced cell death. Targeting – genetically or 305 
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pharmacologically – both catalytic IKKs therefore appears to be a promising approach in 306 
cancer therapy, especially for tumor cells resistant to TNF-induced cell death.  307 
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Materials and methods 308 
Statistical analysis 309 
All statistical tests were performed using GraphPad Prism 5 (GraphPad Software, La Jolla, 310 
USA). Data is presented as the mean of at least three independent experiments ± SEM if not 311 
stated otherwise. The statistical test used is mentioned in the respective figure legend. ns, 312 
not significant, *p<0.05, **p<0.01, ***p<0.001.  313 
 314 
Target design and cloning 315 
Single guide RNAs (sgRNAs) were designed using the online prediction tool from the 316 
University of Heidelberg (47). Nicking pairs were chosen as described by Ran and colleagues 317 
(34). For efficient gene knockout we designed two nicking pairs creating a deletion spanning 318 
an intron-exon border within the respective gene. sgRNAs for IKK1 and IKK2 knockout were 319 
cloned into pSpCas9n(BB)-2A-Puro (PX462) V2.0 (Addgene plasmid #62987) essentially as 320 
described (48), while sgRNAs for knockout of RELA were cloned into pX335_G2P (modified 321 
Addgene plasmid #42335, kindly provided by Boris Greber) 322 
 323 
Cell culture and transfection 324 
HEK293 cells were cultivated in Dulbecco's Modified Eagle's Medium (DMEM) (Sigma 325 
Aldrich, Taufkirchen, Germany) containing 10% (v/v) heat-inactivated fetal calf serum (FCS) 326 
(VWR, Darmstadt, Germany), 2 mM L-glutamine (Sigma Aldrich) and 100 U/ml 327 
Penicillin/Streptomycin (P/S) (Sigma Aldrich) at 37°C and 5% CO2 at saturated humidity.  328 
Transfection was performed either using standard calcium-phosphate precipitation or 329 
TurboFect transfection reagent (Thermo Fisher Scientific) according to manufacturer’s 330 
guidelines.  331 
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 332 
Genomic PCR 333 
Cells were harvested at 300 g for 5 min and resuspended in cell lysis buffer (0.1 µg/mL 334 
Gelatine, 50 mM KCl, 1.5 mM MgCl2, 0.45% NP40, 10 mM TRIS pH 8.3, 0.45 % TWEEN 20, 335 
200 µg/mL Protein kinase K). Lysate was incubated for 1 h at 55°C and 5 min at 95°C before 336 
being used as template for genomic PCR. The following primers were used: IKBKA-fwd 5’-337 
GCCTTGGAACAACTGTGGAAC-3’, IKBKA-rev 5’-GGACGCACACATTCCCAAAG-3’, IKBKB-fwd 5’-338 
CCACCTTGTTTGCCTGCTTG-3’, IKBKB-rev 5’-GTCTCCCCATCCCTCTTCCT-3’, RELA-fwd 5’-339 
GGAGCAGAGGGAACCTTGAC-3’, RELA-rev 5’-GTATCTGTGCTCCTCTCGCC-3’.  340 
 341 
RT-PCR and quantitative real-time PCR 342 
Total RNA was isolated using TRI Reagent (Sigmal-Aldrich) according to the manufacturer’s 343 
protocol. 1 µg of RNA was used for cDNA synthesis. For RT-PCR, 1 µL cDNA was used as 344 
template and for quantitative real-time PCR (qPCR), cDNA was diluted 1:100 and 2 345 
µL/reaction were used. qPCR was carried out with SYBR Green Master Mix (Thermo Fisher 346 
Scientific). The following primers were used: IKK1-fwd 5’-CTTCGGGAACGTCTGTCTGTA-3’, 347 
IKK1-rev 5’-TTGGCATGGTTCAACTTCTTCAT-3’, IKK2-fwd 5’-GCTGACCCACCCCAATGTG-3’, 348 
IKK2-rev 5’-TAAGCGCAGAGGCAATGTCA-3’, RelA-fwd 5’-CTGTTCCCCCTCATCTTCCC-3’, 349 
RelA-rev 5’- GCCATTGATCTTGATGGTGGG-3’, IκBα-fwd 5’-CCCTACACCTTGCCTGTGAG-3’, 350 
IκBα-rev 5’-TAGACACGTGTGGCCATTGT-3’, A20-fwd 5’-CTGAAAACGAACGGTGACGG-3’, 351 
A20-rev 5’-TCCAGTTGCCAGCGGAATTT-3’, IL8-fwd 5’-TCTGTGTGAAGGTGCAGTTTTG-3’, 352 
IL8-rev 5’-TTTCTGTGTTGGCGCAGTGT-3’. Ct values obtained in qPCR were normalized to the 353 
reference genes GAPDH (fwd 5’-CATGAGAAGTATGACAACAGCCT-3’; rev 354 
5’-AGTCCTTCCACGATACCAAAGT-3’), eEF2 (fwd 5’-AGGTCGGTTCTACGCCTTTG-3’; rev 355 
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5’-TTCCCACAAGGCACATCCTC-3’) and RPLP0 (fwd 5’-TGGGCAAGAACACCATGATG-3’; rev 356 
5’-AGTTTCTCCAGAGCTGGGTTGT-3’).  357 
 358 
Western blotting 359 
Protein extracts were made using RIPA buffer (1 mM EGTA, 150 mM NaCl, 1 mM Na2EDTA, 1 360 
mM Na3VO4, 1% (w/v) NP-40, 1 µg/mL leupeptin, 1 % (w/v) sodium deoxycholate, 2.5 mM 361 
sodium pyrophosphate, 20 mM Tris-HCl (pH 7,5), 1 mM β-glycerophosphate) and equal 362 
amounts of protein were separated by SDS-PAGE and transferred to a PVDF membrane. 363 
Membranes were blocked using PBS containing 0.05% Tween 20 and 5% milk powder, 364 
followed by probing with primary antibodies (rabbit anti-IKK1 (#7182; Santa-Cruz 365 
Biotechnology, Dallas, USA), rabbit anti-IKK2 (#2370; Cell Signaling, Danvers, USA), rabbit 366 
anti-p65 (#8242; Cell Signaling), mouse anti-IκBα (#4814; Cell Signaling) overnight at 4°C. 367 
Horseradish peroxidase-conjugated secondary antibodies were applied for 1h at room 368 
temperature. Blots were developed using enhanced chemiluminescence. GAPDH (#32233; 369 
Santa-Cruz Biotechnology) served as loading control. 370 
 371 
Immunocytochemistry 372 
For immunocytochemical stainings cells were cultivated on coverslips. Fixation was done 373 
with 4% paraformaldehyde (PFA) for 10 min at RT. Prior to application of the primary 374 
antibodies (rabbit anti-p65 (#8242; Cell Signaling), rabbit anti-cleaved caspase-3 (#9661; Cell 375 
Signaling)) cells were permeabilized and blocked using PBS containing 0.02 % Triton X-100 376 
and 5 % goat serum. After repetitive washing, secondary fluorochrome-conjugated 377 
antibodies (goat anti-rabbit/mouse Alexa Fluor 555, Thermo Fisher Scientific) were applied, 378 
followed by nuclear counterstaining with DAPI (1µg/mL) and finally mounting using 379 
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Mowiol/DABCO. Imaging was done by confocal laser scanning microscopy (LSM 780, Carl 380 
Zeiss, Oberkochen, Germany) and image processing was performed using Fiji (49) and Corel 381 
Draw (Corel Corporation, Ottawa, Canada).  382 
 383 
Dual luciferase reporter assay 384 
Cells were transiently transfected with TK (NF-κB)6 LUC vector (50) and pRL-CMV (Promega 385 
Cooperation) using TurboFect Transfection Reagent (Thermo Fisher Scientific) according to 386 
manufacturer’s guidelines. 24h after transfection, cells were stimulated with TNFα or left 387 
untreated. The next day, cells were lysed in 1 × Passive Lysis buffer (Promega Corporation) 388 
and Luciferase activity was measured using the Dual-Luciferase® Reporter Assay System 389 
(Promega Corporation). Signals were normalized as a ratio of Firefly luciferase activity to 390 
Renilla luciferase activity. 391 
 392 
RealTime Glo Annexin V Apoptosis Assay 393 
Apoptosis was analyzed using the RealTime-Glo™ Annexin V Apoptosis Assay (Promega 394 
Corporation) according to manufacturer’s guidelines. One day prior to stimulation, 10.000 395 
cells were seeded in white, tissue culture-treated 96-well multiwell plates (BRAND, 396 
Wertheim, Germany). Cells were stimulated as indicated and simultaneously detection 397 
reagent – prepared according to the manufacturer’s protocol – was added. Annexin V-based 398 
luminescence was measured at the times indicated using a GloMax®-Multi Plus Detection 399 
System (Promega Corporation). No-cell controls were used for background subtraction.  400 
 401 
Flow cytometric analysis  402 
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DNA content was measured essentially as described (51). Briefly, 1 x 106 cells – treated as 403 
indicated – were harvested and fixed for 5 min using 70 % (v/v) ethanol. After centrifugation 404 
at 300 g cells were stained with staining solution (PBS containing 1 mg/ml glucose (Roth), 50 405 
mg/ml propidium iodide (Partec, Sysmex Deutschland GmbH, Bornbarch, Germany) and 100 406 
Kunitz units RNaseA (Thermo Fisher Scientific) for 60 min under exclusion of light. PI-staining 407 
was analyzed using a Gallios™ 10/3 flow cytometer (Beckman Coulter, Brea, CA, USA). Data 408 
analysis was done using FlowJo Software (TreeStar, Olten, Switzerland), doublet 409 
discrimination was assured by gating FL3-A- versus FL3-W signals. 410 
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Figure S1. Database mining using COSMIC for overexpression of IKBKA and IKBKB in 
various tissues. cancer.sanger.ac.uk 05-02-2017 13:05  
  
  
Figure S2. No reduction of RelA protein in IKK-deficient cells. IKK-deficiency did not result in 
prominent downregulation of the NF-κB subunit RelA.   
 Figure S3. Flow Cytometric analysis revealed TNFα-induced cell death in IKK1/2-deficient 
cells. DNA content measurement of propidium iodide stained cells showed a strong increase 
in the amount of apoptotic cells in IKK1/IKK2-double-deficient cells upon TNFα stimulation 
(24 h; 20 ng/mL). This effect was not observed in cell deficient for either IKK1 or IKK2.  
 
